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Abstract 
Introduction Trace element status may be important in acutely-inflamed 
patients. Plasma concentrations of trace elements are known to alter during the 
evolution of the acute phase response, however, erythrocyte trace element 
concentrations do not. It is not known whether either erythrocyte or plasma 
concentrations reflect the status of the tissues where trace elements are 
utilised. Therefore trace element concentrations were examined in tissues and 
blood from non-inflamed patients, with plasma and erythrocyte concentration 
changes studied during the evolution of the acute phase response. 
Methods 31 patients undergoing liver resection had liver, rectus muscle, and 
blood samples obtained pre-operatively, and blood sampling for 3 days post-
operatively. Se, Cu and Zn concentrations were obtained by inductively coupled 
mass spectrometry after nitric acid digestion. Erythrocyte glutathione 
peroxidase (GPx) was measured by spectrophotometry. C-reactive protein and 
albumin concentration were measured on each day.  
Results C-reactive protein increased and albumin concentration decreased over 
the 3 days postoperatively. Plasma Zn and Se concentration changed in the 3 
days post-operatively (p<0.001); erythrocyte Cu, Zn and Se concentration, GPx 
activity and plasma Cu concentration did not change. Preoperatively, liver Cu 
concentration was associated with erythrocyte Cu concentration (r2 15.9%; 
p=0.036) but not plasma Cu concentration (r2 4.3%; p=0.264); plasma Zn 
concentration was associated with liver Zn concentration (r2 14.4%; p=0.046) but 
erythrocyte Zn concentration was not (r2 0.1%; p=0.896); and liver Se 
concentration was associated with erythrocyte Se concentration (r2 17.1%; 
p=0.023), erythrocyte glutathione peroxidase (r2 22.6%; 0.008) and plasma Se 
concentration (r2 43.1%; p<0.001). 
Conclusions Erythrocyte Cu and Se concentration, and GPx activity are 
associated with liver Cu and Se concentration respectively, and do not change 
during the evolution of the acute phase response. They should be considered as 
potential markers of Cu and Se status. Plasma Zn is associated with liver Zn 
concentration but the concentration changes during the acute phase response; 
caution should be taken interpreting results in patients with inflammation, and 
further work is required to find a suitable alternative marker of Zn status. 
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Chapter 1 
Introduction 
 
1.1 Background 
 
The Scottish Trace Element and Micronutrient Laboratory is based at Glasgow 
Royal Infirmary. It is funded by the National Health Service (NHS) and provides a 
supra-regional assay service for trace elements and micronutrients for all of the 
NHS in Scotland, as well as receiving samples from the rest of the UK, overseas 
and industry. During the year 2009-2010, the laboratory received 5073 requests 
for plasma copper measurement, 3459 requests for plasma zinc measurement 
and 1726 requests for plasma selenium measurement from hospitals within 
Scotland alone.  
It is now well established that plasma concentrations of trace element 
micronutrients can be affected by the acute phase response seen during acute 
and chronic disease1; however these are exactly the types of patients that 
clinicians wish to know the micronutrient status of. The Scottish Trace Element 
and Micronutrient laboratory only has access to information about the 
inflammatory state of patients in a small percentage of the samples which have 
been sent from Glasgow Hospitals, and which the laboratory has access to other 
blood results from. The remainder of the samples will be analysed with no 
knowledge of whether the result will have been potentially invalidated by an 
inflammatory response within the patient.  
The purpose of this thesis is to find a potential solution to this problem which 
will be applicable to an NHS laboratory with a high through-put of samples. 
Previous work carried out in the Scottish Trace Element and Micronutrient 
Laboratory found that erythrocyte trace element micronutrients did not alter 
with the acute phase response2, making them a potentially suitable marker for 
trace element micronutrient status in patients with inflammation. Therefore, 
this work concentrates on plasma and erythrocyte trace element micronutrient 
concentrations: developing methods for their measurement that are robust 
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enough for use in a routine laboratory, establishing whether they are an 
accurate reflection of whole body trace element status, while also examining 
the changes seen during the acute phase response to elucidate the potential 
predictors of the magnitude of the concentration changes seen.  
 
1.2 Trace Elements 
 
A trace element is an inorganic micronutrient which is present in humans at very 
low concentrations: µg/L in body fluids and µg/g in tissue. Trace elements 
include iron, iodine, cobalt, selenium, copper, zinc, manganese, chromium, 
molybdenum, vanadium, bromine, fluorine, cadmium, lead, strontium, lithium 
and tin3. 
 
An essential trace element is one is in which dietary deficiency can lead to 
physical effects which improve upon dietary supplementation. An example of 
this is zinc deficiency resulting in skin lesions which improve significantly with 
oral zinc supplementation. In most cases a biochemical basis for the elements 
essential function is known, such as an enzyme containing the trace element (a 
metallo-enzyme) in which the element is essential for the enzyme’s function or 
activation. The essential trace elements include iron, zinc, copper, cobalt, 
iodine, molybdenum and selenium. Essential functions have been found for 
Manganese but a physiologically detrimental deficiency state has never been 
identified in humans4.  
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1.3 The acute phase response 
 
Both acute and chronic inflammation result in systemic changes that are known 
as the acute phase response5. The acute phase response involves changes in the 
concentrations of many plasma proteins which are known as acute phase 
proteins; an acute phase protein is defined as one whose plasma concentration 
increases (positive acute phase reactant) or decreases (negative acute phase 
reactant) by at least 25 percent during inflammatory disorders6. Changes are 
most likely due to increased or decreased hepatic synthesis. A substantial acute 
phase response with large changes in acute phase proteins is seen in infection, 
post-trauma, in autoimmune inflammatory diseases (e.g. rheumatoid arthritis) 
and advanced cancer.  
 
C-reactive protein is the archetypal positive acute phase reactant. A protein 
with a physiological role to bind to phosphocholine expressed on the surface of 
bacteria and dead or dying cells in order to activate the complement system, it 
can increase by up to a 1000 percent in response in inflammation. Other positive 
acute phase reactants include haptoglobin, fibrinogen, plasminogen, ferritin and 
serum amyloid A. Negative acute phase reactants include albumin, transferrin 
and thyroxine binding globulin7. Albumin is the most abundant protein in blood 
and maintains the colloid osmotic pressure along with acting as the major 
transport protein for many molecules, including drugs and micronutrients. An 
advantageous reason for decreasing concentrations of negative acute phase 
reactants has yet to be found; it may simply be that available amino acids are 
diverted to the production of positive acute phase proteins which have an 
immunological role to fulfil during inflammation7. 
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1.4 The importance of trace element status during the acute phase response 
 
Patient who are unwell are at higher risk of trace element deficiencies than the 
general population. This is due to a reduced nutritional intake, increased losses 
and possible increased requirements8.  
 
Reduced appetite is common in patients who are unwell with an inflammatory 
response. Abdominal surgery and mechanical ventilation both cause patients to 
be physically unable to eat for several days. Patients who are chronically 
malnourished, for example those in nursing homes and chronic alcoholics are 
also more susceptible to acute illness and make up a disproportionate amount of 
the hospital population. If patients receive artificial nutrition, such as enteral or 
parenteral nutrition, monitoring is required to ensure trace elements and other 
micronutrients are adequate replaced9.  
 
Increased loss of trace elements is especially common in surgical and burns 
patients. Losses include those from diarrhoea or gastric fluid and loss from burns 
exudates. Treatments such as dialysis can also lead to micronutrient depletion10. 
 
Moreover, while having a higher risk for nutritional deficiency, unwell inflamed 
patients may also have higher requirements for trace element micronutrients. 
Requirements for trace elements may increase during the catabolism associated 
with inflammation as they have a role as coenzymes for catabolic pathways11. 
There is also the role of trace elements, such as selenium12, in anti-oxidant 
pathways which will be required to manage the increased oxidative stress found 
with inflammation. Once the illness has resolved the patient will need increased 
micronutrients both to compensate for increased consumption during illness and 
also when regaining weight13. 
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1.4.1 Critical illness 
 
Trace elements are of interest in critical illness because they are thought to 
have a role in the reduction of oxidative damage from free radical production. 
The major complication of critical illness is systemic inflammatory response 
syndrome (SIRS) which includes the production of free radicals, cytokines and 
other mediators; associated conditions include sepsis, pancreatitis, major 
trauma and burns14. Critical illness and SIRS is associated with a redistribution of 
selenium and zinc from the circulation to tissues and organs1. It has been 
hypothesised that the redistribution of trace elements during the acute phase 
response may be detrimental if prolonged due to depletion of antioxidants from 
the circulation14. 
 
However, if trace element micronutrients and their relative deficiency were an 
important factor in morbidity and mortality from critical illness, then 
supplementation during critical illness would seem appropriate. Selenium has 
been of particular interest and there have been many small studies of selenium 
supplementation in critically ill patients. A Cochrane systematic review of 
selenium supplementation in the critically ill was inconclusive15. It examined five 
trials of selenium selenite supplementation in critically ill patients; there was no 
reduction in mortality (RR 0.71, 95% CI 0.43 to 1.17). However, when general 
intensive care patients were examined alone there was a suggestion of benefit 
(RR 0.75, 95% CI 0.59 to 0.96). However the main problems were that these were 
small studies with a short follow up period and statistical heterogeneity was 
high. 
 
A recent Scottish Trial (SIGNET) attempted to overcome some of the 
methodological problems of previous studies by enrolling 500 patients in a 2 x 2 
factorial randomised controlled trial. This compared 4 groups of differing 
supplementation of parenteral nutrition: selenium, glutamine, selenium and 
glutamine and no supplementation, with a primary outcome of episodes of 
infection in the first 14 days after starting treatment16. This showed no 
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difference in rate of infections in any group; subgroup analysis did show a 
significant reduction in infections in those receiving selenium for greater than 5 
days duration17. 
 
Studies of zinc supplementation in critical illness have had similar problems of 
small sample sizes and poorly defined outcomes making meta-analysis difficult. 
Heyland and colleagues performed a systematic review of 4 randomised 
controlled trials of zinc supplementation in critical illness which showed no 
effect on mortality (RR 0.63, 95%CI 0.25 to 1.69)18.  
 
While trials to date have been inconclusive for the need for trace element 
supplementation in critical illness this does not necessarily mean that trace 
element status during critical illness is not important. Further work is required 
to examine the links between trace element status and outcome in critical care. 
As plasma trace elements are redistributed during the acute phase response an 
accurate measure of trace element status during the acute phase response is 
required. Having an assessment of trace element status during critical illness 
may also be helpful for guiding the need for supplementation; perhaps if robust 
supplementation trials were carried out on patients known to be deficient in 
trace elements positive results on morbidity and mortality would be more 
forthcoming. 
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1.4.2 Chronic inflammatory conditions 
 
If trace element status is important in critical illness due to increased free 
radicals and a relative decrease in circulating trace elements, them the same 
could be said for chronic inflammatory conditions such as inflammatory bowel 
disease, rheumatoid arthritis and chronic infections. These conditions are far 
more complex with the potential for a remitting course over many years, as 
opposed to an acute critical illness in a previously well individual. How this 
affects trace element status and whether supplementation would be beneficial 
is unknown. 
 
Chronic inflammatory conditions have additional potential risk factors for trace 
element deficiencies. While perhaps less likely to cause immediate problems in a 
previously well individual, decreased appetite, cachexia and malabsorption 
(especially in gastrointestinal inflammation) over a long period of time makes 
the patient with chronic inflammation at greater risk of trace element 
deficiency.  
 
As for critical illness, a robust measure of trace element status during 
inflammation would help establish the incidence of trace element deficiencies, 
risk factors and how quickly deficiency develops and if supplementation has 
benefit on long term outcomes. 
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1.5 Copper 
 
1.5.1 Copper and health 
 
Copper is an essential trace element because it is crucial for the activity of 
many enzymes including those involved in iron metabolism, antioxidant 
defenses, neuropeptide synthesis and immune function19. These include: 
 
• Ceruloplasmin – a ferroxidase necessary for the conversion of iron II to 
iron III in the plasma 
• cytochrome c oxidase – the terminal step in the electron transport chain 
• lysyl oxidase – essential for crosslinking between the polypeptide chains in 
collagen and elastase 
• tyrosinase – involved in the synthesis of melanin 
• dopamine hydroxylase – converts dopamine to noradrenaline 
• superoxide dismutase – destroys free radicals20 
 
1.5.2 Copper homeostasis 
 
Copper is absorbed in the duodenum. Copper is transported from the intestine to 
the liver, via the portal vein. Copper is stored in the liver and then redistributed 
to other organs. Copper status is regulated via the intestine by duodenal 
absorption and biliary excretion. High copper exposure will result in down-
regulation of duodenal absorption and increased biliary excretion21. 
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In plasma copper is mainly (90%) bound to the protein ceruloplasmin, with one 
molecule of ceruloplasmin containing six copper ions20. Hepatic synthesis of 
ceruloplasmin is dependent on adequate copper intake. As the majority of 
copper is bound to ceruloplasmin, plasma copper is in turn dependent on 
ceruloplasmin synthesis22.  
 
Copper concentration is highest in the brain, heart, liver and kidneys. Liver 
contains 10% of total body copper and muscle 30% 23.  
 
1.5.3 Effects of copper deficiency 
 
Copper deficiency is rare and is usually a result of severe malnutrition and/or 
malabsorption. Another possible cause is a high zinc intake which prevents the 
absorption of copper. The clinical features of copper deficiency include 
microcytic anaemia, neutropenia and osteoporosis20. 
 
Copper deficiency in the population has been related to cardiovascular disease. 
The original link was made as cattle with very low copper intake were dying 
from sudden cardiac death. Later studies examining the hearts of people who 
had died from ischaemic heart disease found a low concentration of copper in 
their cardiac tissue at autopsy24. Total cholesterol does increase in men fed a 
copper-deficient diet25 and it is also linked to impaired glucose tolerance26. 
Conversely, there are several epidemiological studies linking higher copper 
status with an increased incidence of risk factors for ischaemic heart 
disease27;28. 
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1.6 Zinc  
 
1.6.1 Zinc and health 
 
Zinc is an essential trace metal micronutrient as it is a constituent for more than 
150 enzymes, functioning at the active site, as a structural component or both. 
It is the most common catalytic metal ion in the cytoplasm of cells. Zinc 
metalloenzymes include carbonic anhydrase, alkaline phosphatase, 
carboxypeptidase, transferases, DNA/RNA polymerase, reverse transcriptase and 
superoxide dismutase20. Genes have recently been identified which are 
potentially regulated by zinc, some positively, some negatively. These include 
genes that regulate the redox state, signal transduction, growth factor activity 
and fatty acid synthesis and degradation. Zinc is necessary for insulin synthesis 
and action and also helps the stability of proinsulin and insulin by the formation 
of complexes29.  
 
1.6.2 Zinc homeostasis 
 
Zinc is absorbed in the proximal small intestine. It is then bound to 
(metallo)thionein, a protein which acts as a control over the supply of zinc to 
the blood stream by  having an increased synthesis when zinc intake is high and 
decreased synthesis when zinc intake is low. Metallothionein binds copper with a 
higher affinity than zinc which is why a high zinc intake can lead to copper 
deficiency20. Zinc is then transferred to the liver and released into the blood 
stream where is bound mainly to albumin (90 percent) and a2-macroglobulin (10 
percent)30. 
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1.6.3 Effects of zinc deficiency 
 
Symptomatic zinc deficiency is rare in developed countries and mainly seen in 
patients with malabsorption due to surgical resection of the small intestine 
without adequate parenteral supplementation20. However, it is a large problem 
in some developing countries where a combination of helmintic infestations, 
high phytate content in unleavened breads and high prevalence of diarrhoeal 
disease leads to a far greater number of severe deficiency states29. 
 
Features of zinc deficiency include poor wound healing, immune deficiency, 
decreased taste and a variety of dermatitis20. In severe cases, particularly 
chronic zinc deficiency, there can be stunted growth in children, hypopigmented 
hair, hypogondadism and delayed sexual maturation. Night blindness can occur 
due to secondary vitamin A deficiency as zinc is a coenzyme for the conversion 
of retinol to retinaldehyde by retinol dehydrogenase29.  
 
1.7 Selenium  
 
1.7.1 Selenium and health 
 
Selenium, as selenocysteine, is a component of many important selenoproteins 
which function as enzymes. The three most studied classes of selenoproteins are 
the glutathione peroxidases, the thioredoxin reductases and the deiodinases; in 
all of which selenium functions as a redox centre. 
 
Glutathione peroxidases are antioxidant enzymes. They reduce hydrogen 
peroxide, lipid and phospholipid hyproperoxides to water and alcohols12. 
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Thioredoxin reductases regulate transcription factors through redox control, 
regulate apoptosis, acts as a cytokine, a chemokine and stimulate eosinophils31.  
Deiodinases are required for the formation of tri-iodothyronine (T3) as they 
catalyse the deiodination of T4, thus generating T3, reverse T2 and T232. 
As such, selenium is felt to be an essential component of the immune system and 
antioxidant defence. 
 
1.7.2 Selenium homeostasis 
 
The two most common forms of selenium that are absorbed from the diet are 
selenomethionine from plants and selenocysteine from meat. Absorption takes 
place primarily in the duodenum with close to 100% of selenomethionine 
absorbed. Absorption appears to be independent of selenium status33.  
 
The primary tissues for uptake of selenium are heart, kidney, lung, liver, 
pancreas and muscle. Except for the lens of the eyes, the liver has the highest 
concentration of selenium in the body34.  
 
Selenium homeostasis is regulated by urinary (50-67%) and faecal (40-50%) 
excretion, with urinary excretion being the main system under physiological 
control33. 
 
1.7.3 Effects of Selenium deficiency 
 
The archetypical selenium deficiency state in humans is Keshan disease, a 
cardiomyopathy, possibly with coxsackie virus as a cofactor in its development. 
It has been seen in areas of rural China with very low levels of soil selenium with 
selenium supplementation virtually eliminating the disease12. Selenium 
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deficiency is a costly problem in farm animals grazing in selenium poor fields, 
known as white muscle disease as skeletal and cardiac muscle gets abnormal 
calcium deposition32.  
 
However, given its role in the immune system and antioxidant defences, 
selenium deficiency is hypothesised to be causally linked in a number of other 
conditions. Selenium appears to be important in HIV, with in vitro studies 
showing it can inhibit viral replication and selenium status being a strong 
predictor of outcome35. A recent randomised selenium supplementation study in 
patients with HIV helped support this theory by showing a decreased progression 
of viral burden and improvement in CD4 count with selenium supplementation36. 
 
The effect of selenium deficiency on other conditions has a far poorer evidence 
base, with associations seen in epidemiological analysis, not being backed up by 
consistent positive outcomes from supplementation studies; these conditions 
include cardiovascular disease, male infertility, and cancer. It is however 
possible that the reason that these trials have been inconclusive so far is that 
they have primarily been carried out in selenium replete areas of the world and 
positive results would be more likely in area with a selenium deplete 
population12. 
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1.8 Biomarkers of trace element status  
 
There are many potential blood components and tissues which can act as 
biomarkers for trace element status including plasma, erythrocytes, hair and 
measuring the activity of metal containing enzymes. 
 
1.8.1 Plasma 
 
Plasma concentration has been used in both clinical practice and in research as a 
biomarker for trace element status. It is easy to sample blood and is a sample 
type that patients are comfortable and familiar with. It requires little sample 
processing with centrifugation to separate the plasma, which is a familiar 
process in routine clinical biochemistry laboratories. 
 
There are however few studies showing that plasma is a reliable biomarker for 
any trace metal micronutrient22. For many trace elements, concentrations in 
plasma are low and dependent on protein binding. However, as homeostatic 
mechanisms may exist which maintain plasma levels within set concentrations 
except in severe deficiency, plasma trace elements may be more useful in 
identifying severe deficiency states. Plasma levels are generally presented in 
either simple mass or molar units. 
 
1.8.2 Erythrocytes 
 
Erythrocyte trace element concentrations are of interest as potential biomarkers 
of trace element status because, as circulating cells, they may reflect other 
cellular levels and act as a surrogate for tissue concentrations. As erythrocytes 
have a lifespan of 120 days they may be a marker of longer term status, however 
this may also have the disadvantage of changes in status not being seen for 
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several weeks. They may also be affected by blood transfusion. As per plasma, 
erythrocytes are easy to obtain, however they do require greater processing by 
the laboratory than many routine clinical samples23.  
 
Erythrocytes are separated by centrifugation of the sample; however this should 
happen quickly after sampling so as to avoid ion exchange. The plasma along 
with the leucocytes and platelets (buffy coat) need to be removed so as to avoid 
contamination. After centrifugation, the cells will be in a gradient from young to 
old and samples will either require homogenization or standardisation of the 
height of sampling23. Accurate pipetting of red cells is very difficult given their 
viscosity. Some feel that washing of the red blood cells in trace element-free 
isotonic saline solution is required to avoid contamination from plasma. All these 
steps and potential sources of inaccuracy make the use of erythrocytes in 
clinical practice challenging. 
 
Results from erythrocytes can be expressed in a number of ways with per litre of 
packed cells, per gram of haemoglobin, per number of cells and per gram of dry 
material most commonly used. However, expressing the results by a further 
measurement adds an additional analytical step and potential for yet more 
error. The haemoglobin concentration of red blood cells obtained via a standard 
haematology analyser and the iron concentration measured by ICP-MS have been 
found to correlate (r=0.93, p<0.001) over a  range of whole blood haemoglobin 
concentrations including anaemia (5.6-18.2 g/dL)2 providing an alternative way 
to express results. If iron can be measured simultaneously with trace elements 
on erythrocyte samples, some of the potential additional error would be reduced 
and analysis would be simplified. 
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1.8.3 Hair 
 
Body hair is a potential marker for long term trace element status. It is easy to 
obtain and can be sent over long distances using conventional post with no 
concerns about sample deterioration, but there is little evidence for its use in 
assessing nutritional status22. There are also many potential contaminants most 
notable shampoos and hair dyes which contain many trace elements. Using hair 
for monitoring for toxic trace elements is better established, with hair mercury 
felt to be a marker of chronic mercury exposure37.  
 
1.8.4 Other cell types 
 
Platelets, mononuclear and polynuclear cells can be used for trace element 
determination. These cells require larger sample sizes due to low concentrations 
of cells in whole blood, complicated separation techniques and fast processing 
times, making their use in routine practice limited. They also need to be 
expressed by either cell count or protein concentration adding a further 
analytical step (at low concentrations) with the potential for high error rates.  
 
1.8.5 Functional indices 
 
As part of the essentiality of trace elements is their incorporation into metallo-
enzyme, in which the trace element is essential for the enzyme’s function or 
activation, the measurement of metallo-enzyme activity may be an accurate 
measure of clinically significant deficiency. Examples of functional indices 
include superoxide dismutase, glutathione peroxidase and alkaline phosphatase. 
However, many of these enzymes are so vital that during deficiency the body 
will channel all of the available trace element to their production; resultantly 
the enzyme activity may not decrease until there is a very severe deficiency. 
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1.9 Study designs to assess biomarkers 
 
A useful biomarker of trace element status is one which reflects tissue status, 
decreases in deficiency states and increases with supplementation.  There are 
many studies that look at changes in biomarker concentrations or activity in 
patients who are given trace element supplements; however these studies are 
complicated as the trace element needs to be supplemented in a bio-available 
form. Also, as volunteers for such studies will be healthy and so be unlikely to 
have any trace element deficiencies, the response measured may be blunted 
compared to that of the more clinically relevant deficient patient. Inducing 
deficiency is also very difficult, not least due to ethical regulations; subjects 
would have to be supplied with a specially made diet deficient in the element of 
interest for several weeks, and comply fully in order to detect any change in 
status.  
 
Several studies have looked at the trace element concentrations in the organs of 
the deceased undergoing autopsy. This of course does not allow for comparison 
with blood concentrations.  
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1.10 Assessing copper status 
 
1.10.1 Plasma copper 
 
Plasma copper is the most frequently used biomarker of copper status. While 
plasma copper does decrease in copper deficiency states, it plateaus when 
adequate intake is reached and no longer reflects intake. 22.  
 
A meta-analysis of copper supplementation studies with plasma copper as the 
outcome measure, including 2 supplementation studies and 2 depletion studies 
(total of 35 participants), showed no response of plasma copper to 
supplementation; copper supplementation/depletion altered the mean plasma 
copper concentration by 1.02 µmol/L (95% CI -0.92, 2.96)38. However in a study 
of 17 children recovering from malnutrition and copper deficiency, copper 
supplementation resulted in a mean increase in plasma copper of 10.48 µmol/L 
(95% CI 2.35, 18.61)39.  
 
The evidence for plasma copper to reflect copper status marked by a response 
to copper supplementation or depletion is very limited; however, there is some 
evidence of its use in monitoring copper repletion in previously deplete patients.  
 
Plasma copper can be affected by the sex of the patient and especially the use 
of hormone treatments and pregnancy. This is because ceruloplasmin 
concentrations increase in the presence of oestrogens with women resultantly 
having higher plasma copper than men, and hormone treatments and pregnancy 
resulting in large increases in plasma copper, often above the population 
reference interval40. 
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1.10.2 Ceruloplasmin 
  
A similar meta-analysis of copper supplementation studies with plasma 
ceruloplasmin as the outcome measure included 8 supplementation and 2 
depletion studies (total of 100 participants)38. In contrast to plasma copper, 
ceruloplasmin responded to changes in copper intake with a mean increase of 
0.035 g/L (95% CI -2.08, 3.77) (p=0.03).  
 
When the data was split into those who were either copper replete or deplete at 
baseline, ceruloplasmin only increased significantly in those studies where the 
participants were copper deplete at baseline. In those who were copper replete 
the mean difference was -0.009 g/L (95% CI -0.03, 0.011) but in those deplete at 
baseline it was 0.258 g/L (95% CI 0.225, 0.29) (p<0.001)38.  
 
So, as with plasma copper, while the volume of evidence is low, ceruloplasmin 
appears to respond to copper supplementation when the patient is deplete at 
baseline.  
 
1.10.3 Erythrocyte Copper/Zinc Superoxide Dismutase 
 
Erythrocyte Copper/Zinc Superoxide Dismutase (SOD) is a copper containing 
enzyme which has been assessed as a potential biomarker of copper status. A 
meta-analysis of the results of 6 copper supplementation and 2 copper depletion 
studies (97 participants in total) showed no effect of the intervention on 
erythrocyte SOD activity; mean increase 51.05 U/g Hb (95% CI -54.96, 157.06)38. 
However it should be noted that the time scale of these studies ranges from 30-
91 days which is within the lifespan of erythrocytes so may not have been 
sufficiently long enough to see a difference in an erythrocyte measurement. 
Also, the meta-analysis took no account for methodological validity of the assays 
used in the studies. 
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1.10.4 Erythrocyte Copper 
 
There are no studies evaluating the use of erythrocyte copper as a marker of 
copper status. However, compared to plasma, red blood cell copper does not 
increase with oral contraceptive use41. 
 
1.10.5 Liver copper  
 
As the liver is one of the main stores of copper, liver copper concentration is felt 
to be the only precise indicator of copper load42. A study of autopsy material 
from healthy young adults who were accident victims showed that the liver had 
the highest concentration of copper of all the available tissues43. 
 
The decrease in liver copper during copper deficiency was shown through 
autopsy results of children dying of malnutrition compared to children dying of 
other causes; controls had a higher mean liver copper concentration (22.4 µg/ g 
dry weight) versus children who had died from kwashiorkor (3.9 µg/ g dry 
weight) or marasmus (12.8 µg/ g dry weight)44.  
 
1.10.6 Effects of the acute phase response 
 
Ceruloplasmin is an acute phase reactant and therefore its concentration is 
increased during the acute phase response due to increased hepatic synthesis; as 
ceruloplasmin is the main copper carrying protein in plasma, plasma copper 
concentration also increases45. As such, changes in copper seen during the acute 
phase response are of a similar magnitude to changes seen in ceruloplasmin 
concentration46.  
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The rise in ceruloplasmin concentration, and therefore the rise in plasma copper 
concentration, is late in the acute phase response, with the maximum rise seen 
after 7 days. In studies following patients with an acute phase response to 
surgery, major surgery resulted in copper concentrations that were 30% higher46 
while with minor surgery they were 12% higher47. 
 
 A study which followed erythrocyte copper both immediately before and 3 days 
after elective knee arthroplasty showed no difference in erythrocyte copper 
concentration despite the evolution of the acute phase response2.  
 
1.11 Assessing zinc status 
 
1.11.1 Plasma zinc 
 
Plasma zinc is the most widely used biomarker of zinc status despite being 
acknowledged to have poor sensitivity and specificity22. It is the only 
biochemical measure recommended by the World Health Organisation for the 
assessment of the zinc status of populations48.  
 
A meta-analysis of zinc supplementation studies with plasma zinc as the 
outcome measure, including 35 supplementation studies and 10 depletion studies 
(total of 1454 participants), showed a significant response of plasma zinc to 
dietary zinc intake; zinc supplementation/depletion altered the mean plasma 
zinc concentration by 2.9 µmol/L (95% CI 2.2, 3.5)49.  
 
The number of participants in this meta-analysis allowed subgroup analysis to 
assess the validity of plasma zinc as a biomarker of dietary zinc intake in a 
variety of age groups and baseline zinc statuses. The usefulness of zinc as a 
biomarker of zinc intake was unclear in children and adolescents, post-
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menopausal women and those with high-normal status at baseline, however this 
may have been confounded by very small numbers of studies in these group49.  
 
1.11.2 Erythrocyte Zinc 
 
In a meta-analysis of studies of erythrocyte zinc as a marker of dietary intake, 5 
supplementation and 2 depletion studies were included. Neither the meta-
analysis nor any individual study suggested a significant change in red blood cell 
zinc in response to changes in dietary intake. Importantly, the majority of these 
studies were of >20 weeks duration so far greater than the lifespan of red blood 
cells, and changes would have be expected if erythrocyte zinc was an accurate 
biomarker of intake49. 
 
1.11.3 Mononuclear cell, polynuclear cell and platelet zinc 
 
Meta-analysis of 5 supplementation studies suggested that mononuclear cell zinc 
is not a useful biomarker with a mean difference in concentration of -0.05 
µmol/1010 cells (95% CI -0.21, 0.11)49.  
Pooling of results from 5 supplementation and 1 depletion study evaluating 
polynuclear cell zinc as a biomarker of zinc intake revealed no significant 
response to changes in zinc intake49.  
 
Platelet zinc was examined in 2 supplementation and 3 depletion studies; meta-
analysis did not show a significant response to zinc supplementation or depletion 
with a mean difference of 0.09 nmol/109 cells (95% CI -1.12, 1.30)49.  
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1.11.4 Hair Zinc 
 
Hair zinc was examined in 3 supplementation studies which included a total of 
93 participants with either low or moderate zinc intakes. Hair zinc was found to 
increase significantly after supplementation with a mean difference of 13.24 
ppm (95% CI 11.91, 14.56)49.  
 
1.11.5 Plasma alkaline phosphatase activity 
 
Alkaline phosphatase is a zinc dependent metalloenzyme20. 6 studies were 
pooled in a meta-analysis; 3 supplementation and 3 depletion studies. No 
significant change in activity was found with changes in zinc intake with a mean 
difference of 4.14 IU/L (95% CI -2.38, 10.66)49. 
 
1.11.6 Liver zinc 
 
5% of zinc is stored in the liver, 30% in bone and 60% in skeletal muscle with the 
majority of the remainder intra-cellular or bound to protein in plasma23. A study 
of autopsy material from healthy young adults who were accident victims 
showed that the liver had the highest concentration of zinc of all the available 
tissues43. 
Liver zinc has been shown to be lower in cases of malnutrition in children.  Zinc 
deficiency was shown through autopsy results of children dying of malnutrition 
compared to children dying of other causes; controls had a higher mean liver 
zinc concentration (163.0 µg/ g dry weight) versus children who had died from 
kwashiorkor (31.4 µg/ g dry weight) or marasmus (102.5 µg/ g dry weight)44.  
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1.11.7 Effects of acute phase response 
 
Plasma zinc is a negative acute phase reactant. After major surgery, serum zinc 
falls by 40-50% within 6 hours46. This fall is medicated by cytokines which 
promote the uptake of zinc by the liver where it is used for the synthesis of new 
proteins50. There is also a local role around the site of inflammation, possibly 
immunological or tissue regeneration51. The majority of the decrease in zinc can 
be related to the decrease in albumin, it main carrier protein, but there is a 
drop in zinc further to the decrease in albumin seen through a decrease in the 
zinc: albumin ratio46.  
 
Erythrocyte zinc was studied in patients undergoing elective knee arthroplasty. 
There was no difference in erythrocyte zinc concentration 3 days after surgery 
compared to values from immediately before surgery, despite the evolution of 
the acute phase response2. 
 
1.12 Assessing Selenium status 
 
1.12.1 Plasma selenium 
 
Plasma selenium is the most commonly used biomarker of selenium status. Its 
usefulness as a biomarker was confirmed in a meta-analysis of selenium 
supplementation studies with plasma selenium as the outcome measure, 
including 9 randomised supplementation studies (total of 512 participants). 
Selenium supplementation significantly increased plasma selenium concentration 
with a  mean difference in  plasma selenium concentration of  0.9 µmol/L (95% 
CI 0.67, 1.14)52. Subgroup analyses confirmed the usefulness of plasma selenium 
as a biomarker of selenium intake in participants with low, medium or high 
status at baseline and for a wide variety of dosing regimes. 
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1.12.2 Erythrocyte selenium 
 
In a meta-analysis of studies investigating the use of erythrocyte selenium as a 
marker of dietary intake, 6 supplementation studies were included. Two studies 
reported results in micromoles per litre and four in nanomoles per gram of 
haemoglobin so the results could not be combined. However, using both 
measures erythrocyte selenium increased significantly with supplementation. 
Mean increases in erthryocyte selenium were 1.4 µmol/L (95% CI 1.16, 1.64) and 
1.48 nmol/g Hb (95% CI 0.45, 2.52)52. All these studies gave the supplement for 
at least 8 weeks allowing time for erythrogensis.  
 
 
1.12.3 Whole blood selenium 
 
Four supplementation studies were assessed in a meta-analysis to examine the 
usefulness of whole blood selenium as a marker of dietary intake. Whole blood 
selenium increased significantly with supplementation with a mean increase in 
whole blood selenium of 1.07 µmol/L (95% CI 0.39, 1.76)52. 
 
1.12.4 Plasma glutathione peroxidase activity 
 
Glutathione peroxidase (GPx) is a selenium containing metallo-enzyme. The 
usefulness of plasma GPx activity as a marker of dietary intake was examined in 
a meta-analysis of 8 supplementation studies (319 participants).  Plasma GPx 
was found to be a useful marker with a mean increase of 0.37 µmol NADPH 
oxidised.min-1.g protein-1 (95% CI 0.15, 0.60)52. 
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1.12.5 Platelet glutathione peroxidase activity 
 
In a meta-analysis of four supplementation studies (109 participants) platelet 
GPx was found to increase significantly with platelet supplementation; mean 
difference 69.4 U/g protein (95% CI 12.6, 126.2)52. 
 
1.12.6 Whole blood glutathione peroxidase activity 
 
Four studies, which included 73 participants, of selenium supplementation were 
included in a meta-analysis. Whole blood GPx increased significantly with 
selenium supplementation with a mean difference of 3.18 U/g Hb (95% CI 0.07, 
6.29)52. 
 
1.12.7 Erythrocyte glutathione peroxidase activity 
 
Three randomised trials of selenium supplementation measuring erythrocyte GPx 
activity were combined in a meta-analysis. This only included 23 participants 
receiving supplementation and no significant difference in erythrocyte GPx 
activity was seen with a mean difference of 3.37 µmol NADPH oxidised.min-1.g 
haemoglobin-1 (95% CI -0.99, 7.74)52. All these studies gave the supplement for at 
least 8 weeks allowing time for erythrogenesis.  
 
1.12.8 Plasma Selenoprotein P 
 
Selenoprotein P is the most common selenoprotein found in the plasma. A meta-
analysis of three selenium supplementation studies (68 participants) showed a 
statistically significant increase in plasma selenoprotein P concentration with 
selenium supplementation; mean increase 2.19 µg/mL (95% CI 0.25, 4.12)52. 
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1.12.9 Liver selenium 
 
Liver selenium has been relatively poorly studied with no report of liver 
concentrations from patient likely to have severe nutritional deficiencies. There 
are however several autopsies studies that have reported liver selenium 
concentrations; these results range from a mean of 0.3 µg/g wet weight in 
patients from New Zealand53, an area known to have low selenium levels, to 0.54 
µg/g wet weight  in patients from the USA where soil selenium is far higher54.  
 
1.12.10 Effects of acute phase response 
 
Selenium is a negative acute phase reactant; patients in an intensive care unit 
were found to have plasma selenium concentrations 40-60% lower than the 
population reference interval55. Plasma selenium was also found to fall after 
minor surgery, with a 10% decrease after 24 hours47. One case report showed a 
reciprocal relationship between the fall and rise in plasma selenium and the rise 
and fall of C-reactive protein during the acute phase response in a patient with a 
constant selenium intake due to total parenteral nutrition56. 
Erythrocyte selenium has been studied in patients undergoing elective knee 
arthroplasty. No difference was found in erythrocyte selenium concentration 3 
days after surgery compared to values from immediately before surgery, despite 
the evolution of the acute phase response2. 
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1.13 Methods for the measurement of trace element concentrations 
 
1.13.1 Pre-analytical considerations, sample collection and preparation 
 
As trace elements are at low concentrations, they are very susceptible to 
contamination. Sources of contamination include needles and surgical blades, 
where stainless steel has been found to increase the concentration of cobalt and 
nickel. Powder in surgical gloves can also cause contamination, as can skin, 
sweat and dust on glassware. Recommendations for sample collection and 
handling therefore include powder-free plastic gloves, ultra-pure reagents and 
water and acid washing of laboratory containers57. 
 
For the collection of blood in clinical setting, special tubes are available which 
are contaminant free. They contain sodium heparin as the anticoagulant as it is 
does not contain potentially contaminating trace elements; EDTA can contain 
both chromium and zinc. 
 
Tissue samples will require cutting and trimming; while the use of stainless steel 
knives is a potential source of contamination, studies have not shown any effect 
on the measurement of aluminium, cadmium, chromium, copper, mercury, 
nickel, lead or selenium. However, it is considered good practice to use a 
titanium knife for the preparation of samples for trace element analysis58. 
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1.13.2 Analytical techniques for the measurement of trace elements 
 
There are four main spectrochemical techniques for the measurement of trace 
element concentration: flame atomic absorption spectrometry (FAAS), graphite 
furnace atomic absorption spectrometry (GFAAS), inductively coupled plasma 
atomic emission spectrometry (ICP-AES) and inductively coupled plasma mass 
spectrometry (ICP-MS)57.  
 
1.13.2.1 Flame atomic absorption spectrometry 
 
The element is dissociated from its chemical bonds by a flame but it left in a 
neutral state. A beam is produced by a hollow cathode lamp with a cathode 
made from the element under study. The ground-state atoms in the flame will 
absorb the light thus decreasing the light detected at the detector4.  
 
This technique is limited by requirements for an aqueous sample with a volume 
of several millilitres and high limits of detection making precision very poor for 
samples with concentrations at µg/L levels and below57.  
 
1.13.2.2 Graphite furnace atomic absorption spectrometry 
 
GFAAS is a similar technique to FAAS, however instead of a flame the 
atomisation occurs in a graphite furnace heated by an electrical current. A small 
sample size is required (5-100µL) and the sample is dried, charred and atomized 
in the furnace. Absorption using a hollow cathode lamp is identical to FAAS57. 
 
There are many advantages to GFAAS over FAAS. These include a far lower limit 
of detection (as low as 0.01 µg/L) and smaller sample size. The technique also 
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allows for correction of background signal (the Zeeman Effect): the analyte is 
placed in a pulsed magnetic field, splitting the absorption signal into high and 
low wavelengths that can be detected separately to background absorption. The 
graphite furnace allows a variety of solid and slurry sample types to be used, 
rather than limiting to aqueous samples. GFAAS does take longer than FAAS but 
multi-element technology is becoming available59. 
 
1.13.2.3 Inductively coupled plasma atomic emission spectrometry 
 
Inductively coupled plasma is a mix of argon, argon ions and electrons and can 
conduct electricity; it is produced by atomisation and ionisation of argon gas by 
a high-energy, radio-frequency field and reaches an excitation temperature of 
7000-10,000˚K. A sample is sprayed into the plasma as an aerosol mixed with 
argon gas and the sample is excited, atomised and ionised. The electrons in the 
sample are unstable in a high-energy state and release their excess energy as 
photons of a certain wavelength; in atomic emission spectrometry this light is 
detected. Line spectra of wavelengths of light emitted are specific for each 
element60.  
 
ICP-AES does have multi-element capability, either simultaneously or 
sequentially, but the limit of detection is high and similar to FAAS. ICP has a 
wide linear dynamic range allowing analysis of several elements covering a range 
of concentrations in the same sample57.  
 
1.13.2.4 Inductively coupled plasma mass spectrometry (ICP-MS) 
 
ICP-MS combined inductively coupled plasma as an ion source and a mass 
spectrometer. Mass spectrometers separate the sample on the basis of mass: 
charge ratio by using one of a variety of techniques to ensure only ions with the 
mass: charge ratio of interest reaches the detector; one way to do this is a 
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system of rods with rapidly charging voltage and polarity that cause all other 
ions except for those of interest to follow a corkscrew trajectory, while the ions 
of interest continue in a stable path4.  
 
The ICP-MS offers all the advantages of inductively coupled plasma (high linear 
dynamic range) with the extremely low detection limits of mass spectrometry. 
Multi-element analysis screening is simple and efficient with low sample volumes 
required and allowance for low concentration samples61. 
 
A diagram summarising the principles of spectrochemical techniques can be seen 
in figure 1.1  
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Dilution/ Digestion/ 
preconcentration
Atomisation/ 
ionisation
Light
Wavelength 
selector
Absorbance
(FAAS, 
GFAAS)
Emission
(ICP-AES)
Wavelength 
selector
Light 
detector
Signal 
processor
Mass 
spectrometry
(ICP-MS)
 
Fig 1.1 Summary of spectrochemical techniques. Reproduced from Bolann et al, 
Scan J Clin Lab Invest 200757, with permission. 
 
1.13.3 Interferences 
 
Spectrochemical methods are subject to interference which can be divided into 
matrix and spectral interferences. 
 
Matrix interferences are either physical interferences from dissolved solids or 
chemical interferences from chemical reactions that happen during the 
atomisation process. The physical interferences can occur in all methods but are 
more severe in ICP-MS; methods to minimise these interferences include matrix 
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matching of standards and blanks to the sample, chemical separation methods, 
standard additions or sample dilution62. Chemical interferences are common in 
FAAS and GFAAS when the analyte can form new compounds that act differently 
to the standards use; background correction methods and standard addition can 
help to control these problems62. 
 
Spectral interferences can occur in ICP-AES when there is wavelength overlap 
from an interfering element; the use of high resolution spectrometers, or 
selection of an alternative wavelength, are possible methods to reduce spectral 
interferences63. In ICP-MS spectral interferences can be causes by the isotope of 
another element (isobaric interference), doubly charge ions or polyatomic ions 
such as those formed with argon (polyatomic interference) having the same mass 
number as the analyte; these interferences are predictable and the solution is to 
measure an isotope of the analyte that is less abundant but less prone to 
interferences64. 
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1.14 Magnesium  
 
Magnesium is not a trace element; it is the fourth most abundant mineral in the 
body65. Magnesium is the main intracellular divalent cation and is essential for 
all energy-dependent transport systems, glycolysis, and oxidative energy 
metabolism as well as being an integral part of intracellular signalling pathways, 
receptor activity and phosphorylation pathways66.  
Despite its importance to normal physiology, a suitable biomarker of tissue 
status has not yet been found67. As it can be measured using the same analytical 
techniques as those used for trace element analysis it was included within this 
study. 
 
1.14.1 Magnesium and health 
 
There has been increasing interest in magnesium status and the effects on 
human health. This is particularly true of cardiovascular disease and diabetes 
and is due to magnesium’s role in pathways for glucose metabolism, anti-
arrhythmic effects, role in platelet aggregation and relaxation of vascular 
smooth muscle tone66. Magnesium is a vital component of muscle insulin tyrosine 
kinase and hypomagnesaemia can result in impaired glucose uptake68.  
 
The effects of magnesium are utilised through its role as a therapeutic agent. 
Intravenous magnesium therapy is now established as part of the treatment of 
acute severe asthma69; in women with pre-eclampsia, intravenous magnesium 
was effective in prophylaxis of seizures70. High doses of intravenous magnesium 
are given during cardiac surgery to stabilise the myocardium and it is also used 
in the management of arrhythmias71.  
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There is however less evidence for the use of magnesium supplementation in 
chronic conditions. Patients with type 1 and type 2 diabetes have been shown to 
have lower serum magnesium concentrations than non-diabetic controls72;73, and 
the magnesium concentration appears to be inversely correlated with glycaemia 
and complications74, however there have been no successful supplementation 
studies showing an improvement in these factors with increasing magnesium 
concentration, suggesting that the link may not be causal75. 
 
1.14.2 Magnesium homeostasis 
 
Magnesium is distributed between bone (65%), the intracellular space (34%) and 
the extracellular fluid (1%)66.  Magnesium is absorbed in the small intestine, in 
part under the influence of vitamin D, with 30-50% of dietary intake absorbed76; 
the percentage of the dietary intake that is absorbed decreases with increased 
intake, aging and chronic renal impairment. Magnesium absorption can be up-
regulated by as much as 40% during deficiency77. 
 
Magnesium is excreted in the urine, determined by the rate of filtration and 
tubular reabsorption. Urinary magnesium excretion is increased during a high 
natriuresis, high osmotic load and metabolic acidosis77. 
 
1.14.3 Effects of Magnesium deficiency  
Magnesium deficiency can present as muscle weakness, convulsions, tetany or 
cardiac arrhythmias. As magnesium is required for parathyroid hormone 
secretion, the major symptoms can be related to hypocalcaemia. Refractory 
hypokalaemia, due to the renal tubules selectively reabsorbing magnesium 
ahead of potassium, is often the main issue raising concern. Both hypokalaemia 
and hypocalcaemia will improve on magnesium supplementation78. 
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1.14.4 Assessing Magnesium status 
 
Despite magnesium having many vital physiological functions, biomarkers of 
tissue status have been poorly investigated, with serum/plasma magnesium 
being the most commonly used marker. 
 
1.14.4.1 Magnesium retention test 
 
The magnesium retention test is a physiological balance study which examines 
magnesium retention post magnesium infusion. It does this through 
measurement of urinary magnesium excretion in the 24 hours after an oral or 
intravenous magnesium load; obviously it relies on normal renal function79. 
Retention of magnesium is thought to be higher in magnesium deficient patients 
and it has been used to investigate the validity of other magnesium biomarkers.  
The major problem with the magnesium loading test is the lack of a standard 
protocol leading to variation in the result achieved, and lack of any evidence 
that the deficits measured are proportional to the total body magnesium 
deficit67. 
 
1.14.4.2 Serum magnesium 
 
Serum magnesium is the most commonly measured biomarker of magnesium 
status. However, there is very little evidence that is reflects total body status. 
Patients with critical illness who had high magnesium retention on retention 
testing did not have a serum magnesium level that would have allowed them to 
be differentiated from those with normal magnesium retention80, though 
whether this reflects the lack of usefulness of serum magnesium, magnesium 
retention testing or both is unclear.  
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Certainly serum magnesium concentrations do increase with oral magnesium 
supplementation. In a study where patients with type 2 diabetes were given 30 
mmol oral magnesium per day for three months, their serum magnesium 
increased to that of a non-diabetic control72.  
 
The main problem with serum magnesium as biomarker of magnesium status is 
that, as it is has such a vital physiological role, the serum concentration will be 
maintained via homeostasis for as long as the total body magnesium allows; by 
the time it is depleted, body stores will be very low.  
 
1.14.4.3 Ionised Magnesium 
 
Ionised magnesium is fraction of plasma magnesium that is not bound to albumin 
or other proteins, and is felt to be the biologically active fraction of total 
plasma magnesium; it is measured using an ion-selective electrode. There are 
very few studies including ionised magnesium, but those that have investigated 
it have found strong correlation with total serum magnesium questioning its 
advantage. One possible advantage may be in critical illness where albumin 
concentration decrease may affect the total serum magnesium but leave the 
ionised fraction within the normal range81. 
 
1.14.4.4 Erythrocyte Magnesium 
 
It is hypothesised that erythrocyte magnesium is an indicator of long-term 
magnesium status and deficiency82. In a study of 12 post-menopausal women 
who were placed on a magnesium deficient diet for 93 days, followed by a 
magnesium repletion diet for 49 days, erythrocyte magnesium concentration 
decreased significantly from baseline during the depletion phase and increased 
again during the repletion phase. In a study of 34 children recently diagnosed 
with type 1 diabetes, erythrocyte magnesium was found to negatively correlate 
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with magnesium retention after a loading test (r=-0.44; p<0.01) when serum 
magnesium did not, leading the authors to suggest that erythrocyte magnesium 
concentration may be a more sensitive test83.  
 
1.14.4.5 Leukocyte Magnesium 
 
Lymphocytes have been suggested as a potentially useful biomarker of tissue 
magnesium deficiency as studies of induced magnesium deficiency in rats have 
shown that the lymphocyte magnesium concentration decreases at a similar rate 
to that of cardiac and skeletal muscle84.  
 
One study in 30 patients with Crohn’s disease showed a significant increase in 
mononuclear cell magnesium concentration after an intravenous infusion of 60 
mmol magnesium85. However, a study of patients in intensive care who were 
receiving intravenous magnesium infusions for hypomagnesaemia (diagnosed by 
serum concentration), showed no increase in intracellular magnesium 
concentration86; this may be due to the diagnosis being made via serum 
concentration and thus the patients may not have had an intracellular 
magnesium deficiency at baseline. 
 
1.14.4.6 Muscle Magnesium 
 
Given that skeletal muscle is a major store and utiliser of magnesium, muscle 
seems a sensible tissue to use as a surrogate of total body status. Muscle 
magnesium is an indicator of long-term magnesium status and deficiency82. In a 
study of 12 post-menopausal women who were placed on a magnesium deficient 
diet for 93 days, followed by a magnesium repletion diet for 49 days, muscle 
magnesium concentration decreased significantly from baseline and increased 
again during the repletion phase87. This correlated with erythrocyte magnesium 
concentration and negatively correlated with magnesium retention. 
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One study compared serum magnesium and muscle magnesium concentrations in 
patient with chronic obstructive pulmonary disease and acute respiratory 
failure: low muscle magnesium concentration was found in 47% of the patients 
with normal serum magnesium concentration88.   
 
1.14.4.7 Effects of acute phase response 
 
There are no studies which have followed changes in magnesium status 
throughout the development and resolution of the acute phase response. The 
changes in magnesium concentration during the acute phase response are of 
interest given the increased medical attention given to magnesium replacement 
during acute illness. Albumin, which decreases during the acute phase response, 
has a linear relationship with serum magnesium concentration at concentrations 
below the reference interval, due to around 25% of circulating magnesium being 
bound to albumin89.  
 
Total and ionised serum magnesium concentrations were compared in patients in 
intensive care units; 51.3% of patients had a total serum magnesium 
concentration below the reference interval, however, only 29% of these patients 
had an ionised magnesium concentration below the reference interval. This led 
the authors to conclude that the low total serum magnesium concentrations seen 
were a result of the acute phase response and not a true representation of body 
status, and the ionised magnesium should be used in critically ill patients. 
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1.15 Suitable tissues to act as a maker for whole body trace element status 
 
In order to identify suitable biomarkers of trace element status, a suitable 
surrogate for whole body status is required for comparison. Tissue would seen a 
suitable material for this and it would have to have a high concentration of the 
trace element of interest, preferably a role in metabolism and homeostasis and 
be known to vary it’s concentration in response to depletion and repletion. It 
also has to be a tissue that can be easily and ethically sampled. Liver and 
skeletal muscle would fulfil these roles. 
As outlined in the preceding sections: 
The liver is one of the main stores of copper42 and decreases in copper 
deficiency44.  
5% of zinc is stored in the liver23. Liver zinc has been shown to be lower in cases 
of malnutrition in children44.  
Except for the lens of the eyes, the liver has the highest concentration of 
selenium in the body34.  
Skeletal muscle is a major store and utiliser of magnesium with evidence of 
change in magnesium concentration with depletion and repletion87. 
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1.16 Summary  
 
Trace elements and magnesium have an important role in human health. The 
availability of simple and reliable biomarkers for their status is invaluable for 
further clinical research into the efficacy of supplementation regimes. There is a 
particular problem of measuring trace element status during acute and chronic 
illnesses, when changes in binding proteins due the acute-phase response lead to 
changes in plasma levels of trace elements.  
 
There have been limited studies of biomarkers during depletion and 
supplementation, but these have only studied blood markers and not the 
concentrations in tissues where the trace elements and magnesium are stored 
and utilised.  
 
To further the evidence base in this area the trace element and magnesium 
concentration in human liver and skeletal muscle will be compared to plasma 
and erythrocyte concentrations to ascertain if they are a suitable biomarker for 
tissue status. The effects of the acute phase response on trace element and 
magnesium concentration in plasma and erythrocytes will also be studied and 
related to the initial tissue concentrations.  
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1.17 Thesis aims 
 
1. To establish the relationship between liver, muscle, plasma and 
erythrocyte selenium (including glutathione peroxidase activity), zinc, 
copper (including ferroxidase activity and ceruloplasmin mass) and 
magnesium concentrations in individuals with no systemic inflammation. 
 
2. To determine the changes in plasma and erythrocyte selenium (+ 
glutathione peroxidase), zinc, copper (+ ferroxidase activity and 
ceruloplasmin mass) and magnesium concentrations during the evolution 
of the acute phase response. 
 
3. To investigate factors that affect the magnitude of any change in plasma 
and erythrocyte selenium (+ glutathione peroxidase), zinc, copper (+ 
ferroxidase and Ceruloplasmin mass) and magnesium concentrations 
during the evolution of the acute phase response; these include baseline 
tissue concentration, change in albumin and other binding protein 
concentrations and baseline plasma and erythrocyte concentration. 
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1.18 Thesis objectives 
 
1. To establish methods for the measurement of plasma and erythrocyte 
selenium, zinc, copper and magnesium that will be simple to perform in 
the routine clinical biochemistry laboratory and reproducible to a 
standard acceptable for a clinical assay. 
 
2. To establish methods for whole blood and erythrocyte glutathione 
peroxidase that will be simple to perform in the routine clinical 
biochemistry laboratory and reproducible to a standard acceptable for a 
clinical assay. 
 
3. To develop a laboratory reference interval for whole blood and 
erythrocyte glutathione peroxidase. 
 
4. To design a study using a suitable patient cohort that will allow paired 
blood and tissue samples (liver and skeletal muscle) to be taken when 
there is no systemic inflammation (low C-reactive protein) and also allow 
blood sampling during the evolution of the acute phase response. 
 
5. To question how the results will affect clinical practice and suggest what 
further studies would be required in this area. 
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Chapter 2 
Trace Element and Magnesium Methods: 
Acid digestion and inductively coupled plasma mass spectrometry 
 
2.1 Principle of the method 
 
Samples (tissue, cells or plasma) were digested in nitric acid therefore breaking 
down all protein structures but leaving the trace element micronutrients 
unchanged, thus removing any potential matrix interference in the method.  
The inductively coupled plasma mass spectrometer (ICP-MS) ionises trace 
elements in high temperature plasma. The ions produced are separated by mass 
spectrometry and the response on the detector system is proportional to their 
concentrations. 
 
2.2 General points 
All plastic and Pyrex test tubes used in these methods were pre-washed with 20% 
nitric acid prior to use to decrease the incidence of trace metal contamination. 
All experimental results were performed in duplicate and the mean result is 
presented in the results section. 
 
2.3 Specimen Requirements 
 
2.3.1 Human tissue samples  
 
Approximately 75mg of human liver or muscle sample was used. Samples were 
stored at -50˚C and defrosted before use. The samples were trimmed using a 
titanium knife to avoid metal contamination. 
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2.3.2 Red blood cells 
 
100µl of red blood cells were required. Red blood cells are obtained from blood 
collected in specialist sodium heparin trace element-free blood tubes. The 
samples were separated by centrifugation within 4 hours of collection. The 
plasma was removed along with careful removal of the buffy coat by pipette. 
Red blood cells were stored at -50˚C and defrosted before use. 
 
2.3.3 Plasma 
 
100µl of plasma was required. Plasma was obtained from blood collected in 
specialist sodium heparin trace element-free blood tubes. The samples were 
separated by centrifugation within 4 hours of collection. The plasma was 
removed by pipette, carefully avoiding contamination with the buffy coat. 
Plasma was stored at -50˚C and defrosted before use. 
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2.4 Reagents 
 
Nitric Acid. 60% UltraPur Grade (McQuilken, East Kilbride, UK) 
Copper Standard 1000mg/L Spectrosol Grade (BDH Prolabo, Lutterworth, UK) 
Zinc Standard 1000mg/L Spectrosol Grade (BDH Prolabo, Lutterworth, UK) 
Selenium Standard 1000mg/L Spectrosol Grade (BDH Prolabo, Lutterworth, UK) 
Magnesium Standard 1000mg/L Spectrosol Grade (BDH Prolabo, Lutterworth, UK) 
Iron Standard 1000mg/L Spectrosol Grade (BDH Prolabo, Lutterworth, UK) 
Scandium Standard 1000mg/L Spectrosol Grade (BDH Prolabo, Lutterworth, UK) 
Germanium ICP Standard 1000mg/L (Merck Chemical, Darmstadt, Germany) 
 
All reagents were stored at room temperature and were stable until expiry date. 
 
2.5 Standards  
 
2.5.1 Human Tissue Samples 
 
A stock standard was made containing: 
3.5mL of 1000mg/L Magnesium Standard 
1mL of 1000mg/L Copper Standard 
700µL of 1000mg/L Zinc Standard 
20µL of 1000mg/L Selenium Standard 
This was made up to 100mL with 1% UltraPur nitric acid. 
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Working standards were made, and stored at room temperature, using dilutions 
outlined in table 2.1a, which resulted in standards with concentrations as seen 
in table 2.1b. 
Standard Stock Standard 1% UltrPur nitric acid 
1 0 µL 20 mL 
2 25 µL 19.975 mL 
3 50 µL 19.95 mL 
4 200 µL 19.8 mL 
5 1 mL 19 mL 
6 4 mL 16 mL 
7 20 mL 0 mL 
Table 2.1a Dilutions required for stock standard for tissue trace element 
analysis 
 
 
 Conc. of 
Std 1 
(µg/L) 
Conc. of 
Std 2 
(µg/L) 
Conc. of 
Std 3 
(µg/L) 
Conc. of 
Std 4 
(µg/L) 
Conc. of 
Std 5 
(µg/L) 
Conc. of 
Std 6 
(µg/L) 
Conc. of 
Std 7 
(µg/L) 
Mg 0 43.75 87.5 350 1750 7000 35000 
Cu 0 12.50 25 100 500 2000 10000 
Zn 0 8.75 17.5 70 350 1400 7000 
Se 0 0.25 0.5 2 10 40 200 
Table 2.1b Concentrations of working standards for tissue trace element 
analysis 
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2.5.2 Red blood cell and plasma samples 
 
A stock standard was made containing: 
10mL of 1000mg/L Iron Standard 
5mL of 1000mg/L Magnesium Standard 
400µL of 1000mg/L Copper Standard 
1.4ml of 1000mg/L Zinc Standard 
40µl of 1000mg/L Selenium Standard 
This was made up to 100ml with 1% UltraPur nitric acid. 
Working standards were made for each run using dilutions outlined in table 2.2a, 
which resulted in standards with concentrations as seen in table 2.2b. 
 
Standard Stock Standard 1% UltraPur nitric acid 
1 0 µL 500 µL 
2 50 µL 450 µL 
3 100 µL 400 µL 
4 300 µL 200 µL 
5 500 µL 0 µL 
Table 2.2a Dilutions required for stock standard for red blood cell and plasma 
trace element analysis 
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Conc. of 
Std 1 
(µg/L) 
Conc. of 
Std 2 
(µg/L) 
Conc. of 
Std 3 
(µg/L) 
Conc. of 
Std 4 
(µg/L) 
Conc. of 
Std 5 
(µg/L) 
Fe 0 10000 20000 60000 100000 
Mg 0 5000 10000 30000 50000 
Cu 0 400 800 2400 4000 
Zn 0 1400 2800 8400 14000 
Se 0 40 80 240 400 
Table 2.2b Concentrations of working standards for red blood cell and plasma 
trace element analysis 
 
2.5.3 Internal Standards 
A diluting reagent was made which contained the internal standards; 50 µg/L 
Germanium and 50 µg/L Scandium. 25 µL of 1000mg/L Scandium standard and 25 
µL of 1000mg/L Germanium standard were added to 500ml of 1% UltraPur nitric 
acid. Scandium acted as the internal standard for Magnesium whereas 
Germanium was used for all other elements, as recommended by the 
manufacturer. 
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2.6 Pre analytical specimen preparation  
 
2.6.1 Human tissue samples  
 
Samples were placed in a Pyrex test tube and put in an oven at 90˚C for 12 hours 
until dried to a constant weight. Once dried, samples were carefully weighed 
using a second acid-washed Pyrex test tube to avoid contamination. Once 
cooled, 3mL of 60% UltraPur nitric acid was added and the test tube was covered 
with 2 layers of parafilm and left at room temperature for 24 hours. It was then 
placed in an oven at 70˚C for 12 hours. After this time the sample was a clear 
yellow liquid with no particulate matter. 
For analysis, 200µl of sample (or standard) was added to 2300µl of diluting 
reagent (which included internal standards). 
 
2.6.2 Red blood cell and plasma samples 
 
100µl of red blood cells or plasma were placed in a plastic test tube and dried in 
a heating block at 70˚C for 3 hours. 500µl of 60% UltraPur nitric acid was added 
and the tubes were capped and heated in a heating block for at 85˚C for 4 
hours. After this time the samples were a clear straw-coloured liquid with no 
particulate matter. 
For analysis, 4500µl of diluting reagent (which included internal standards) was 
added to the sample tubes or standards. 
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2.7 Analysis 
 
The ICP-MS used was an Agilent 7500ce ICP-MS, with operational control using 
Agilent ChemStation Windows software. All analyses were performed in helium 
gas mode except Selenium which was measured using hydrogen gas mode, as 
recommended by the manufacturer. The machine was rinsed between samples 
with 1% UltraPur nitric acid. 
 
Iron was measured using the less abundant isotope at 54 g/ mol (rather than 56 
g/ mol) as it was at far higher concentration than the rest of the analytes. 
Magnesium (24 g/ mol), selenium (78 g/ mol), copper (63 g/ mol) and zinc (66g/ 
mol), where measured using their most abundant isotopes. 
 
2.8 Calculation of results 
 
2.8.1 Human tissue samples  
 
Human tissue sample results were presented as µg/g dry weight. 
As they were diluted 1:3 for acid digestion results achieved were multiplied by 3 
(this was done via the ICP-MS software).  
Trace element concentration (µg/g dry weight) = (µg/L x 3)/ dry weight (g) 
 
2.8.2 Red blood cells 
Red blood cell results were presented as µg/µg Fe: 
Trace element concentration (µg/µg Fe) = (µg/L trace element) / (µg/L Fe) 
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2.8.3 Plasma  
Plasma results were presented as µg/L and required no calculation.  
They were also converted to molar units: 
Mg mmol/L = (µg/L / 24.3)/1000 
Cu µmol/L = (µg/L / 63.55) 
Se µmol/L = (µg/L / 78.96) 
Zn µmol/L = (µg/L / 65.38) 
 
2.9 Method development 
 
For liver and tissue method development bovine liver and muscle obtained from 
a local butcher were used. For red blood cell and plasma method development 
the remainder of samples from the routine laboratory were used. 
 
2.9.1 Choice of standard concentration  
 
2.9.1.1 Human tissue samples  
As the concentrations of trace element micronutrients in liver and muscle 
samples were not available from published literature a set of standards were 
used that simply had 400 µg/L, 80 µg/L, 20 µg/L, 4 µg/L, 1 µg/L and 0.5 µg/L of 
each element. Results obtained on runs of bovine liver and muscle were then 
used to alter the concentrations of the standards so that they covered the 
appropriate concentration range. 
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2.9.1.2 Red blood cells 
Ranges of red blood cell concentrations of some trace elements were available 
from the handbook of the SAS Trace Elements Laboratories (Ed. Andrew Taylor. 
4th Edition, Guildford 2006) and the concentration calculated for a high iron or 
haemoglobin level. The upper ranges were: 
Zinc up to 12420 µg/L 
Copper up to 800 µg/L 
Selenium up to 181 µg/L 
Iron up to 950 mg/L 
A concentration range for red blood cell magnesium was not available, but a 
previous study was found with a mean red blood cell magnesium concentration 
of 150 µg/ g Hb82. This was then calculated for a maximum haemoglobin of 34 g/ 
dL which calculated as 51 mg/L.  
 
2.9.1.3 Plasma  
Plasma standard concentrations were decided upon by use of the upper limit of 
the laboratory reference intervals; zinc 1175 µg/L, copper 1398 µg/L, 
magnesium 24.3mg/L, and selenium 158 µg/L. 
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2.9.2 Precision Studies  
2.9.2.1 Liver 
Intra-assay precision was assessed using 10 pieces of one bovine liver, which had 
gone through all pre-analytical preparation as separate samples, assayed in one 
batch. Results can be seen in table 2.3a. 
 
Sample 
Mg 
(µg/g dry 
weight) 
Cu 
(µg/g dry 
weight) 
Zn 
(µg/g dry 
weight) 
Se 
(µg/g dry 
weight) 
1 552.28 237.16 100.83 1.27 
2 578.89 243.65 102.65 1.29 
3 569.42 219.50 102.86 1.14 
4 575.59 233.74 103.91 1.29 
5 575.17 206.01 102.71 1.20 
6 610.63 250.42 110.21 1.27 
7 591.76 244.60 101.13 1.18 
8 597.21 242.08 109.37 1.28 
9 589.51 230.69 101.84 1.18 
10 578.16 249.11 101.04 1.21 
Mean 581.86 235.70 103.66 1.23 
SD 16.2 14.0 3.4 0.05 
CV(%) 2.8 5.9 3.3 4.4 
Table 2.3a Mg, Zn, Cu and Se concentration (µg/g dry weight) for 10 samples of 
one piece of bovine liver performed in one batch. Mean, standard deviation, and 
co-efficient of variation (CV) values are given for each. 
Intra-assay co-efficient of variation was satisfactory for zinc (3.3%), copper 
(5.9%), magnesium (2.8%) and selenium (4.4%). 
Inter-assay precision was assessed using a 10 pieces of one bovine liver, which 
had gone through all pre-analytical preparation as separate samples, assayed 
each on separate days using new standards each time. Results can be seen in 
table 2.3b. 
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Sample 
Mg 
(µg/g dry 
weight) 
Cu 
(µg/g dry 
weight) 
Zn 
(µg/g dry 
weight) 
Se 
(µg/g dry 
weight) 
1 571.81 231.77 100.73 1.28 
2 552.28 237.16 100.83 1.27 
3 584.36 239.51 105.83 1.23 
4 561.02 218.42 107.29 1.19 
5 554.06 212.25 108.01 1.31 
6 641.97 225.82 98.76 1.31 
7 554.66 228.54 112.35 1.27 
8 584.67 236.51 108.33 1.12 
9 572.90 233.98 101.24 1.31 
10 543.85 200.28 101.66 1.23 
Mean 572.16 226.42 104.50 1.25 
SD 28.2 12.6 4.4 0.06 
CV(%) 4.9 5.6 4.3 4.9 
Table 2.3b Mg, Zn, Cu and Se concentration (µg/g dry weight) for 10 samples of 
one piece of bovine liver each performed on separate days using new standards. 
Mean, standard deviation, and CV values are given for each. 
 
Inter-assay co-efficient of variation was satisfactory for zinc (4.3%), copper 
(5.6%), magnesium (4.9%) and selenium (4.9%). 
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2.9.2.2 Muscle 
Intra-assay precision was assessed using a 10 pieces of piece of bovine muscle, 
which had gone through all the pre-analytical preparation as separate samples, 
assayed in one batch. Results can be seen in table 2.4a. 
 
Sample 
Mg 
(µg/g dry 
weight) 
Cu 
(µg/g dry 
weight) 
Zn 
(µg/g dry 
weight) 
Se 
(µg/g dry 
weight) 
1 924.68 2.83 160.51 0.24 
2 907.32 4.06 140.73 0.20 
3 932.08 2.91 156.10 0.24 
4 842.31 2.70 143.16 0.26 
5 878.02 3.34 158.73 0.21 
6 878.46 3.85 136.59 0.22 
7 933.40 2.89 163.44 0.21 
8 918.27 4.00 148.70 0.22 
9 921.03 3.24 155.91 0.25 
10 920.39 11.28 151.32 0.22 
Mean 905.60 4.11 151.52 0.23 
SD 29.7 2.6 9.0 0.02 
CV(%) 3.3 62.5 6.0 8.8 
Table 2.4a Mg, Zn, Cu and Se concentration (µg/g dry weight) for 10 samples of 
one piece of bovine muscle performed in one batch. Mean, standard deviation, 
and CV values are given for each. 
 
Intra-assay co-efficient of variation was satisfactory for zinc (6.0%), magnesium 
(3.3%) and selenium (8.8%) but not for copper (62.5%). 
Inter-assay precision was assessed using a 10 pieces of one bovine muscle, which 
had gone through all pre-analytical preparation as separate samples, assayed 
each on separate days using new standards each time. Results can be seen in 
table 2.4b. 
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Sample 
Mg 
(µg/g dry 
weight) 
Cu 
(µg/g dry 
weight) 
Zn 
(µg/g dry 
weight) 
Se 
(µg/g dry 
weight) 
1 897.44 4.11 145.44 0.36 
2 932.08 2.91 156.10 0.24 
3 907.47 3.08 165.49 0.40 
4 911.26 0.00 139.73 0.01 
5 890.46 2.63 172.35 0.31 
6 941.54 3.31 148.72 0.28 
7 919.88 4.81 155.69 0.31 
8 933.45 10.08 155.62 0.13 
9 865.61 3.48 152.51 0.18 
10 902.08 5.84 139.97 0.30 
Mean 910.13 4.03 153.16 0.25 
SD 22.9 2.6 10.4 0.12 
CV(%) 2.5 65.0 6.8 46.8 
Table 2.4b Mg, Zn, Cu and Se concentration (µg/g dry weight) for 10 samples of 
one piece of bovine muscle each performed on separate days using new 
standards. Mean, standard deviation, and CV values are given for each. 
 
Intra-assay co-efficient of variation was satisfactory for zinc (6.8%) and 
magnesium (2.5%). They were not satisfactory for copper (65.0%) or selenium 
(46.8%). Due to the low concentration of selenium and copper found in muscle, 
the measurement of these cannot be done precisely. Therefore, muscle selenium 
and copper were not reported in this study. 
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2.9.2.3 Plasma 
Intra-assay precision was assessed using one plasma sample in 10 aliquots which 
had gone through all the pre-analytical preparation as separate samples, assayed 
in one batch. Results can be seen in table 2.5a. 
 
Sample 
Mg 
(µg/L) 
Cu 
(µg/L) 
Zn 
(µg/L) 
Se 
(µg/L) 
1 20610 2004 809.4 130.8 
2 19540 2101 875.0 130.3 
3 19210 1941 785.4 129.3 
4 19360 1953 792.0 127.3 
5 19540 1966 793.3 128.9 
6 19410 1952 777.4 128.1 
7 19570 1981 794.2 129.4 
8 19240 1968 778.4 128.0 
9 20390 2037 816.4 129.6 
10 19430 1968 818.7 127.9 
Mean 19630 1987 804.0 129.0 
SD 477.0 48.9 28.9 1.1 
CV(%) 2.4 2.5 3.6 0.9 
Table 2.5a Mg, Zn, Cu and Se concentration (µg/L) for 10 aliquots of one plasma 
sample performed in one batch. Mean, standard deviation, and CV values are 
given for each. 
 
Intra-assay co-efficient of variation was satisfactory for zinc (3.6%), copper 
(2.5%), magnesium (2.4%) and selenium (0.9%). 
Inter-assay precision was assessed using a one plasma sample in 10 aliquots 
which had gone through all the pre-analytical preparation as separate samples, 
assayed each on separate days using new standards each time. Results can be 
seen in table 2.5b. 
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Sample 
Mg 
(µg/L) 
Cu 
(µg/L) 
Zn 
(µg/L) 
Se 
(µg/L) 
1 20610 2004 809.4 130.8 
2 20190 2024 826.1 135.2 
3 21400 2106 898.5 142.5 
4 19530 1963 845.5 135.6 
5 21640 2136 910.1 143.8 
6 21470 2092 911.1 142.9 
7 20940 2111 921.8 143.6 
8 18660 1825 827.5 125.2 
9 18660 1867 831.8 127.5 
10 19390 2195 879.3 133.7 
Mean 20249 2032 866.1 136.1 
SD 1138.5 119.5 42.4 6.9 
CV(%) 5.6 5.9 4.9 5.1 
Table 2.5b Mg, Zn, Cu and Se concentration (µg/g dry weight) for 10 aliquots of 
one plasma sample each performed on separate days using new standards. Mean, 
standard deviation, and CV values are given for each. 
 
Intra-assay co-efficient of variation was satisfactory for zinc (4.9%), copper 
(5.9%), magnesium (5.6%) and selenium (5.1%). 
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2.9.2.4 Red blood cells 
Intra-assay precision was assessed using one red blood cell sample in 10 aliquots 
which had gone through all the pre-analytical preparation as separate samples, 
assayed in one batch. Results can be seen in table 2.6a. 
 
Sample 
Mg 
(µg/ µg Fe) 
Cu 
(µg/ µg Fe) 
Zn 
(µg/ µg Fe) 
Se 
(µg/ µg Fe) 
1 0.0561 0.00070 0.01246 0.000264 
2 0.0561 0.00071 0.01247 0.000259 
3 0.0561 0.00073 0.01266 0.000256 
4 0.0565 0.00068 0.01262 0.000259 
5 0.0541 0.00068 0.01260 0.000256 
6 0.0589 0.00072 0.01260 0.000263 
7 0.0521 0.00074 0.01261 0.000259 
8 0.0500 0.00065 0.01255 0.000252 
9 0.0506 0.00065 0.01260 0.000254 
10 0.0513 0.00068 0.01264 0.000257 
Mean 0.0542 0.00069 0.01258 0.000258 
SD 0.0030 0.00003 0.00007 0.0000036 
CV(%) 5.6 4.4 0.6 1.4 
Table 2.6a Mg, Zn, Cu and Se concentration (µg/ µg Fe) for 10 aliquots of one 
red blood cell sample performed in one batch. Mean, standard deviation, and CV 
values are given for each. 
 
Intra-assay co-efficient of variation was satisfactory for zinc (0.6%), copper 
(4.4%), magnesium (5.6%) and selenium (1.4%). 
Inter-assay precision was assessed using a one plasma sample in 10 aliquots 
which had gone through all the pre-analytical preparation as separate samples, 
assayed each on separate days using new standards each time. Results can be 
seen in table 2.6b. 
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Sample 
Mg 
(µg/ µg Fe) 
Cu 
(µg/ µg Fe) 
Zn 
(µg/ µg Fe) 
Se 
(µg/ µg Fe) 
1 0.0561 0.00070 0.01246 0.000264 
2 0.0474 0.00069 0.01263 0.000270 
3 0.0484 0.00067 0.01236 0.000261 
4 0.0492 0.00066 0.01240 0.000265 
5 0.0527 0.00071 0.01252 0.000266 
6 0.0537 0.00076 0.01249 0.000269 
7 0.0560 0.00069 0.01250 0.000263 
8 0.0697 0.00076 0.01238 0.000270 
9 0.0537 0.00076 0.01288 0.000272 
10 0.0521 0.00069 0.01239 0.000263 
Mean 0.0539 0.00071 0.01250 0.000266 
SD 0.0063 0.00004 0.00016 0.000004 
CV(%) 11.7 5.3 1.3 1.4 
Table 2.6b Mg, Zn, Cu and Se concentration (µg/ µg Fe) for 10 aliquots of one 
red blood cell sample each performed on separate days using new standards. 
Mean, standard deviation, and CV values are given for each. 
 
Intra-assay co-efficient of variation was satisfactory for zinc (1.3%), copper 
(5.3%), magnesium (11.7%) and selenium (1.4%). 
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2.9.3 Accuracy  
2.9.3.1 Tissue samples 
The accuracy of the tissue trace metal methods was assessed by running 
certified reference materials: Bovine Liver 1577a and H4 Animal Muscle. The aim 
was to achieve results similar to the reference values, though the reference 
materials were all >20 years old and the values would have been assigned by 
methods that are less accurate than ICP-MS.  
Bovine Liver was analysed 4 times and Animal Muscle 5 times; results, including 
reference values, can be seen in table 2.7. 
 
 
Reference 
value 
(µg/g dry 
weight)  
Run 1 
(µg/g dry 
weight) 
Run 2 
(µg/g dry 
weight) 
Run 3 
(µg/g dry 
weight) 
Run 4 
(µg/g dry 
weight) 
Run 5 
(µg/g dry 
weight) 
Mean 
(µg/g 
dry 
weight) 
Bovine Liver       
Zn 142 140.07 136.85 122.99 134.17  133.52 
Cu 189 206.23 204.19 183.43 197.19  197.75 
Se 0.45 0.71 0.69 0.59 0.52  0.63 
Mg N/A 723.23 706.49 635.31 616.49  670.38 
Animal Muscle       
Zn 82.54 81.01 79.34 79.04 80.69 77.49 79.51 
Cu 3.95 3.83 3.80 3.88 3.69 3.75 3.79 
Se 0.34 0.35 0.37 0.33 0.34 0.32 0.34 
Mg 1019.73 1102.32 1080.04 1073.63 1060.20 1043.05 1071.85 
 Table 2.7 Reference and obtained values for bovine liver and animal muscle 
reference material 
Mean values obtained for reference materials are similar to the assigned 
reference values. 
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2.9.3.2 Red blood cell and plasma samples 
No certified reference materials were available for red blood cell or plasma 
trace elements. There was however a preparation of lyophilised whole blood 
which had been assigned an average value from measurements by several 
laboratories (Seronorm), and this was used for comparison. The values had been 
assigned using different methods to ICP-MS (namely ICP-sector field mass 
spectrometry and electrothermal atomic absorption spectroscopy).  
Three levels of sample were available and each were re-constituted as per the 
instructions and run as normal samples 5 times; results, including laboratory 
mean values, can be seen in table 2.8. 
 
 
Assigned 
value 
(µg/L) 
Run 1 
(µg/L) 
Run 2 
(µg/L) 
Run 3 
(µg/L) 
Run 4 
(µg/L) 
Run 5 
(µg/L) 
Mean 
(µg/L) 
Seronorm Level 1       
Zn 5500 4793 4790 4739 4657 4705 4737 
Cu 564 547 560.4 554.6 544.0 560.0 553 
Se 79.8 111.5 111.7 111.7 110.4 110.9 111.2 
Mg 19600 19100 20380 20220 19220 19920 19768 
Fe 432000 417300 411600 405300 412100 407000 410660 
Seronorm level 2       
Zn 5038 4620 4947 4654 4636 4435 4658 
Cu 604.6 591.9 643.6 604.3 598.9 665.4 621 
Se 123 163.3 168.6 167.4 166.8 164.2 166.1 
Mg 20100 17780 20320 18900 19390 17620 18802 
Fe 433000 392800 396300 395400 395700 380200 392080 
Seronorm level 3       
Zn 8032 7424 7211 7439 7069 7481 7325 
Cu 1741 1542 1508 1547 1461 1558 1523 
Se 146 243.6 237.5 240.6 229.6 247.3 239.7 
Mg 21700 21680 21600 22270 20180 22510 21648 
Fe 471000 447700 434300 446800 430900 449200 441780 
Table 2.8 Assigned and obtained values for Seronorm whole blood level 1-3  
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Values obtained for iron and magnesium concentration were broadly comparable 
with slightly lower values obtained for copper and zinc. Selenium values 
obtained were high compared to the assigned values: standards had been 
checked and this was not an analytical error (it is not high by a given percentage 
at each level). This difference may be due to matrix effects in the laboratories 
assigning the values; they are very unlikely to have used an acid digestion 
method for whole blood measurement.  
 
Differences in these values do not affect the use of this methods within the 
study; the values are not reference values (reference values in the tissue 
reference materials were far closer), and the precision of the methods is 
excellent which is the important factor in a study where the main outcome is 
correlation and change, rather than exact values.  
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2.9.4 Limit of Detection 
The limit if detection was calculated by running 10 blank samples which went 
through all the pre-analytical steps, including heating in a heating block. Limit 
of detection was calculated as the mean of 10 blank samples plus 3 standard 
deviations. Results can be seen in table 2.9. 
Sample 
Mg 
(µg/L) 
Cu 
(µg/L) 
Zn 
(µg/L) 
Se 
(µg/L) 
1 0 0 0 0 
2 0 5.35 0 0 
3 0 0 0 0 
4 0 0 0 0 
5 0 0 0 0 
6 0 0 0 0 
7 0 0 0 0 
8 0 5.17 0 0 
9 0 0 0 0 
10 0 0 0 0 
Mean 0 1.05 0 0 
SD 0 2.22 0 0 
LoD 0 7.70 0 0 
Table 2.9 Mg, Zn, Cu and Se concentration (µg/L) for 10 blank samples 
performed in one analytical run. Mean, standard deviation, and limit of 
detection (LoD) values are given for each. 
 
Only copper was detected in the blank samples, giving it a limit of detection of 
7.7 µg/L. 
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2.9.5 Recovery 
 
A recovery experiment was performed using 3 bovine liver and 3 bovine muscle 
samples.  
200 µl of sample was added to 2.3 ml of diluting reagent and 50 µl of tissue 
standard (A) or 50 µl of 1% UltraPur nitric acid (B). 
Recovery was calculated for each trace element: 
((concentration A – concentration B) / (concentration of standard * 0.25)) * 100% 
Results can be seen in table 2.10 below. 
Almost all the recovery results achieved were acceptable, being between 90-
110% and consistent across all the samples. The exception was selenium were 
recovery was lower in the third liver and muscle samples. Selenium 
concentration was far lower in these samples and the decision had already been 
made that due to high imprecision at low concentrations, muscle selenium was 
not going to be reported. 
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Liver 1 Standard (µg/L) A (µg/L) B (µg/L) Recovery (%) 
Mg 35000 24870 16020 101.1 
Fe 8000 5364.5 3166 109.9 
Cu 10000 8427.5 5788 105.6 
Zn 7000 4701.5 2959 99.6 
Se 200 73.48 27.64 91.7 
Liver 2 Standard (µg/L) A (µg/L) B (µg/L) Recovery (%) 
Mg 35000 30470 21370 104.0 
Fe 8000 6697 4571.5 106.3 
Cu 10000 11265 8671 103.8 
Zn 7000 5596.5 3869 98.7 
Se 200 85.71 37.81 95.8 
Liver 3 Standard (µg/L) A (µg/L) B (µg/L) Recovery (%) 
Mg 35000 22875 13885 102.7 
Fe 8000 6983.5 4841 107.1 
Cu 10000 6903.5 4252 106.1 
Zn 7000 4598.5 2886 97.9 
Se 200 50.87 8.12 85.5 
Muscle 1 Standard (µg/L) A (µg/L) B (µg/L) Recovery (%) 
Mg 35000 35020 26020 102.9 
Fe 8000 3908 1721.5 109.3 
Cu 10000 2742 77.345 106.6 
Zn 7000 6430 4738.5 96.7 
Se 200 49.81 5.67 88.3 
Muscle 2 Standard (µg/L) A (µg/L) B (µg/L) Recovery (%) 
Mg 35000 26245 17180 103.6 
Fe 8000 3380.5 1228 107.6 
Cu 10000 2718.5 52.895 106.6 
Zn 7000 4655 3001 94.5 
Se 200 45.61 3.30 84.6 
Muscle 3 Standard (µg/L) A (µg/L) B (µg/L) Recovery (%) 
Mg 35000 25845 16875 102.5 
Fe 8000 3034.5 953.1 104.1 
Cu 10000 2723 60.33 106.5 
Zn 7000 2965 1278.5 96.4 
Se 200 43.83 3.06 81.5 
Table 2.10 Results of recovery experiment using 3 liver and 3 muscle samples 
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Chapter 3 - Red blood cell Glutathione Peroxidase method  
 
3.1 Principle of the method 
 
Glutathione peroxidase was measured as described by Paglia and Valentine90. 
GPX catalyses the oxidation of Glutathione (GSH) by Cumene Hydroperoxide. In 
the presence of Glutathione Reductase (GR) and NADPH, the oxidised 
Glutathione is immediately converted to the reduced form with a concomitant 
oxidation of NADPH to NADP+. The oxidation of NADPH is used to monitor the 
progress of the reaction via a decrease in absorbance measured at 340nm. 
 
 
Drabkin’s reagent (K3Fe[CN6]) is added prior to the assay to minimise the positive 
interference caused by the pseudoperoxidative activity of haemoglobin. 
Red blood cell GPX activity is reported per gram of haemoglobin. Haemoglobin is 
initially reduced to methaemoglobin using Drabkin’s reagent and then reacts 
with the cyanide in the Drabkin’s reagent to form cyanmethaemoglobin. The 
absorbance of cyanmethaemoglobin is this measured at the main wavelength of 
546nm and a bichromatic wavelength of 700nm. The absorbance of this 
derivative at 546nm is directly proportional to the haemoglobin content in the 
blood. 
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3.2 Specimen Requirements 
 
3.2.1 Red blood cells 
 
50µl of red blood cells were required. Red blood cells are obtained from blood 
collected in specialist sodium heparin trace element-free blood tubes. The 
samples were separated by centrifugation within 4 hours of collection. The 
plasma was removed along with careful removal of the buffy coat by pipette. 
Red blood cells were stored at -50˚C and defrosted before use. 
 
3.2.2 Whole blood 
 
100µl of whole blood was required, collected in specialist sodium heparin trace 
element-free blood tubes. Samples were stored at -50˚C and defrosted before 
use. 
 
3.3 Reagents  
 
Ransel Glutathione Peroxidase kit (Randox, Co. Antrim, UK) 
Drabkin’s reagent (Gainland Chemical Company, Sandycroft, Deeside, UK) 
Bovine haemoglobin (Sigma Aldrich, St Louis, Missouri, USA) 
 
3.4 Preparation of reagents 
 
3.4.1 Ransel Glutathione Peroxidase kit 
 
Diluting Reagent (reagent 3) – the contents of one vial were reconstituted with 
200ml of deionised water. It was stored between 2-8˚C and was stable for 4 
weeks. 
 
Buffer (reagent 1b) – this was ready to use and stable at 4˚C until expiry date. 
 
Working Reagent (reagent 1a) – the contents of one vial were reconstituted with 
10ml of buffer (reagent 1b). This was then stable at 4˚C for 48 hours. This was 
heated to 37˚C in a water bath before the assay was performed. 
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Cumene Hydroperoxide (reagent 2) – 20µl was added by reverse pipetting 
technique to 10ml of deionised water. This was then mixed by vortex mixer for 2 
minutes. This was required to be prepared fresh for every assay. This was heated 
to 37˚C in a water bath before the assay was performed. 
 
3.4.2 Drabkin’s reagent 
 
25ml of concentrate was diluted to 1l with deionised water. Reconstitued 
reagent was stable for 4 months when stored in a dark bottle at room 
temperature. 
 
3.4.3 Double strength Drabkin’s reagent 
 
25ml of concentrate was diluted to 500mL with deionised water. Reconstitued 
reagent was stable for 4 months when stored in a dark bottle at room 
temperature. 
 
3.4.4 Haemoglobin standard 
 
2g of bovine haemoglobin was dissolved in 6mL of deionised water. This was 
then transferred to a 10mL volumetric flask and diluted to 10mL with deionised 
water. 
 
The haemoglobin standard value was determined by spectrophotometry: the 
prepared standard was diluted 1:50 in Drabkin’s reagent (50µL Hb standard + 
2.5mL Drabkin’s reagent) and the absorbance measured at 546nm and 700nm. 
The haemoglobin standard value was then calculated: 
 
Hb g/dL = (Abs 546nm – Abs 700nm) x 64458 x 50 
                44000 x 1 x 10 
 
Where 64458 is the molecular weight of haemoglobin and 44000 is the molar 
extinction coefficient. 
The assigned value was ~13.1g/dL. The standard was stored in 150µL aliquots at 
-50˚C. 
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3.5 Pre-analytical specimen preparation  
 
3.5.1 Red blood cell Glutathione Peroxidase 
 
50µL of red cells were added to 450µL of diluting reagent (reagent 3). The 
samples were then mixed by inversion then centrifuged at 10000rpm for 10 
minutes.  
 
3.5.2 Whole blood Glutathione Peroxidase 
100µL of whole blood was added to 400µL of diluting reagent (reagent 3). The 
samples were then mixed by inversion then centrifuged at 10000rpm for 10 
minutes.  
 
3.6 Glutathione Peroxidase analysis 
 
200µL of sample supernatant and 200µL of double strength Drabkin’s reagent 
were added to auto-analyser cups. Deionised water was run as a sample blank. 
Samples were analysed within 20 minutes of adding double strength Drabkin’s 
reagent. 
 
Samples were run on a Sapphire 350 Spectrophotometer (Audit Diagnostics, 
Carrigtwohill, Ireland) autoanalyser using a kinetic method measuring the 
decrease in absorbance at 360nm over 4 minutes. 5µL of  sample, 10µL of 
working reagent and 250µL of cumene hydroperoxide were auto-pipetted by the 
autoanalyser. The molar absorptivity coefficent of NADPH used was 8412. 
 
Glutathione peroxidase concentration was calculated by the Sapphire 350 
Spectrophotometer using the following formula: 
 
Gluthione peroxidase (U/L) = 8412 x ∆A 340nm/ minute 
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3.7 Haemoglobin analysis 
 
200µL of sample supernatant were added to auto-analyser cups. 
Samples were run on a Sapphire 350 Spectrophotometer autoanalyser (Audit 
Diagnostics, Carrigtwohill, Ireland) measuring absorbance at a wavelength of 
546nm with a bichromatic correction at 700nm. 10µL of  sample, and 240µL of 
Drabkin’s reagent were auto-pipetted by the autoanalyser.  
 
3.7.1 Calibration 
 
Haemoglobin standard was used for calibration of the haemoglobin assay and 
diluted 1:5 as per whole blood samples. The Sapphire software calculated a 
factor from the absorbency value of haemoglobin standard and used this to 
calculate haemoglobin concentrations in patient samples: 
 
Factor =   [calibrator]______         
                               Abs 546nm – Abs 700nm 
Hb in patient sample = factor x (Abs 546nm – Abs 700nm) 
 
3.8 Calculation of results 
 
Red blood cell GPX (U GPX/g Hb) = 20(GPX-water blank) 
          20 x Hb 
 
GPX is multiplied by 20 to correct for the effect of dilution (diluting reagent and 
double strength Drabkin’s reagent). Hb is multiplied by 20 to correct for 
different dilution of samples and standard (samples are diluted 1:10 while 
calibrator is diluted1:5) and to convert haemoglobin to g/L. 
 
Whole blood GPX (U GPX/g Hb) = 10(GPX-water blank) 
        10 x Hb 
 
GPX is multiplied by 10 to correct for the effect of dilution (diluting reagent and 
double strength Drabkin’s reagent). Hb is multiplied by 10 to convert 
haemoglobin to g/L. 
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3.9 Method development 
 
A method for measuring whole blood Glutathione Peroxidase (GPX) was already 
in use within the laboratory. However, many changes had been made to the 
method including the use of a new spectrophotometer since the method had last 
been validated. A full method evaluation was therefore undertaken. 
 
The existing method had a 1:21 dilution of whole blood with diluting reagent 
(reagent 3) for sample preparation and a 1:20 dilution of sample supernatant 
with Drabkin’s reagent for haemoglobin measurement. 
 
3.9.1 Precision 
 
Precision was assessed for the overall assays (i.e. Units GPX/ g Hb) with an aim 
of achieving a coefficient of variation (CV) <10%. From 75 patient samples 
initially assayed high, medium and low range GPx activity pools were selected. 
These were analysed to establish intra and inter assay coefficients of variation. 
Intra-assay precision was assessed by the measurement of the same sample 20 
times. CV was 4% for the high activity pool, 9.8% for the medium activity pool 
and 10% for the low activity pool. 
 
Inter-assay precision was measured by assaying individual samples of low, mid 
and high activity pools on separate days, using freshly prepared reagents and 
calibrator each time. It was planned to investigate inter assay CV over 20 
separate assay runs. However the CV for the low, medium, and high activity 
pools was unacceptable at 11.3%, 11.4% and 13.5% respectively. Investigation of 
this indicated that the problem lay with precision of the haemoglobin assay. 
Another assay in the laboratory that also relied on the Sapphire 
spectrophotometer for Hb measurement reported an increased CV in its internal 
quality control material. The problem was traced to contaminated cuvettes and 
these were replaced. The CV for the internal QC for the other assay returned to 
its previous level. 
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3.9.1.1 Haemoglobin Concentration 
 
Haemoglobin was being measured at very low concentrations. An existing 
method in the laboratory also used the Sapphire for the measurement of 
Haemoglobin but used a concentration that was higher and had better precision. 
A standard curve was created by measuring absorbance over a range of 
haemoglobin concentrations (fig 3.1). 
 
 
Fig 3.1 Standard curve of Hb (g/dL) against Absorbance 
 
The volume of Drabkin’s Reagent added to the haemolysate was changed to a 
1:5 dilution. Consequently a 7g/dL sample would be diluted to 0.066g/dL and an 
18g/dL sample to 0.17g/dL. The standard curve shows linearity over this range.  
 
3.9.1.2 Concentration of Sample 
 
Precision was then checked for a given sample intra-assay. This sample had a 
very low GPX activity (approx 16U/g Hb) and the CV was 24.2%. It was felt that 
at such low concentration (1:21) precision may be poorer and small variations in 
the results would be amplified. The concentration was changed to a 1:5 dilution 
(100µl of sample to 400µl of diluting agent) and linearity was confirmed (fig 3.2). 
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Fig 3.2 Absorbance at 340nm versus time in milliseconds for a sample at a 1:5 
dilution 
 
To compensate for the increase in concentration of the haemoslyate, 
haemoglobin concentration was altered to give a concentration of 0.12g/dL 
(absorbance approx 0.6) for a sample with a haemoglobin of 14g/ dL. This was 
achieved by altering the dilution of the haemosylate with Drabkin’s Solution to 
1:24. 
 
3.9.1.3 Precision Studies 
 
With the above modification to the assays, the precision studies were restarted. 
Intra-assay precision was assessed using a single patient sample repeated 20 
times in one batch. Results can be seen in table 3.1a. The overall intra-assay CV 
for the combination of the GPX and Hb assays was 3.6%. 
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Sample U GPX Hb U GPX/g Hb 
1 540.5 13.1 41.26 
2 546.1 12.9 42.33 
3 551.3 13.2 41.77 
4 530.7 13 40.82 
5 564.8 12.9 43.78 
6 548.4 12.5 43.87 
7 541.7 12.9 41.99 
8 520.9 12.9 40.38 
9 543.4 12.7 42.79 
10 565.8 12.9 43.86 
11 534.2 12.9 41.41 
12 547.9 12.5 43.83 
13 563.2 12.5 45.06 
14 511 12.8 39.92 
15 571.6 12.7 45.01 
16 551.2 12.9 42.73 
17 523.5 12.1 43.26 
18 563.5 12.6 44.72 
19 552.8 12.7 43.53 
20 555.1 12.7 43.71 
mean 546.38 12.77 42.80 
SD 16.20 0.25 1.52 
CV(%) 3.0 2.0 3.6 
Table 3.1a GPX activity (U GPX), Hb, and GPX activity/g Hb for 20 samples (1-
20) performed within one batch. Mean, standard deviation, and CV values are 
given for each. 
 
Inter-assay precision was assessed by measuring a patient sample 20 times on 
separate days, using new reagents and calibrator each time. Results are shown 
in table 3.1b. The overall CV for the combination of GPX and Hb assays was 
7.7%. 
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Sample U GPX Hb (g/dL) U GPX/g Hb 
1 563.7 12.7 44.39 
2 590.4 12.5 47.23 
3 595.4 12.5 47.63 
4 562.4 12.1 46.48 
5 544.4 13.3 40.93 
6 580.1 13.4 43.29 
7 556.3 13.2 42.14 
8 570.7 13.4 42.59 
9 536.5 13.2 40.64 
10 526.3 13.3 39.57 
11 554.1 13.6 40.74 
12 574.6 11.5 49.97 
13 585.3 13.7 42.72 
14 592.8 13.5 43.91 
15 599.5 12.5 47.96 
16 624.3 12 52.03 
17 627.4 12.6 49.79 
18 597.5 13.2 45.27 
19 594.5 13.1 45.38 
20 580.2 13.3 43.62 
mean 577.82 12.93 44.81 
SD 26.67 0.60 3.46 
CV(%) 4.6 4.6 7.7 
Table 3.1b GPX activity (U GPX), Hb, and GPX activity/g Hb for 20 alloquots of 
one sample (1-20) each performed on separate days using new reagents and 
calibrator. Mean, standard deviation, and CV values are given for each. 
 
3.9.2 Accuracy 
 
Accuracy of the assays (GPX and haemoglobin) could not be assessed as no 
reference materials were available. 
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3.9.3 Red blood cell versus whole blood values 
 
Glutathione Peroxidase can be measured on red bloods cells as well as whole 
blood. In order to determine concentration differences in GPX and Hb 
measurements, three samples were analysed. Fresh samples were collected in 
Lithium heparin and 500µL of whole blood was alloquoted. The remaining sample 
was spun at X x g for 10 mins to separate plasma and red blood cells, plasma and 
the buffy coat was carefully pipetted and discarded, and 500µL of red cells 
pipetted and stored.  
 
GPX activity and Haemoglobin concentration were calculated as above for red 
blood cells and whole blood. All samples were analysed in duplicate and mean 
results are given in table 3.2. 
 
  U GPX Hb (g/dL) U GPX/ g Hb 
1 Red cells 392.9 27.4 35.4 
 Whole blood 566.6 13.4 27.9 
2 Red cells 588.9 26.6 49.9 
 Whole blood 1000.6 13.9 44.9 
3 Red cells 654.8 26.3 55.0 
 Whole blood 1040.7 13.6 45.1 
Table 3.2 GPX activity (U), Haemoglobin concentration (g/dL) and GPX activity/ 
g Hb (U/ g Hb) for 3 samples (1-3), measured in whole blood and red blood cells. 
 
The concentration of haemoglobin was approximately double for red blood cells 
versus whole blood. Therefore, for red blood cells, the original dilution of 
sample with Diluting Agent was changed from 1:5 to 1:10 (50µL sample with 
450µL diluting agent). This would bring the concentration of Hb measured by the 
spectrophotometer into the same range as was used for calculating precision of 
the assay. The red cell values for GPX activity/ g Hb are slightly lower than 
whole blood values, likely due to the small contribution from plasma GPX but 
not significantly as to affect assay precision. 
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3.9.3.1 Haemoglobin calibrator for RBC Glutathione Peroxidase Assay 
 
In order to dilute the red cells to get concentrations of haemoglobin comparable 
to that in the precision studies, the bovine haemoglobin used for calibration 
would need to be diluted (calibrator has a concentration of ~13g/dL). This would 
then be at a lower concentration than the concentration levels which were 
validated. It was felt that the calibrator could continue to be diluted 1:5 and the 
Hb values obtained for samples doubled. To see if this would be accurate, GPX 
activity and Hb was measured in red blood cells using three patient samples. For 
each sample, the calibrator was either diluted 1:10, or diluted 1:5 with the 
values obtained being doubled. All samples were analysed in duplicate and mean 
results are given in table 3.3. Using a paired T-test, no difference was found in 
the values obtained when the calibrator was diluted 1:5 and the result doubled 
(p=0.723). 
 
  U GPX Hb (g/dL) Hb x2 U GPX/g Hb 
1 Calibrator 1:10 383.7 27.4  28.01 
 Calibrator 1:5  13.4 26.8 28.63 
2 Calibrator 1:10 570.8 26.6  42.92 
 Calibrator 1:5  13.9 27.8 41.06 
3 Calibrator 1:10 529.5 26.3  40.27 
 Calibrator 1:5  13.6 27.2 38.93 
Table 3.3 GPX activity (U), Haemoglobin concentration (g/dL) and GPX activity/ 
g Hb (U/ g Hb) for 3 samples (1-3), measured in red blood cells with the 
calibrator (bovine haemoglobin) either diluted 1:5 or 1:10 with diluting agent. 
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3.9.4 Anticoagulant  
 
In order to ascertain if there is any difference in GPX activity measured in red 
blood cells or whole blood collected in EDTA or Lithium heparin, fresh samples 
were collected from 5 healthy volunteers, and 500µL of whole blood was 
aliquoted. Red blood cells were separated as before and 500µL of red cells 
pipetted and stored. GPX was measured in duplicate as above and the mean 
results can be seen in table 3.4. A paired t-test was performed, and no 
difference in GPX activity measure was found between the two anticoagulants; 
whole blood (p=0.643), red blood cells (p=0.505).  
 
Whole Blood 
EDTA 
GPX Activity 
(U/g Hb) 
 
Li Hep 
GPX Activity 
(U/g Hb) 
1 31.9  32.0 
2  31.9  32.1 
3  33.1  32.5 
4  32.1  32.6 
5  33.7  34.5 
Red Blood Cell 
EDTA 
GPX Activity 
(U/g Hb) 
 Li Hep 
GPX Activity 
(U/g Hb) 
1  31.9  29.9 
2  33.5  32.0 
3  30.1  30.3 
4 31.3  27.5 
5  30.4  33.5 
Table 3.4 GPX activity (U/g Hb) on 5 samples with the anticoagulant EDTA or 
Lithium heparin and separated into whole blood or red blood cells.  
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3.9.5 Stability 
 
As the assay is for use in a specialist trace element laboratory, samples will be 
sent from labs throughout the country for analysis. The stability of samples in 
storage conditions of room temperature (20˚C) for two days, to simulate 
delivery by first class post, was compared to storage at -50˚C for two days. 5 
patient samples taken in both lithium heparin and EDTA sample tubes were used. 
All samples were analysed in duplicate and mean results are given in table 3.5. 
 
 GPX (U/g Hb) 
Sample Li Hep -50˚C EDTA -50˚C Li Hep 2/7 20˚C EDTA 2/7 20˚C 
1 30.7 30.6 33.1 32.7 
2 35.1 34.7 35.0 32.8 
3 25.8 27.2 25.9 25.3 
4 25.3 24.2 26.3 25.9 
5 26.8 26.8 24.3 25.6 
Table 3.5 GPX activity/g Hb for 5 samples taken in Li heparin and EDTA and 
stored at -50˚C or 20˚C for 2/7 
 
Friedman nonparametric analysis was used to examine differences between 
samples stored at 20˚C or -50˚C, by anticoagulant used. There was no difference 
found in measured GPX activity between storage methods; Li heparin p=0.951, 
EDTA p=0.931. 
 
3.9.6 Reference intervals 
 
120 samples were obtained from male and female healthy volunteers, not 
hospitalised or living in an institution, aged 25-75 years old. The samples were 
collected by the MRC for a social health study but were available for use for this 
reference range. Whole blood and red blood cells were obtained in the 
anticoagulant EDTA. All were analysed in duplicate and the mean values 
calculated. 
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3.9.6.1 Whole blood reference interval 
 
Mean whole blood GPX results from the 120 samples can be seen in appendix 1. 
 
A probability plot (fig 3.3a) and a histogram (GPX values have been rounded to 
the nearest 5 U/g Hb) (fig 3.3b) of whole blood GPX reference interval data 
were plotted and had a normal distribution (p=0.147). 
 
The reference range was calculated as a 95% interpercentile interval by 
calculating two standard deviations from the mean. The mean result was 33.56 
U/g Hb and 1 SD was 9.39, therefore the reference interval is 15-52 U/g Hb. 
 
 
 
 
Fig 3.3a Probability plot of whole blood GPX reference interval 
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Fig 3.3b Histogram of whole blood GPX reference interval samples (U/g Hb) 
 
 
3.9.6.2 Red blood cell reference interval 
 
Mean red blood cell GPX results from the 120 samples can be seen in appendix 1. 
 
A probability plot (fig 3.4a) and a histogram (GPX values have been rounded to 
the nearest 5 U/g Hb) (fig 3.4b) of whole blood GPX reference interval data 
were plotted and a normal distribution was seen (p=0.505).  
 
The reference range was calculated as a 95% inter-percentile interval by 
calculating two standard deviations from the mean. The mean result was 35.85 
U/g Hb and 1 SD was 9.03, therefore the reference interval is 18-54 U/g Hb. 
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Fig 3.4a. Probability plot of red blood cell GPX reference interval  
 
 
 
Fig 3.4b. Histogram of red blood cell GPX reference interval samples (U/g Hb)  
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3.10 Summary 
 
• The existing Glutathione Peroxidase method in use previously was 
imprecise, likely due to high sample dilution resulting in low 
concentrations. 
• Increasing sample concentrations achieved coefficients of variation of 
3.6% intra-assay at 42.8 U/g Hb (546 U/L GPX, 12.7 g/dL Hb) and 7.7% 
44.8 U/g Hb (578 U/L GPX, 12.9 g/dL Hb) inter-assay. 
• Both EDTA and lithium heparin are suitable anticoagulants. 
• Glutathione Peroxidase is stable at room temperature for 2 days, allowing 
sample delivery by first class postage. 
• The reference interval for whole blood is 15-52 U/g Hb; red blood cells 
18-54 u/g Hb. 
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Chapter 4  
Other Methods 
 
4.1 Serum Albumin 
 
Serum Albumin was performed as part of the routine patient care using the 
routine biochemistry laboratory at Glasgow Royal Infirmary. This was a 
bromcresol purple albumin method by Abbot Laboratories on an Abbot Architect 
Analyser (Abbot Park, Ilinois). 
 
The principle of the method is that bromocresol purple bind specifically with 
human albumin to form a coloured complex. The absorbance of the complex at 
604 nm is directly proportional to the albumin concentration in the sample.  
 
The intra-assay precision was 0.5% at 24 g/L, 0.5% at 33 g/L and 0.4% at 42 g/L. 
Inter-assay the precision was 0.8% at 25 g/L, 0.6% at 32 g/L and 0.5% at 38 g/L. 
 
4.2 Serum C-reactive protein 
 
Serum C-reactive protein was performed as part of the routine patient care 
using the routine biochemistry laboratory at Glasgow Royal Infirmary. This was a 
latex immunoassay method by Abbot Laboratories (CRP Vario) on an Abbot 
Architect Analyser (Abbot Park, Illinois).  The assay is a high-sensitivity CRP 
method, with a limit of detection of 0.01 mg/L.  
 
The principle of the method is that an antigen-antibody reaction occurs between 
CRP in a sample and anti-CRP antibody, which has been absorbed to latex 
particles and agglutination results. This agglutination is detected as an 
absorbance change (572 nm) with the change being proportional to the quantity 
of CRP in the sample. 
 
The intra-assay precision was 0.7% at 17.3 mg/L and 0.6% at 50 mg/L. Inter-
assay the precision was 2.7% at 7 mg/L, 0.5 % at 41 mg/L and 2.1% at 173 mg/L. 
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4.3 Ceruloplasmin  
 
Plasma ceruloplasmin concentration was measured for use in the study using the 
routine method in the biochemistry laboratory at Stobhill Hospital, Glasgow. This 
was an immunoturbidimetric method by Abbot Laboratories on an Abbot 
Architect Analyser (Abbot Park, Illinois).   
 
The principle of the method is that an immunoturbidimetric reaction occurs 
between an anti-ceruloplasmin polyclonal antiserum and its corresponding 
antigen in the presence of polyethylene glycol. The turbidity of the immune 
complex is proportional to the concentration of the analyte in the sample. 
 
The intra-assay precision was 1.1% at 0.2 g/L and 2.7% at 0.49 g/L. Inter-assay 
the precision was 1.8% at 0.16 g/L and 2.3% at 0.42 g/L. 
 
4.4 Ferroxidase activity 
 
Plasma ferroxidase activity measurement was performed by Dr David Preiss 
(Specialist Registrar, Chemical Pathology, Glasgow Royal Infirmary). 
 
4.4.1 Principle of the method  
 
The principle of the method is that the serum sample is incubated with a known 
amount of ferrous ion (Fe2+) in buffer solution and then during the catalytic 
oxidation by ceruloplasmin, ferrous ions are oxidized to ferric ions (Fe3+). The 
chromogen forms a highly coloured blue complex in combination with ferrous 
ions but it does not form a coloured complex with ferric ions. The chromogen is 
added at the end of the incubation period and a coloured complex is quickly 
formed between the chromogen and the remaining non-oxidized ferrous ions, 
and absorbance is measured spectrophotometrically at 600 nm.  
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4.4.2 Reagents 
 
Buffer solution 0.45 mol/L acetate buffer solution, pH 5.8: 
36.91 g of sodium acetate (BDH, Poole, UK) was dissolved in 1000 mL of 
deionised water. 25.9 mL reagent grade glacial acetic acid (BDH, Poole, UK) was 
diluted to 1000 mL with deionised water. 940 mL of the sodium acetate solution 
was added to 60 mL acetic acid solution, giving 0.45 mol/L acetate buffer with 
pH 5.8 checked by pH meter 
 
Substrate Solution 367 µmol/L: 
9.9 g thiourea (Sigma Aldrich, St Louis, Missouri, USA) was dissolved in 1000 mL 
deionised water, before the addition of 0.144 g iron (II) ammonium sulphate 
[Fe(NH4)2(SO4)2.6H2O] (Sigma Aldrich, St Louis, Missouri, USA). The order in 
which reagents is added is crucial. A drop of Brij 35 solution (Sigma Aldrich, St 
Louis, Missouri, USA) was added thereafter. The substrate solution is stable at 4o 
Celsius for at least six months.  
 
Volumes of the acetate buffer and substrate solution were mixed before each 
run in a ratio of 14:3. The mixing of the reagents prior to the addition of sample 
had no measurable detrimental effect. The mixture is referred to as Reagent A 
hereafter. The concentration of Fe2+ in the sample mixture after addition of 
Reagent A, sample and chromogen solution was chosen as 60 µmol/. Reagent A is 
also stable for at least 6 months at 4o Celsius but is only stable for 24 hours if 
left unrefrigerated.  
 
Chromogen Solution: 
0.8899g of 3-(2-pyridyl)-5,6-bis(2-[5-furylsulfonic acid])-1,2,4-triazine (Sigma 
Aldrich, St Louis, Missouri, USA) was dissolved in 100 ml of the acetate buffer 
solution. This chromogen is light yellow in solution but forms a deep blue colour 
in contact with Fe2+ with peak absorption at 590-600 nm. The chromogen was 
present in excess.  
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4.4.3 Procedure 
 
Samples were run on a Sapphire 350 Spectrophotometer (Audit Diagnostics, 
Carrigtwohill, Ireland). 
 
2 µL of sample was added to 284 µL of Reagent A at 0 seconds thus commencing 
the reaction at 37oC. After a further 225 seconds, 20 µL of chromogen solution 
was added as a stop reagent and chromogen. The change in absorption (which 
reflects the fall in Fe2+ concentration) was then measured at a wavelength of 600 
nm after a further 25 seconds. Zero absorption is taken before the addition of 
the chromogen due to the instantaneous development of blue coloration.  
 
4.4.4 Calibration 
 
There are no available sources of human enzymatic ceruloplasmin calibrators. A 
two-point negative calibration curve was therefore used: 
 
a. Zero calibrator: The first calibrator, reagent grade water, gave 
maximal absorbance in the region of ≈1.5 – 1.7A. This is equivalent to a sample 
with no ferroxidase activity, all Fe2+ ions remaining in the Fe2+ form. Water was 
ascribed a ferroxidase value of 0.0 U/L. 
 
b. Maximum calibrator: 25 mmol/L potassium EDTA solution gave 
effectively zero absorbance due to chelation of all available Fe2+. This is 
equivalent to a sample with theoretically maximal ferroxidase activity where all 
60 µmol/L Fe2+ has been converted to Fe3+. The EDTA calibrator was ascribed the 
maximal ferroxidase value of 2448 units/L, as described below. 
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4.4.5 Calculation of maximum ferroxidase value and derivation of units 
 
The difference in the ferrous ion concentration before (known) and after 
(unknown) the enzymatic reaction indicates the amount of oxidized ferrous ion. 
The amount of enzyme that converts 1 µmol of substrate into product per minute 
is defined as one unit. Using Fe concentration of 60 µmol/L gives a possible 
maximum ferroxidase activity of 2448 U/L with an undiluted sample. 
 
 
 
 
 
4.4.6 Precision 
 
The intra-assay precision was 1.8% at 1253 U/L 3.1% at 808.3/L and 4.6% at 381 
U/L. Inter-assay the precision was 6.5% at 783 U/L 6.8% at 665 U/L and 12.1% at 
241 U/L. 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme activity = [∆substrate concentration] X dilution factor 
                           Reaction time 
Maximum Ferroxidase Activity  
  = [∆Fe2+ concentration  x  dilution factor] / reaction time 
  = [60 µmol/L  x 306µL/ 2 µL] / 3.75 min 
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Chapter 5 
Experimental design 
 
The aim of this study was to compare the concentrations of trace metals and 
magnesium in plasma and red blood cells with liver and muscle levels in the non-
inflamed patient, and also to be able to investigate the changes in the 
concentrations of trace metals and magnesium in plasma and red blood cells 
during the acute phase response. Therefore this study was designed to allow 
tissue and blood sampling prior to the development of an acute phase response, 
and subsequent blood sampling during the acute phase response. 
 
5.1 Approvals 
Favourable ethical opinion was received from the Glasgow Royal Infirmary 
Research Ethics Committee; management approval was granted by NHS Greater 
Glasgow and Clyde (appendix 2). 
 
5.2 Inclusion Criteria 
• Patient in Glasgow Royal Infirmary under the care of Consultant Surgeon 
Mr Paul Horgan and due to have a liver resection for metastatic cancer, 
primary cancer or benign cyst.  
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5.3 Exclusion Criteria 
• Blood transfusion in previous 3 months or blood transfusion given intra- or 
post-operatively. 
 
Suitable participants were identified and consented by a member of Mr Paul 
Horgan’s team on the day prior to the operation (invite letter, patient 
information sheet, consent form can be found in appendix a). 
The aim was to recruit 30 participants. No previous studies were available on 
which to base a power calculation and as such this study should be considered as 
a preliminary investigation. 
 
5.4 Samples  
The following samples were obtained by a member of Mr Paul Horgan’s team and 
then transferred to the biochemistry laboratory: 
Day 0 (in theatre during operation):  
• Approximately 300g of healthy liver tissue from the resected lobe avoiding 
any areas of tumour – placed in plain universal container 
• Approximately 150g of rectus muscle – placed in plain universal container 
• 20mL of blood collected in sodium heparin trace element – free blood 
tubes 
• Routine serum sample for liver function tests including albumin and C-
reactive protein 
• Routine EDTA sample for haematology including haematocrit 
Day 1-3 (collected daily while patient is an inpatient): 
• 20mL of blood collected in sodium heparin, trace element free blood 
tubes 
• Routine serum sample for liver function tests including albumin and C-
reactive protein 
• Routine EDTA sample for haematology including haematocrit 
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The protocol is summarised in figure 5.1. 
 
Figure 5.1 Summary of protocol 
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5.5 Processing and storage of samples 
Tissue samples were stored at -50˚C in the universal container they were 
collected in. 
The sodium heparin blood samples were separated by centrifugation within 4 
hours of collection. The plasma was removed and separated into four aliquots.  
The buffy coat was carefully removed by pipette leaving the red blood cells in 
the original blood tube. Red blood cell and plasma samples were stored at -
50˚C. 
Serum samples for biochemistry and EDTA whole blood for haematology were 
processed as part of the routine patient care. 
 
5.6 Statistical Methods 
 
All statistical analyses were performed using Minitab Version 15 (Microsoft).  
Statistical methods are described throughout the results section and briefly 
here.  
Given the small sample size and differences in numbers of samples each day, 
nonparametric methods of comparison were used when possible.  
 
5.6.1 Normality of data 
 
The Anderson-Darling test of normality was used to assess the normality of 
results data with p<0.05 taken to indicate non-normal distribution. 
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5.6.2 Comparisons between groups 
 
Kruskal-Wallis non-parametric one-way analysis of variance was used to make 
comparisons between groups with p<0.05 taken to indicate statistical 
significance. 
Where a difference between groups was found, Mann-Whitney comparisons were 
performed it identify which group or groups were different. The Bonferroni 
correction was used to correct the p-value for multiple comparisons (n) and 
p=(0.05/n) was used to indicate statistical significance. 
True (non-transformed) data was used for these analyses. 
 
5.6.3 Relationship between two variables 
 
To assess possible linear relationships between two variables, simple linear 
regression was used with p<0.05 taken to indicate statistical significance. 
Transformed data was used to fulfil the underlying assumption of the data being 
normally distributed. 
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Chapter 6 
Participant Demographics and baseline results  
 
Throughout the results sections, “day 0” will refer to the sample taken 
immediately pre-operatively, and “day 1”, “day 2” and “day 3” refer to 24, 48 
and 72 hours post operatively respectively.  
 
6.1 Participants  
6.1.1 Participant Demographics 
 
31 participants were recruited who were having liver resections between April 
2008 and July 2009. There were 14 males and 17 females. Mean age was 64 
(range 35-79) years. 26 patients had liver resections due to metastatic colorectal 
cancer, 1 because of metastatic breast cancer, 2 because of hydatid cysts and 2 
had liver resections due to radiological liver lesions and previous cancers but 
infact had normal histopathology. 
 
None of the participants had a blood transfusion in the 3 months prior to the 
operation or in the 3 day post-operatively. 
 
All of the participants, with the exception of the two with hydatid cysts, had 
bowel preparation prior to surgery. This consisted of 4 sachets of Klean-Prep 
(polyethylene gycol) reconstituted with 4 litres of water taken the day prior to 
surgery. 
 
Age, sex and reason for operation for each participant can be found in appendix 
3, alongside baseline biochemistry results. 
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6.1.2 Numbers of samples available at each time point 
 
CRP and Albumin were available for all participants on days 0-3. Liver and 
Muscle samples were available for all participants on days 0. Plasma and red cell 
trace metal samples were available for all participants on day 0, 22 participants 
on day 1, 15 participants on day 2 and 10 participants on day 3. Appendix 3 
contains details of which samples were available for which participants. 
 
6.2 C-Reactive Protein 
 
6.2.1 Normality of data  
 
To ensure the normality of the data and exclude any outlying samples, the 
Anderson-Darling test for normality was performed. The results are summarised 
below and further details and probability plots can be found in appendix 4. 
 
Serum CRP Day 0 (pre-operative sample) was found to not be normally 
distributed (p<0.005) and was therefore logarithmically transformed to achieve 
normality (p=0.132). Post-operatively, CRP on day 1, CRP on day 2, and CRP on 
day 3 were all found to be normally distributed (p=0.849, 0.635, 0.907 
respectively). 
 
In order to allow pooling of results, it would be ideal to log transform all CRP 
data; unfortunately logarithmic transformation of day 2 and 3 rendered them 
non-normal (day 1 p=0.356, day 2 p<0.005, day 3 p=0.015) so this was not done. 
Transformed data was used for linear regression analysis only. 
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6.2.2 Change in CRP with the acute phase response 
 
The CRP increases during the acute phase response with the peak CRP seen on 
day 2. The median CRP and the interquartile range from Day 0-3 can be seen in 
table 6.1 and also graphically in figure 6.1. 
 
Kruskal-Wallis (non-parametric) one way analysis of variance was performed to 
see if CRP concentration varied during the acute phase response; it was found to 
vary significantly (p<0.001). 
Mann-Whitney comparisons were performed to assess the significance of change 
each day (Bonferroni correction p=0.017 is significant): day 0-1 p<0.001, day 1-2 
p<0.001, day 2-3 p=0.430. Therefore, a significant increase in CRP occurs 
between day 0 and day 1, and day 1 and day 2. 
 
 Median CRP (mg/L) (IQR) 
Day 0 5.0 (1.3-7.4) 
Day 1 95 (69-122) 
Day 2 164 (137-217) 
Day 3 154 (114-207) 
Table 6.1 Median (IQR) values of CRP (mg/L) on days 0-3 
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Fig 6.1 Boxplot of median and interquartile range of CRP (mg/L) on Day 0-3 
 
 
6.3 Albumin 
 
6.3.1 Normality of data  
 
Using the Anderson-Darling test for normality, Albumin Day 0, Day 1, Day 2 and 
Day 3 were found to all be all normally distributed (p=0.306, 0.177, 0.267, 0.135 
respectively). Further details and probability plots can be found in appendix 4. 
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6.3.2 Change in Albumin with the acute phase response 
 
Serum Albumin falls with the acute phase response and has not started to rise by 
day 3. The change in median Albumin and the interquartile range from Day 0-3 
can be seen in table 6.2 and also graphically in figure 6.2.  
 
Kruskal-Wallis (non-parametric) one way analysis of variance was performed to 
see if albumin concentration varied during the acute phase response; it was 
found to vary significantly (p<0.001). 
Mann-whitney comparisons were performed to assess the significance of change 
each day (Bonferroni correction p=0.017 is significant): day 0-1 p<0.001, day 1-2 
p=0.136, day 2-3 p=0.075. Therefore, the significant decrease in serum albumin 
occurs between day 0 and day 1. 
 
 Median Albumin (g/L) (IQR) 
Day 0 38 (36-41) 
Day 1 28 (26-32) 
Day 2 27 (26-30) 
Day 3 26 (23-29) 
Table 6.2 Median (IQR) values of albumin (g/L) on days 0-3 
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Fig 6.2 Boxplot of median and interquartile range of Albumin (g/L) on Day 0-3.  
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6.4 Haematocrit 
 
6.4.1 Normality of data  
 
Using the Anderson-Darling test for normality, haematocrit on day 0 was 
normally distributed (p=0.760).  Examination of probability plots for haematocrit 
on day 1, 2 and 3 revealed outlying samples: day 1 samples 8, 10 and 21; day 2 
samples 10, 18 and 22; day 3 sample 10. With these removed all samples were 
normally distributed: day 0 p=0.760, day 1 p=0.208, day 2 p=0.322 and day 3 
p=0.410. Further details and probability plots can be found in appendix 4. 
 
6.4.2 Change in Haematocrit with the acute phase response 
 
Haematocrit falls from day 0 to day 1-3 – this may be due to the acute phase 
response or intravenous fluid therapy. The change in median haematocrit and 
the interquartile range from Day 0-3 can be seen in table 6.3 and also 
graphically in figure 6.3.  
 
Kruskal-Wallis (non-parametric) one way analysis of variance was performed to 
see if haematocrit concentration varied during the acute phase response; it was 
found to vary significantly (p<0.001). 
 
Mann-Whitney comparisons were performed to assess the significance of change 
each day (Bonferroni correction p=0.017 is significant): day 0-1 p<0.001, day 1-2 
p=0.108, day 2-3 p=0.301. Therefore, the significant decrease in haematocrit 
occurs between day 0 and day 1. 
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 Median haematocrit (i/L) (IQR) 
Day 0 0.391 (0.368-0.419) 
Day 1 0.332 (0.309-0.356) 
Day 2 0.322 (0.298-0.338) 
Day 3 0.312 (0.293-0.330) 
Table 6.3 Median (IQR) values of haematocrit (i/L) on days 0-3 
 
 
Fig 6.3 Boxplot of median and interquartile range of haematocrit (i/L) on Day 0-
3. 
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6.5 The relationship between changes in albumin and haematocrit 
 
Changes in haematocrit are due to dilution from fluid retention by the body as a 
physiological part of the acute phase response, and possibly the effect of high 
volumes of intravenous fluids given post-operatively. Changes in albumin may 
also be a dilution effect, or may be due to the albumin moving from the 
intravascular to the extracellular compartments.  
 
To investigate this the percentage change in the haematocrit from day 0 to day 
1-3 was compared to the percentage change in albumin concentration from day 
0 to day 1-3 using simple linear regression (table 6.4 and fig 6.4). 
 
There is a linear relationship between the percentage change in haematocrit 
from day 0 and the percentage change in albumin for day 0, on day 1-3. 
However, between 55-65% of the variance in serum albumin is not accounted for 
by change in haematocrit, suggesting that the change in serum albumin 
concentration may be due to more than simple dilution, perhaps including 
redistribution to the extracellular compartment. 
 
As dilution appears to play a role in the change in serum albumin concentration, 
metal: albumin ratios shall be examined where appropriate to correct for these 
changes. 
 % change in haematocrit Vs % change in albumin 
 r2(%) p value 
Day 1 44.4 <0.001 
Day 2 35.0 0.001 
Day 3 34.9 0.001 
Table 6.4 Relationship between % change in haematocrit and % change serum 
albumin concentration from day 0 on days 1-3, using simple linear regression 
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Fig 6.4 Scatterplot of % change in haematocrit versus % change serum albumin 
concentration from day 0 on days 1-3 
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6.6 Copper 
 
6.6.1 Normality of data and outliers  
 
The Anderson-Darling test for normality was performed to ensure the normality 
of the data and exclude any outlying samples. The results are summarised below 
and further details and probability plots can be found in appendix 4. 
 
Liver copper concentrations were found to be normally distributed (p=0.100). 
 
Plasma copper concentrations on days 0, 2 and 3 were normally distributed 
(p=0.661, 0.132 and 0.782 respectively). Plasma copper concentration on day 1 
was not normally distributed (p=0.015). After logarithmic transformation, days 
0-3 were all normally distributed (p=0.595, 0.097, 0.390 and 0.576 respectively). 
 
Plasma ferroxidase activity was non-normal on day 0 (p=0.018). An outlier (study 
number 18) was identified and removed from future analyses. After this 
removal, plasma ferroxidase activities on days 0-3 were all normally distributed 
(p=0.656, 0.411, 0.874 and 0.828 respectively).  
 
Initial examination of probability plots for plasma ceruloplasmin concentration 
showed outlying samples on day 0 (study number 21) and day 1 (study number 
1); these were removed from further analyses. Day 2 was seen to be non-
normally distributed (p=0.045). Logarithmic transformation and removal of 
outliers resulted in days 0-3 all being normally distributed (p=0.6, 0.599, 0.118 
and 0.804 respectively).  
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Day 0 and day 1 red blood cell copper concentrations were non-normally 
distributed (both p<0.005). As the data was right-skewed it was logarithmically 
transformed, but day 0 and day 1 were still non-normal (p<0.005). Three high 
concentration outlying samples from day 0 (study numbers 11, 20, and 26) and 
one high concentration outlying sample (study number 26) from day 1 were 
therefore removed from further analyses and the distribution was normalised 
(p=0.280 and p=0.933 respectively). 
Transformed data was used for linear regression analysis only. 
 
6.6.2 Copper status of the study population at baseline 
 
As plasma copper is routinely measured in our laboratory, a reference interval of 
10-22µmol/L is in place. The plasma copper status of the study population at 
baseline was investigated. Median plasma copper concentration was 15.1 µmol/L 
(inter-quartile range 12.6-16.5). The range of plasma copper concentrations, and 
the relationship with the reference interval, can be seen in figure 6.5. 
Within the study population, the majority of samples fall within our laboratory 
reference interval with only one sample below (9 µmol/L) and one above (24 
µmol/L). 
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Fig 6.5 Histogram of plasma copper concentration (µmol/L) on day 0. Upper (22 
µmol/L) and lower (10 µmol/L) limits of the reference interval are marked by 
dotted lines. 
 
6.6.3 The contribution of baseline CRP to plasma copper concentration 
 
To investigate if the participants with a higher plasma copper concentration had 
a higher CRP, the data was split into tertiles of day 0 CRP: tertile 1 0.5-2.2 g/L, 
tertile 2 3.0-6.8 g/L, tertile 3 7.0-17.0 g/L.  
 
Median (IQR) of plasma copper by tertile of CRP was: tertile 1 12.9 µmol/L (11.5-
15.5), tertile 2 13.4 µmol/L (11.7-15.6), tertile 3 16.9 µmol/L (15.7-17.8); this is 
shown in fig 6.6. Kruskal-Wallis (non-parametric) one way analysis of variance 
was performed and a difference in plasma copper concentration was found 
between the three tertiles (p=0.019). Mann-Whitney comparisons were 
performed (Bonferroni correction p=0.017 is significant): there was no difference 
in copper concentration between tertile 1 and 2 (p=0.699) but there was a 
difference between tertile 1 and tertile 3 (p= 0.011). The difference between 
tertile 2 and tertile 3 was close to statistical significance (p=0.027). Therefore 
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the higher plasma copper concentrations seen at baseline in the study 
participants are related to differences in CRP concentration. The relationship 
between plasma copper concentration and CRP are discussed in section 8.3. 
 
Fig 6.6 Boxplot of plasma copper concentration (µmol/L) by tertile of CRP 
 
6.7 Zinc 
 
6.7.1 Normality of data and outliers 
 
To ensure the data followed a normal distribution to allow statistical analyses to 
take place, the Anderson-Darling normality test was performed. The results are 
summarised below and further details and probability plots can be found in 
appendix 4. 
Muscle zinc concentrations (µg/g dry weight) were found to be non-normally 
distributed (p<0.005) therefore the two outlying data points (samples 13 and 29) 
were removed for the zinc statistical analyses. With outliers removed the muscle 
zinc was normally distributed (p=0.14). 
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Analysis of a probability plot of plasma zinc concentration (µg/L) on Day 0 
revealed an outlying sample (sample 10) and this was also removed from further 
statistical analysis of zinc results. After this removal the plasma zinc 
concentration on Day 0 was normally distributed (p=0.727). Plasma zinc 
concentration (µg/L) on day 1, 2 and 3 all had a normal distribution (p=0.642, 
0.778, 0.965 respectively). 
 
Liver zinc concentrations (µg/g dry weight) were normally distributed (p=0.915).  
 
RBC zinc concentrations (µg/ µg Fe) on day 0-3 were all normally distributed 
(p=0.715, 0.532, 0.123, 0.433 respectively). 
 
6.7.2 Zinc status of the study population at baseline 
 
As plasma zinc is routinely measured in our laboratory, a reference interval of 
12-18 µmol/L is in place. The plasma zinc status of the study population at 
baseline was investigated. Median plasma zinc concentration was 11.6 µmol/L 
(inter-quartile range 10.6-12.8). The range of plasma zinc concentrations, and 
the relationship with the reference interval, can be seen in figure 6.7. 
 
Within the study population, 16 samples fall below our laboratory reference 
interval with the rest of the samples all being at the lower end of the reference 
interval. 
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Fig 6.7 Histogram of plasma zinc concentration (µmol/L) on day 0. Upper (18 
µmol/L) and lower (12 µmol/L) limits of the reference interval are marked by 
dotted lines. 
 
6.7.3 The contribution of baseline CRP to plasma zinc concentration 
 
To investigate if the participants with a lower plasma zinc concentration had a 
higher CRP, the data was split into tertiles of day 0 CRP: tertile 1 0.5-2.2 g/L, 
tertile 2 3.0-6.8 g/L, tertile 3 7.0-17.0 g/L.  
 
Median (IQR) of plasma zinc by tertile of CRP was: tertile 1 11.4 µmol/L (10.6-
12.4), tertile 2 11.3 µmol/L (9.8-13.0), tertile 3 12.0 µmol/L (10.9-13.8); this is 
shown in fig 6.8. Kruskal-Wallis (non-parametric) one way analysis of variance 
was performed and no difference in plasma zinc concentration was found 
between the three tertiles (p=0.436). Therefore the low plasma zinc 
concentrations seen at baseline in the study participants are not due to 
differences in CRP concentration. 
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Fig 6.8 Boxplot of plasma zinc concentration (µmol/L) by tertile of CRP 
 
6.8 Selenium  
 
6.8.1 Normality of data and outliers 
 
The Anderson-Darling test for normality was performed to ensure the normality 
of the data and exclude any outlying samples. The results are summarised below 
and further details and probability plots can be found in appendix 4. 
 
Liver selenium concentrations were found to be normally distributed (p=0.232).  
 
The Anderson-Darling normality test was performed on plasma selenium 
concentrations on day 0-3 and outlying samples were identified. Outlying 
samples (day 0 sample 10, day 1 samples 20 and 29) were removed and all 
plasma selenium concentrations on day 0-3 were normally distributed; day 0 
p=0.726, day 1 p=0.522, day 2 p=0.891, day 3 p=0.559.  
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Examination of probability plots of red blood cell selenium concentration on 
days 0-3 revealed outlying samples. Sample 20 on day 0, 1 and 2 was removed 
from analysis and red blood cell selenium concentration was then normally 
distributed; day 0 p=0.479, day 1 p=0.625, day 2 p=0.233, day 3 p=0.257. 
 
Red blood cell glutathione peroxidase was normally distributed on day 0-3; day 0 
p=0.353, day 1 p=0.702, day 2 p=0.748, day 3 p=0.391. 
 
6.8.2 Selenium status of the study population at baseline 
 
As plasma selenium is routinely measured in our laboratory, a reference interval 
of 0.8-2.0 µmol/L is in place. The plasma selenium status of the study 
population at baseline was investigated. Median plasma selenium concentration 
was 0.96 µmol/L (inter-quartile range 0.80-1.09). The range of plasma copper 
concentrations, and the relationship with the reference interval, can be seen in 
figure 6.9. 
 
Within the study population, 6 samples fall below our laboratory reference 
interval with the rest of the samples all being at the lower end of the reference 
interval. 
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Fig 6.9 Histogram of plasma selenium concentration (µmol/L) on day 0. Upper 
(2.0 µmol/L) and lower (0.8 µmol/L) limits of the reference interval are marked 
by dotted lines. 
 
6.8.3 The contribution of baseline CRP to plasma selenium concentration 
 
To investigate if the participants with a lower plasma selenium concentration 
had a higher CRP, the data was split into tertiles of day 0 CRP: tertile 1 0.5-1.9 
g/L, tertile 2 2.2-6.8 g/L, tertile 3 7.0-17.0 g/L.  
 
Median (IQR) of plasma selenium by tertile of CRP was: tertile 1 0.96 µmol/L 
(0.71-1.13), tertile 2 0.80 µmol/L (0.84-1.12), tertile 3 0.98 µmol/L (0.83-1.04); 
this is shown in fig 6.10. Kruskal-Wallis (non-parametric) one way analysis of 
variance was performed and no difference in plasma selenium concentration was 
found between the three tertiles (p=0.991). Therefore the low plasma selenium 
concentrations seen at baseline in the study participants are not due to 
differences in CRP concentration. 
 
148 
 
 
Fig 6.10 Boxplot of plasma selenium concentration (µmol/L) by tertile of CRP 
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Chapter 7 
The Relationship between blood and tissue concentrations at baseline  
 
7.1 Copper 
The relationship between blood concentrations of copper, ceruloplasmin 
concentration, ferroxidase activity and tissue concentrations of copper at 
baseline, when the subject has a low C-reactive peptide and is non-inflamed, 
allows recommendations to be made as to whether plasma or red blood cell 
copper concentrations are a reliable measure of tissue status in the non-
inflamed patient. Therefore, simple linear regression was performed to examine 
the relationship between red blood cell, plasma, and liver copper 
concentrations, along with ceruloplasmin concentration and ferroxidase activity. 
The use of copper: ceruloplasmin ratios allows the relationship between copper 
concentration, ceruloplasmin concentration and the concentrations of other 
potential markers of copper status to be examined while correcting for any 
effect of plasma dilution due to intravenous fluid replacement given to the 
patient post-operatively. 
 
Table 7.1 shows the strength of linear association between each of the copper 
measures.  
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 r2 (p value) 
 
Liver 
Cu 
Log red 
blood 
cell Cu 
Log 
plasma 
Cu 
Log Cp 
Log 
Plasma 
Cu:Log 
Cp 
Ferroxidase 
Activity 
Liver Cu  
15.9% 
(0.036) 
4.3% 
(0.264) 
7.3% 
(0.142) 
2.9% 
(0.357) 
0.6% 
(0.691) 
Log red blood cell 
Cu 
15.9% 
(0.036) 
 
1.7% 
(0.515) 
8.7% 
(0.128) 
3.2% 
(0.341) 
0.0% 
(0.926) 
Log Plasma Cu 
4.3% 
(0.264) 
1.7% 
(0.515) 
 
33.5% 
(0.001) 
56.5% 
(<0.001) 
3.3% 
(0.334) 
Log Cp 
7.3% 
(0.142) 
8.7% 
(0.128) 
33.5% 
(0.001) 
 
94.4% 
(<0.001) 
1.6% 
(0.501) 
Log Plasma 
Cu:Log Cp 
2.9% 
(0.357) 
3.2% 
(0.341) 
56.5% 
(<0.001) 
94.4% 
(<0.001) 
 
10% 
(0.102) 
Ferroxidase 
Activity 
0.6% 
(0.691) 
0.0% 
(0.926) 
3.3% 
(0.334) 
1.6% 
(0.501) 
10% 
(0.102) 
 
Table 7.1 Results of linear regression analysis of each copper measure and its 
association with other copper measures. Values shown are r2 (p value for 
significance). Significant results are highlighted in bold type. (Cp= 
ceruloplasmin). 
 
Scatterplots can be seen at the end of this chapter, showing the relationship 
between each of the other copper measures and liver copper concentration (fig 
7.1a-e), red blood cell copper concentration (fig 7.2a-d), plasma copper 
concentration (fig 7.3a-c), plasma ceruloplasmin concentration (figure 7.4a-b), 
plasma copper: ceruloplasmin ratio (figure 7.5). 
 
The only linear relationship that exists between tissue and blood measures of 
copper is between liver copper concentration and red blood cell copper 
concentration (r2=15.9%, p=0.036). Plasma copper concentration does not have a 
linear relationship with liver copper concentration (r2=4.3%, p=0.264). 
There is a linear relationship between plasma copper and plasma ceruloplasmin 
concentration (r2=33.5%, p=0.001), which is unsurprising as ceruloplasmin is the 
main copper carrying protein in blood.  
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7.2 Zinc 
 
Examination of the relationship between blood concentrations of zinc and tissue 
concentrations of zinc at baseline (day 0), when the subject has a low C-reactive 
peptide and is not inflamed, allows recommendations to be made as to whether 
plasma or red blood cell zinc concentrations are a reliable measure of tissue 
status in a patient without inflammation. Therefore, simple linear regression 
was performed to examine the relationship between red blood cell, plasma, liver 
and muscle zinc concentrations. Table 7.2 shows the strength of linear 
association between each of the zinc measures.  
 
 r2 (p value) 
 
Liver Zn 
Red blood 
cell Zn 
Plasma Zn Muscle Zn 
Liver Zn  
5.3% 
(0.240) 
14.4% 
(0.046) 
3.6% 
(0.339) 
Red blood cell 
Zn 
5.3% 
(0.240) 
 
0.1% 
(0.896) 
7.4% 
(0.161) 
Plasma Zn 
14.4% 
(0.046) 
0.1% 
(0.896) 
 
0% 
(0.924) 
Muscle Zn 
3.6% 
(0.339) 
7.4% 
(0.161) 
0% 
(0.924) 
 
Table 7.2 Results of linear regression analysis of each selenium measure and its 
association with other selenium measures. Values shown are r2 (p value for 
significance). Statistically significant results are highlighted in bold type. 
 
Scatterplots can be seen at the end of this chapter, showing the relationship 
between each of the other zinc measures and liver selenium concentration (fig 
7.6a-c), red blood cell zinc concentration (fig 7.7a-b) and plasma zinc 
concentration (fig 7.8). 
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On day 0 when there is not a significant acute phase response, there is a weak 
linear relationship between plasma zinc concentration and liver zinc 
concentration (r2=14.4%, p=0.046); this relationship does not exist between 
other blood and tissue measures of zinc. 
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7.3 Selenium 
 
The relationship between blood concentrations of selenium and glutathione 
peroxidase activity and tissue concentrations of selenium at baseline (day 0), 
when the subject has a low C-reactive peptide and is not inflamed, allows 
recommendations to be made as to whether plasma or red blood cell selenium 
concentrations are a reliable measure of tissue status in a patient without 
inflammation. Therefore, simple linear regression was performed to examine the 
relationship between red blood cell, plasma, and liver selenium concentrations 
along with glutathione peroxidase activity. Table 7.3 shows the strength of 
linear association between each of the selenium measures.  
 
 r2 (p value) 
 
Liver Se 
Red blood 
cell Se 
Plasma Se 
RBC 
Glutathione 
Peroxidase 
activity 
Liver Se  
17.1% 
(0.023) 
43.1% 
(<0.001) 
22.6% 
(0.008) 
Red blood cell 
Se 
17.1% 
(0.023) 
 
29.7% 
(0.002) 
19.1% 
(0.016) 
Plasma Se 
43.1% 
(<0.001) 
29.7% 
(0.002) 
 
33.6% 
(0.001) 
RBC 
Glutathione 
Peroxidase 
activity 
22.6% 
(0.008) 
19.1% 
(0.016) 
33.6% 
(0.001) 
 
Table 7.3 Results of linear regression analysis of each selenium measure and its 
association with other selenium measures. Values shown are r2 (p value for 
significance). Statistically significant results are highlighted in bold type.  
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Scatterplots can be seen at the end of this chapter, showing the relationship 
between each of the other selenium measures and liver selenium concentration 
(fig 7.9a-c), red blood cell selenium concentration (fig 7.10a-b), plasma 
selenium concentration (fig 7.11). 
 
There are linear relationships between liver selenium concentration and red 
blood cell selenium concentration (r2=17.1%, p=0.023), plasma selenium 
concentration (r2=43.1%, p<0.001) and red blood cell glutathione peroxidase 
activity (r2=22.6%, p=0.008). A linear relationship also exists between red blood 
cell selenium concentration and plasma selenium concentration (r2=29.7%, 
p=0.002). Both red blood cell selenium concentration and plasma selenium 
concentration have a linear relationship with red blood cell glutathione 
peroxidase activity; r2=19.1% (p=0.016) and r2=33.6% (p=0.001) respectively. 
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Liver copper 
 
Fig 7.1a Scatterplot of liver Cu (µg/g dry weight) versus log red blood cell Cu 
(µg/µg Fe)  
 
Fig 7.1b Scatterplot of liver Cu (µg/g dry weight) versus log plasma Cu (µg/L) 
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Fig 7.1c Scatterplot of liver Cu (µg/g dry weight) versus log plasma 
Ceruloplasmin (g/L)  
 
Fig 7.1d Scatterplot of liver Cu (µg/g dry weight) versus log plasma copper: log 
plasma Ceruloplasmin ratio 
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Fig 7.1e Scatterplot of liver Cu (µg/g dry weight) versus plasma ferroxidase 
activity (U/L)  
 
Red blood cell copper 
 
 
Fig 7.2a Scatterplot of log red blood cell Cu (µg/µg Fe) versus log plasma Cu 
(µg/L)  
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Fig 7.2b Scatterplot of log red blood cell Cu (µg/µg Fe) versus log plasma 
ceruloplasmin (g/L)  
 
 
Fig 7.2c Scatterplot of log red blood cell Cu (µg/µg Fe) versus log plasma 
copper: log plasma Ceruloplasmin ratio 
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Fig 7.2d Scatterplot of log red blood cell Cu (µg/µg Fe) versus plasma 
ferroxidase activity (U/L)  
 
Plasma copper 
 
 
Fig 7.3a Scatterplot of log plasma Cu (µg/L) versus log plasma ceruloplasmin 
(g/L)  
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Fig 7.3b Scatterplot of log plasma Cu (µg/L) versus log plasma copper: log 
plasma ceruloplasmin ratio 
 
 
Fig 7.3c Scatterplot of log plasma Cu (µg/L) versus plasma ferroxidase activity 
(U/L)  
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Ceruloplasmin 
 
 
Fig 7.4a Scatterplot of log plasma ceruloplasmin (g/L) versus log plasma copper: 
log plasma ceruloplasmin ratio 
 
 
Fig 7.4b Scatterplot of log plasma ceruloplasmin (g/L) versus plasma ferroxidase 
activity (U/L)  
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Plasma copper: plasma ceruloplasmin ratio 
 
 
Fig 7.5 Scatterplot of log plasma ceruloplasmin (g/L) versus plasma ferroxidase 
activity (U/L)  
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Liver zinc 
 
 
Fig 7.6a Scatterplot of Liver Zn (µg/g dry weight) versus Plasma Zn on Day 0 
(µmol/L) 
 
 
Fig 7.6b Scatterplot of Liver Zn (µg/g dry weight) versus RBC Zn on Day 0 (µg/ 
µg Fe) 
164 
 
 
 
Fig 7.6c Scatterplot of Liver Zn (µg/g dry weight) versus Muscle Zn (µg/g dry 
weight) 
 
Red blood cell zinc 
 
Fig 7.7a Scatterplot of RBC Zn (µg/ µg Fe) versus Plasma Zn on Day 0 (µmol/L) 
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Fig 7.7b Scatterplot of RBC Zn (µg/ µg Fe) versus Muscle Zn (µg/g dry weight) 
 
Plasma zinc 
 
 
Fig 7.8 Scatterplot of Plasma Zn (µmol/L) versus Muscle Zn (µg/g dry weight) 
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Liver Selenium 
 
Fig 7.9a. Scatterplot of Liver Se (µg/g dry weight) versus RBC Se (µg/µg Fe) on 
day 0 
 
Fig 7.9b. Scatterplot of Liver Se (µg/g dry weight) versus plasma Se (µmol/L) on 
day 0 
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Fig 7.9c. Scatterplot of Liver Se (µg/g dry weight) versus RBC glutathione 
peroxidase activity (U/g Hb) on day 0 
 
RBC Selenium 
 
Fig 7.10a Scatterplot of RBC Se (µg/µg Fe) versus plasma Se (µmol/L) on day 0 
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Fig 7.10b Scatterplot of RBC Se (µg/µg Fe) versus RBC glutathione peroxidase 
activity (U/g Hb) on day 0 
 
Plasma Selenium 
 
Fig 7.11 Scatterplot of plasma Se (µmol/L) versus RBC glutathione peroxidase 
activity (U/g Hb) on day 0 
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Chapter 8  
Copper and the acute phase response 
 
8.1 Change in plasma copper, red blood cell copper and ceruloplasmin 
concentration, plus plasma ferroxidase activity, with the acute phase 
response 
 
On days 1-3, while the patients are post-operative, a systemic acute phase 
response develops, marked by a rise in CRP and a fall in serum albumin. Kruskal-
Wallis (non-parametric) one way analysis of variance was performed to see if red 
blood cell copper concentration, plasma copper concentration, plasma 
ceruloplasmin concentration or plasma ferroxidase activity varies during the 
acute phase response.  
 
The change in the concentration of RBC copper can be seen in fig 8.1a, plasma 
copper in fig 8.1b, plasma ceruloplasmin in fig 8.1c and plasma ferroxidase 
activity in fig 8.1d. The change in the plasma copper: ceruloplasmin ratio can be 
seen in fig 8.1e. Median values of red blood cell copper concentration, plasma 
copper concentration, plasma ceruloplasmin concentration and plasma 
ferroxidase activity on days 0-3, are shown in table 8.1. 
 
While there is a suggestion that plasma copper decreases on day 1, there is not 
any significant difference between the median plasma copper concentration on 
days 0-3 (p=0.097). There is no significant change in red blood cell copper 
concentration (p=0.519), plasma ceruloplasmin concentration (p=0.152), plasma 
ferroxidase activity (p=0.510) or plasma copper: ceruloplasmin ratio (p=0.221) 
on days 0-3. 
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 Median (IQR)  
 Day 0 Day 1 Day 2 Day 3 
P value for 
variance 
RBC Cu (µg/ µg Fe) 
0.000685 
(0.000650-
0.000729) 
0.000655 
(0.000617-
0.000718) 
0.000696 
(0.000609-
0.000734) 
0.000739 
(0.000601-
0.000862) 
0.519 
Plasma Cu (µmol/L) 
15.1 
(12.6-16.5) 
11.4 
(10.3-15.5) 
13.5 
(10.0-14.2) 
14.6 
(13.5-17.6) 
0.097 
Cp (g/L) 
0.20 
(0.18-0.24) 
0.19 
(0.17-0.20) 
0.20 
(0.18-0.24) 
0.21 
(0.19-0.26) 
0.152 
Ferroxidase (U/L) 
779 
(673 - 850) 
710 
(652 - 787) 
739 
(562 - 837) 
691 
(576 – 810) 
0.510 
plasma Cu:log Cp ratio 
4502 
(3943-4783) 
4273 
(3719-4752) 
4239 
(3493-4423) 
4372 
(4155-4372) 
0.221 
Table 8.1 Median (IQR) values of red blood cell copper concentration, plasma 
copper concentration, plasma ceruloplasmin (Cp) concentration and plasma 
ferroxidase activity on days 0-3. The significance of variance (p value) is from a 
Kruskal-Wallis (non-parametric) one way analysis of variance. 
 
 
Fig 8.1a Boxplot of median red blood cell copper concentration (µg/ µg Fe) on 
day 0-3 
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Fig 8.1b Boxplot of median plasma copper concentration (µmol/L) on day 0-3 
 
 
Fig 8.1c Boxplot of median plasma ceruloplasmin concentration (g/L) on day 0-3 
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Fig 8.1d Boxplot of median plasma ferroxidase activity (U/L) on day 0-3 
 
 
Fig 8.1e Boxplot of median plasma copper: ceruloplasmin ratio on day 0-3 
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8.2 Changes in linear associations during the acute phase response 
 
8.2.1 Red blood cell copper and liver copper concentration 
 
Although none of the blood measures were found to change significantly during 
days 0-3, there may be differences in their associations. Red blood cell copper 
concentration has been found have a linear relationship with liver copper 
concentration on day 0. Simple linear regression was performed to examine the 
relationship on days 1-3; results are in table 8.2 and can be seen graphically in 
fig 8.2. 
 
Despite not changing significantly during days 0-3, red blood cell copper 
concentration, which has a weak linear relationship with liver copper 
concentration on day 0 (p=0.04), does not have a linear relationship with liver 
copper on day 1 (p=0.480) or day 2 (p=0.782). A stronger linear relationship 
forms again on day 3 (p=0.019). 
 
 Liver Cu(µg/g dry weight) Vs RBC copper (µg/µg Fe) 
 r2(%) p value 
Day 0 15.1 0.041 
Day 1 2.8 0.480 
Day 2 0.7 0.782 
Day 3 51.9 0.019 
Table 8.2 Relationship between RBC copper (µg/ µg Fe) on day 0-3 with liver 
copper concentration (µg/g dry weight), using simple linear regression. 
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Fig 8.2 Scatterplot of liver Cu (µg/g dry weight) versus log red blood cell Cu 
(µg/µg Fe) on day 0-3  
 
8.2.2 Plasma copper, ceruloplasmin and liver copper concentration 
 
None of plasma copper concentration, plasma ceruloplasmin or plasma copper: 
ceruloplasmin were found have a linear relationship with liver copper 
concentration on day 0. Simple linear regression was performed to examine the 
relationship on days 1-3; results are in table 8.3 and can be seen graphically in 
fig 8.3a-c. 
 
While there is no linear relationship between plasma copper concentration, 
plasma ceruloplasmin or plasma copper: ceruloplasmin and liver copper on days 
0-2, a trend does develop by day 3. Although not reaching statistical 
significance, all three measures form a stronger, more linear relationship with 
liver copper by day 3. Copper and Cp are all closely related as ceruloplasmin is 
the main copper carrying protein in blood, so all three measures showing a 
similar pattern strengthens this not simply being a chance finding. 
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 Liver Cu (µg/g dry weight) Vs plasma Cu (µg/L) 
 r2(%) p value 
Day 0 1.7 0.517 
Day 1 1.1 0.645 
Day 2 2.0 0.615 
Day 3 32.9 0.083 
 Liver Cu (µg/g dry weight) Vs plasma Cp (g/L) 
 r2(%) p value 
Day 0 7.3 0.142 
Day 1 2.8 0.460 
Day 2 0.5 0.807 
Day 3 34.9 0.097 
 Liver Cu (µg/g dry weight) Vs Plasma Cu:Cp  
 r2(%) p value 
Day 0 2.9 0.357 
Day 1 1.5 0.601 
Day 2 0.1 0.903 
Day 3 37.4 0.080 
Table 8.3 Relationship between log plasma copper (µg/L), log plasma 
ceruloplasmin (g/L) and log plasma copper: log plasma ceruloplasmin ratio with 
liver copper concentration (µg/g dry weight) on days 0-3, using simple linear 
regression. 
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Fig 8.3a Scatterplot of liver Cu (µg/g dry weight) versus log plasma Cu (µg/L) on 
day 0-3  
 
 
Fig 8.3b Scatterplot of liver Cu (µg/g dry weight) versus log plasma 
ceruloplasmin (g/L) on day 0-3  
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Fig 8.3c Scatterplot of liver Cu (µg/g dry weight) versus log plasma Cu: log 
plasma ceruloplasmin ratio on day 0-3  
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8.2.3 Plasma copper and ceruloplasmin concentration 
 
As mentioned, ceruloplasmin is the main copper carrying protein in plasma. A 
linear relationship between plasma copper and plasma ceruloplasmin 
concentration was found on day 0 (r2=33.5%; p=0.001). Simple linear regression 
was performed to investigate this relationship on days 1-3; results are in table 
8.4 and can be seen graphically in fig 8.4. 
 
The linear relationship between plasma copper and plasma ceruloplasmin 
concentration which was found on day 0 continues on days 1-3 and appears to 
strengthen with 86% of the variation in plasma copper concentration being 
explained by plasma ceruloplasmin concentration on day 3 (p<0.001). 
 
 Plasma Cu (µg/L) Vs Ceruloplasmin (g/L) 
 r2(%) p value 
Day 0 33.5 0.001 
Day 1 54.8 0.000 
Day 2 57.7 0.002 
Day 3 86.3 0.000 
Table 8.4 Relationship between log plasma copper (µg/L) versus log plasma 
ceruloplasmin (g/L) on day 0-3, using simple linear regression. 
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Fig 8.4 Scatterplots of log plasma Cu (µg/L) versus log plasma ceruloplasmin 
(g/L) on day 0-3  
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8.3 Relationship between plasma copper, plasma ceruloplasmin and CRP 
concentration 
 
C Reactive protein is one of the main markers of the acute phase response. 
While none of plasma copper concentration, plasma ceruloplasmin or plasma 
copper: ceruloplasmin ratio changed significantly during the acute phase 
response, there may be a relationship between their concentration and the 
concentration of CRP. Simple linear regression was performed to investigate this 
relationship on days 0-3; results are in table 8.5 and can be seen graphically in 
fig 8.5a-c. 
 
On day 0, there is a linear relationship between plasma copper concentration 
(r2=23.1%; p=0.006), plasma ceruloplasmin concentration (r2=13.1%; p=0.045) 
and therefore plasma copper: ceruloplasmin ratio (r2=24.2%; p=0.005) with CRP 
concentration. This relationship is not present on days 1-3. 
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 CRP (g/L) Vs plasma Cu (µg/L) 
 r2(%) p value 
Day 0 23.1 0.006 
Day 1 0.7 0.721 
Day 2 7.3 0.331 
Day 3 3.5 0.606 
 CRP (g/L) Vs plasma Cp (g/L) 
 r2(%) p value 
Day 0 13.1 0.045 
Day 1 1.1 0.648 
Day 2 14.1 0.185 
Day 3 6.8 0.498 
 CRP (g/L) Vs Plasma Cu:Cp  
 r2(%) p value 
Day 0 24.2 0.005 
Day 1 0.5 0.773 
Day 2 15.0 0.171 
Day 3 7.4 0.478 
Table 8.5 Relationship between log plasma copper (µg/L), log plasma 
ceruloplasmin (g/L), log plasma copper: log plasma ceruloplasmin ratio and CRP 
concentration (g/L) (log CRP day 0) on days 0-3, using simple linear regression. 
 
 
182 
 
 
Fig 8.5a Scatterplots of CRP (g/L) versus log plasma copper (µg /L) on day 0-3  
 
 
Fig 8.5b Scatterplots of CRP (g/L) versus log plasma ceruloplasmin (g /L) on day 
0-3  
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Fig 8.5c Scatterplots of CRP (g/L) versus log plasma Cu: log plasma 
ceruloplasmin ratio on day 0-3  
 
To further examine the relationship between CRP and plasma copper, 
ceruloplasmin and plasma copper: ceruloplasmin ratio, the data was split into 
tertiles of day 0 CRP: tertile 1 0.5-2.2 g/L, tertile 2 3.0-6.8 g/L, tertile 3 7.0-
17.0 g/L. Simple linear regression analysis was performed (fig 8.6a-c, table 8.6) 
 
When day 0 data is split into tertiles of CRP concentration, the relationship 
between plasma copper concentration and CRP disappears, possibly as a result 
of small numbers. However the relationships between plasma ceruloplasmin 
concentration and CRP concentration, and ceruloplasmin: copper ratio and CRP 
concentration are present in tertile 2 and 3 (CRP 3.0-17.0 g/L). Of note, there is 
no linear relationship between plasma and liver copper concentration when only 
those samples with a CRP concentration in tertile 1 were included (r2 1.1%, 
p=0.771). 
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 CRP (g/L) Vs plasma Cu (µg/L) 
 r2(%) p value 
Tertile 1 0.1 0.921 
Tertile 2 8.0 0.398 
Tertile 3 29.6 0.104 
 CRP (g/L) Vs plasma Cp (g/L) 
 r2(%) p value 
Tertile 1 3.2 0.623 
Tertile 2 49.8 0.015 
Tertile 3 40.1 0.049 
 CRP (g/L) Vs Plasma Cu:Cp  
 r2(%) p value 
Tertile 1 4.7 0.546 
Tertile 2 43.4 0.027 
Tertile 3 40.1 0.049 
Table 8.6 Relationship between log plasma copper (µg/L), log plasma 
ceruloplasmin (g/L), log plasma copper: log plasma ceruloplasmin ratio and 
tertile 1-3 CRP concentration (g/L) days 0, using simple linear regression. 
 
 
Fig 8.6a Scatterplots of tertile 1 CRP (g/L) versus log plasma Cu, log plasma 
ceruloplasmin and log plasma copper: ceruloplasmin ratio on day 0  
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Fig 8.6b Scatterplots of tertile 2 CRP (g/L) versus log plasma Cu, log plasma 
ceruloplasmin and log plasma copper: ceruloplasmin ratio on day 0  
 
 
Fig 8.6c Scatterplots of tertile 3 CRP (g/L) versus log plasma Cu, log plasma 
ceruloplasmin and log plasma copper: ceruloplasmin ratio on day 0  
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8.4 Relationship between red blood cell copper concentration, plasma 
ferroxidase activity and CRP concentration 
 
Simple linear regression was performed to investigate the relationship between 
red blood cell copper concentration, plasma ferroxidase activity and CRP 
concentration on days 0-3. Results are in table 8.7 and can be seen graphically in 
fig 8.7a-b. 
 
There is no linear relationship between either red blood cell copper 
concentration or plasma ferroxidase activity, and C reactive protein 
concentration.  
 
 CRP (g/L) Vs RBC Cu (µg/µg Fe) 
 r2(%) p value 
Day 0 5.8 0.219 
Day 1 9.9 0.164 
Day 2 2.6 0.562 
Day 3 0.4 0.861 
 CRP (g/L) Vs ferroxidase (U/L) 
 r2(%) p value 
Day 0 0.8 0.634 
Day 1 2.1 0.516 
Day 2 13.6 0.194 
Day 3 0.1 0.928 
Table 8.7 Relationship between log red blood cell copper (µg/µg Fe), plasma 
ferroxidase activity (U/L) and CRP concentration (mg/L) (log CRP day 0) on days 
0-3, using simple linear regression. 
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Fig 8.7a Scatterplots of CRP (mg/L) versus log red blood cell copper (µg/ µg Fe) 
on day 0-3  
 
 
Fig 8.7b Scatterplots of CRP (mg/L) versus plasma ferroxidase (U/L) on day 0-3  
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8.5 Relationship between liver copper concentration and red blood cell 
copper concentration during the acute phase response 
 
As red blood cell copper was the only blood measure of copper which was found 
to have a linear relationship with liver copper, and as red blood cell copper 
concentration does not change during the acute phase response, it may be a 
suitable marker of copper status regardless of the inflammatory status of the 
patient. However, as seen in table 8.2, the linear relationship between red 
blood cell copper and liver copper was not seen on days 1 and 2. 
 
All red blood cell copper concentrations were combined and figure 8.8 shows the 
red blood cell copper concentrations for day 0-3 plotted against their respective 
liver copper concentration.  
 
 
Fig 8.8 Scatterplots of liver copper (µg/g dry weight) versus log red blood cell 
copper (µg/ µg Fe) on day 0-3  
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Simple linear regression analysis was performed: r2 15.6% (p=0.001). However, 
the sample size of each day is not equal, with day 0 having the most complete 
sample, this means that day 0, where there is known to be a linear relationship 
with liver copper concentration, will have dominance over the overall result.  
 
To see if the relationship existed if day 0 was excluded, the analysis was 
repeated using red blood cell concentrations from day 1-3 only (fig 8.9).  
 
 
Fig 8.9 Scatterplots of liver copper (µg/g dry weight) versus log red blood cell 
copper (µg/ µg Fe) on day 1-3  
 
The linear relationship was found to still exist despite the exclusion of day 0 
from analyses; r2 15.7%, p=0.008. 
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8.6 Summary of findings - Copper 
 
None of the blood copper measures (plasma copper concentration, red blood cell 
copper concentration, ceruloplasmin concentration, ceruloplasmin: copper ratio, 
plasma ferroxidase activity) changed significantly during the evolution of the 
acute phase response on the 3 days post-operatively. 
 
In the pre-operative samples, when the patients were not inflamed, red blood 
cell copper concentration has a linear relationship with liver copper 
concentration. This relationship changes during the evolution of the acute phase 
response and is no longer linear on days 1 and 2 but becomes linear again on day 
3.  
 
When all red blood cell concentrations from day 0-3 were pooled, inflamed and 
non-inflamed samples, there was still a linear relationship with liver copper; 
however, due to different numbers of samples for each day, the non-inflamed 
samples will be dominant and this result may not be truly representative of the 
relationship during inflammation. However the linear relationship persisted 
when the non-inflamed samples were excluded. 
 
There is also a linear relationship between plasma copper concentration and 
ceruloplasmin concentration which is present both when the patients are not 
inflamed and through the evolution of the acute phase response on the 3 days 
immediately post-operatively.  
 
Copper, ceruloplasmin and the copper: ceruloplasmin ratio do not have a linear 
relationship with liver copper concentration when non-inflamed or in the first 
two days of the acute phase response. However, by day 3 of the acute phase 
response all three measure have a strengthened linear relationship with liver 
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copper concentration, but, possibly due to small sample size, these did not 
reach full significance. 
 
Copper, ceruloplasmin and the copper: Ceruloplasmin ratio all have a linear 
relationship with C-reactive protein on day 0, when the C-reactive protein 
concentration is low. Further examination of this relationship by splitting the 
data into tertiles of CRP shows that the linear relationships between 
ceruloplasmin concentration and CRP, and copper: ceruloplasmin ratio and CRP 
are present in tertile 2 and 3 of CRP. These tertiles correspond to a CRP of 3.0-
17.0g/L.  
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Chapter 9  
Zinc and the acute phase response 
 
9.1 Change in plasma and red blood cell zinc with the acute phase response 
 
Over days 1-3 an acute phase response develops as shown by an increase in 
serum CRP and a fall in serum albumin; in order to see if red blood cell or 
plasma concentrations of zinc change during this acute phase, Kruskal-Wallis 
(non-parametric) one way analysis of variance was performed. 
 
The acute phase response evolved over day 1-3 as shown by an increase in CRP 
and a fall in serum albumin. The change in the concentration of RBC Zinc can be 
seen in fig 9.1a and plasma Zinc in fig 9.1b.  
 
 
Fig 9.1a Boxplot of median red blood cell zinc concentration (µg/ µg Fe) on day 
0-3. 
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Fig 9.1b Boxplot of median plasma zinc concentration (µmol/L) on day 0-3 
 
RBC Zinc 
 
RBC zinc does not change significantly over day 0-3 (p=0.510); median values 
(IQR) were day 0 0.011 (0.011 – 0.013) µg/ µg Fe, day 1 0.011 (0.011 – 0.013) µg/ 
µg Fe, day 2 0.012 (0.012 – 0.013) µg/ µg Fe and day 3 0.012 (0.011 – 0.013) µg/ 
µg Fe. Therefore, red blood cell zinc concentration does not change during the 
acute phase response. 
 
Plasma Zinc 
 
Kruskal-Wallis (non-parametric) one way analysis of variance shows that plasma 
zinc concentration changes significantly from day 0 to day 1-3 (p<0.001).  
However there is no significant change in concentration between day 1, day 2 
and day 3 (p=0.533). Median (IQR) values of plasma were 11.6 (10.6 – 12.8) 
µmol/L on day 0, 7.9 (6.4 – 9.5) µmol/L on day 1, 7.9 (5.9- 9.1) µmol/L on day 2 
and 8.9 (7.5 – 9.7) µmol/L on day 3.  
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The median (IQR) percentage change in plasma zinc from day 0 to day 1 was -
31.8% (-47.28 - -15.22), day 0 to day 2 -28.89% (-42.52 - -16.78) and day 0 to day 
3 -25.4% (-30.9 - -15.06); there was no significant difference between these 
percentage changes (p=0.357).  
Plasma zinc concentration decreases with the evolution of the acute phase 
response.  
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9.2 Tertiles of liver zinc  
 
In order to examine the effect of liver zinc concentration on the changes in 
plasma zinc concentration seen during the evolution of acute phase response, 
data was split into tertiles by liver zinc concentration; there were 9, 10 and 9 
patient samples in each of the low, medium and high tertiles respectively. 
Analysis of variance of CRP and Albumin was performed to ensure there were no 
differences in CRP or Albumin between tertiles on any of day 0-3; as it was not 
normally distributed, the logarithmic transformation of CRP day 0 was used. 
Mean values (SD) for CRP and Albumin by liver tertile can be seen in table 9.1. 
No differences in CRP or Albumin concentrations were seen between tertiles of 
liver zinc. 
 
 Tertile liver zinc (range liver zinc (µg/g dry weight)) 
 1 
(111.9-
220.9) 
2 
(230.7-280.1) 
3 
(280.9-384.5) 
p value for 
variance 
CRP day 0 (mg/L) 5.6(2.8) 6.6(3.2) 6.6(3.2) 0.974 
CRP day 1 (mg/L) 92.11(25.0) 102.4(34.3) 102.0(38.1) 0.753 
CRP day 2 (mg/L) 163.2(32.5) 176.0(73.0) 177.4(61.6) 0.852 
CRP day 3 (mg/L) 160.7(39.3) 175.6(76.4) 153.6(59.9) 0.726 
Alb day 0 (g/L) 37.3(7.57) 37.9(3.81) 39.0(2.0) 0.772 
Alb day 1 (g/L) 27.8(4.63) 28.3(3.68) 28.6(2.6) 0.903 
Alb day 2 (g/L) 26.1(3.26) 28.1(3.04) 27.6(2.51) 0.339 
Alb day 3 (g/L) 26.0(3.75) 26.4(3.53) 25.3(2.35) 0.778 
Table 9.1 Mean values (SD) of CRP (mg/L) and Albumin (g/L) on day 0-3 for 
tertiles of liver zinc concentration (µg/g dry weight). 
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9.2.1 Plasma zinc concentrations between tertiles of liver zinc 
 
To see if the relationship found between plasma zinc concentration and liver 
zinc concentration is maintained during the acute phase response, Kruskal-Wallis 
non-parametric analysis of variance was performed between the medians of 
plasma zinc concentration for each of the three tertiles of liver zinc 
concentration on days 0-3; this was also performed for the percentage change in 
plasma zinc to ascertain if the decrease in plasma zinc concentration with the 
acute phase response is related to the liver zinc concentration. 
 
Median concentration of plasma zinc (µmol/L) on day 0-3 and median percentage 
change in plasma zinc, from day 0 to day 1-3, divided by tertile of liver zinc, are 
shown in table 9.2. The median concentration of plasma zinc (µmol/L) for each 
liver tertile, at each time point, can be seen graphically in figure 9.2a and the 
median percentage change in plasma zinc concentration between day 0 and day 
1-3, for tertiles of liver zinc concentration, can be seen in figure 9.2b. 
 
While none of the plasma zinc concentrations vary statistically significantly 
across the tertiles of liver zinc concentration, a trend can be seen for plasma 
zinc concentration to increase through the tertiles. A trend also exists for the 
percentage change in plasma zinc: while none of the percentage changes in 
plasma zinc levels vary with statistical significance, on day 1 and day 2 the trend 
is for the lowest tertile to have the largest percentage drop in plasma zinc 
concentration, and the highest tertile to drop the least. 
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 Tertile liver zinc (range liver zinc (µg/g dry weight)) 
 1 
(111.9-220.9) 
2 
(230.7-280.1) 
3 
(280.9-384.5) 
p value 
for 
variance 
Plasma Zn day 0 
(µmol/L) 
10.5 
(9.5-11.9) 
11.6 
(10.5-13.4) 
12.0 
(11.4-13.1) 
0.122 
Plasma Zn day 1 
(µmol/L) 
6.4 
(4.8-7.9) 
7.4 
(6.0-10.1) 
9.1 
(7.4-9.4) 
0.296 
Plasma Zn day 2 
(µmol/L) 
5.7 
(5.5-6.0) 
8.0 
(6.8-9.6) 
9.1 
(8.2-9.9) 
0.063 
Plasma Zn day 3 
(µmol/L) 
7.3 
(6.2-9.5) 
9.8* 9.0 
(8.3-9.8) 
0.368 
Change plasma 
Zn day 1 (%) 
-45.26 
(-51.09 - -35.05) 
-31.67 
(-49.93 - -11.77) 
-22.36 
(-47.46 - -13.12) 
0.305 
Change plasma 
Zn day 2 (%) 
-40.77 
(-44.5 - -34.10) 
-32.59 
(-47.6 - -11.9) 
-22.61 
(-28.39 - -15.57) 
0.211 
Change plasma 
Zn day 3 (%) 
-25.57 
(-28.79 - -16.42) 
-24.97* -25.28 
(-31.61 - -7.7) 
0.895 
Table 9.2 Median (IQR) values of plasma zinc concentration (µmol/L) on day 0-3 
and % change in plasma zinc concentration between day 0 and day 1-3, for 
tertiles of liver zinc concentration. *only 1 sample available in this category. 
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Fig 9.2a. Boxplot of median plasma zinc concentration (µmol/L) on day 0-3 for 
tertiles of liver zinc concentration 
 
 
Fig 9.2b Boxplot of median % change in plasma zinc concentration between day 
0 and day 1-3, for tertiles of liver zinc concentration 
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9.2.2 Zinc: Albumin ratios 
 
The use of zinc:albumin ratios allows the relationship between albumin 
concentration, zinc concentration and tertile of liver zinc concentration to be 
examined while correcting for any effect of plasma dilution due to intravenous 
fluid replacement given to the patient post-operatively. Figure 9.3a shows the 
median zinc:albumin ratio on days 0-3. Using Mann-Whitney comparisons 
(Bonferroni correction p=0.017 is significant), the zinc:albumin ratio decreases 
from day 0 to day 1 (p=0.064), is similar or day 1 and 2 (p=0.645) and increases 
again on day 3 (p=0.022). 
 
Figure 9.3b shows the median zinc:albumin ratio on days 0-3, divided by tertile 
of liver zinc concentration. Values for the median zinc:albumin ratio for each 
liver zinc tertile on days 0-3 and an analysis of variance can be seen in table 9.3. 
 
On day 0 there is no difference between the zinc:albumin ratios for the three 
tertiles of liver zinc. However, by day one there is an decrease in the 
zinc:albumin ratio in the lowest tertile, and to a smaller effect in the middle 
tertile, relative to the highest tertile of liver zinc (p=0.063); this difference 
appears to have resolved by day 3 (p=0.249).  As we know there is no difference 
in albumin concentrations between the tertiles (table 9.1), the decrease in 
zinc:albumin ratio must reflect a greater drop in plasma zinc concentration on 
day 1 in the lowest tertile of liver zinc, relative to the drop in albumin 
concentration, than the highest tertile of liver zinc. 
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 Tertile liver zinc (range liver zinc (µg/g dry weight)) 
 1 
(111.9-220.9) 
2 
(230.7-280.1) 
3 
(280.9-384.5) 
p value for 
variance 
Zn:Alb day 0  19.58 
(14.84-24.99) 
21.25 
(18.30-22.29) 
20.16 
(19.05-21.44) 
0.783 
Zn:Alb day 1 15.28 
(12.93-17.34) 
18.26 
(14.79-21.83) 
20.13 
(18.55-20.59) 
0.063 
Zn:Alb day 2 16.48 
(15.61-17.63) 
18.55 
(14.48-22.08) 
20.60 
(19.02-23.02) 
0.148 
Zn:Alb day 3 21.60 
(18.43-25.77) 
22.50* 22.60 
(19.41-23.84) 
0.249 
Table 9.3 Median (IQR) values of zinc:albumin ratio on day 0-3 for tertiles of 
liver zinc concentration. *only 1 sample available in this category. 
 
 
Fig 9.3a Boxplot of median zinc:albumin ratio on day 0-3 
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Fig 9.3b Boxplot of median zinc:albumin ratio on day 0-3 for tertiles of liver zinc 
concentration 
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9.3 Regression analysis 
9.3.1 Plasma versus liver zinc concentrations 
 
In order to further examine the relationship between plasma zinc concentration, 
percentage decrease in plasma zinc and liver zinc concentration during the 
acute phase response, simple linear regression was performed; the results can 
be seen in table 9.4. The relationship between plasma zinc concentration (µg/L) 
and liver zinc concentration (µg/g dry weight) on day 0-3 can be seen in figure 
9.4a and the relationship between the percentage change in plasma zinc 
concentration and liver zinc concentration (µg/g dry weight) on day 1-3 can be 
seen in figure 9.4b. 
 
The weak linear relationship found on day 0 between plasma and liver zinc 
concentration is no longer statistically significant on days 1-3. There is no 
relationship between the percentage change in plasma zinc concentration on 
days 1-3 and liver zinc concentration. 
 
 Liver Zn (µg/g dry weight) Vs plasma zinc (µg/L) 
 r2(%) p value 
Day 0 14.4 0.046 
Day 1 11.4 0.145 
Day 2 24.7 0.084 
Day 3 26.6 0.191 
 Liver Zn (µg/g dry weight) Vs % change plasma zinc 
 r2(%) p value 
Day 1 7.2 0.253 
Day 2 9.2 0.313 
Day 3 5.2 0.588 
Table 9.4 Relationship between both plasma zinc (µg/L) on day 0-3, and 
percentage change in plasma zinc from day 0 (%) on day 1-3, with liver zinc 
concentration (µg/g dry weight) using simple linear regression. 
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Fig 9.4a Scatterplots of plasma zinc concentration (µg/L) versus liver zinc 
concentration (µg/g dry weight) on day 0-3. 
 
 
Fig 9.4b Scatterplots of % change plasma zinc concentration from day 0 versus 
liver zinc concentration (µg/g dry weight) on day 1-3 
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9.3.2 Plasma zinc concentrations versus albumin 
 
Linear regression was performed to examine the relationship between serum 
albumin concentration and plasma zinc concentration on day 0-3, and % change 
in plasma zinc concentration on day 1-3; the results can be seen in table 9.5. 
The relationship between plasma zinc concentration (µg/L) and serum albumin 
concentration (g/L) on day 0-3 can be seen in figure 9.5a. The relationship 
between % change of plasma zinc concentration and serum albumin 
concentration (g/L) on day 1-3 can be seen in figure 9.5b. 
 
While there is no linear relationship between serum albumin and plasma zinc 
concentrations on day 0, during days 1-3 a stronger and statistically significant 
linear relationship between serum albumin concentration and plasma zinc 
concentration develops.  There is a suggestion of linear relationship between the 
% change in plasma zinc and the serum albumin on days 1 and 2, though this 
does not quite reach statistical significance; the relationship has lessened by day 
3. 
 
 Albumin (g/L) Vs plasma zinc (µg/L) 
 r2(%) p value 
Day 0 2.5 0.420 
Day 1 30.1 0.012 
Day 2 46.5 0.010 
Day 3 45.1 0.068 
 Albumin (g/L) Vs % change plasma zinc 
 r2(%) p value 
Day 1 14.8 0.094 
Day 2 25.7 0.077 
Day 3 15.3 0.338 
Table 9.5 Relationship between serum albumin (g/L) and plasma zinc (µg/L) on 
day 0-3 and % change plasma zinc on day 1-3, using simple linear regression. 
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Fig 9.5a Scatterplots of plasma zinc concentration (µg/L) versus serum albumin 
concentration (g/L) on day 0-3 
 
 
Fig 9.5b Scatterplots of % change plasma zinc concentration versus serum 
albumin concentration (g/L) on day 1-3 
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9.3.3 Plasma zinc concentrations versus Zinc: Albumin ratio 
 
To further examine the relationship between the zinc: albumin ratio and plasma 
zinc concentration on days 0-3, and % change in plasma zinc concentration on 
day 1-3 , linear regression was carried out; the results can be seen in table 9.6. 
The relationship between plasma zinc concentration (µg/L) and the zinc: 
albumin ratio on day 0-3 can be seen in figure 9.6a. The relationship between % 
change of plasma zinc concentration and the zinc: albumin ratio on day 1-3 can 
be seen in figure 9.6b. 
 
There is a statistically significant linear relationship between plasma zinc 
concentration and the zinc: albumin ratio on days 0-3 (p≤0.01). The relationship 
between the percentage change in plasma zinc concentration and the zinc: 
albumin ratio is statically significant on days 1 and 2 (p≤0.001), but absent by 
day 3 (p=0.264). 
 
 Zinc: albumin Vs plasma zinc (µg/L) 
 r2(%) p value 
Day 0 38.5 0.000 
Day 1 75.3 0.000 
Day 2 74.6 0.000 
Day 3 70.0 0.010 
 Zinc: albumin  Vs % change plasma zinc 
 r2(%) p value 
Day 1 67.6 0.000 
Day 2 65.1 0.001 
Day 3 20.2 0.264 
Table 9.6 Relationship between zinc: albumin ratio and plasma zinc 
(µg/L) on day 0-3 and % change plasma zinc on day 1-3, using simple 
linear regression. 
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Fig 9.6a Scatterplots of plasma zinc concentration (µg/L) versus zinc: albumin 
ratio on day 0-3. 
 
 
Fig 9.6b Scatterplots of % change plasma zinc versus zinc: albumin ratio on day 
1-3 
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9.3.4 Plasma zinc concentrations versus C-reactive protein 
 
In order to examine the relationship between C-reactive protein concentration 
and plasma zinc concentration on days 0-3, and % change in plasma zinc 
concentration on day 1-3 , linear regression was carried out; the results can be 
seen in table 9.7. The logarithmic transformation of CRP day 0 was used. The 
relationship between plasma zinc concentration (µg/L) and serum CRP 
concentration (mg/L) on day 0-3 can be seen in figure 9.7a. The relationship 
between % change of plasma zinc concentration and serum albumin 
concentration (g/L) on day 1-3 can be seen in figure 9.7b. 
 
No linear relationship is found between plasma zinc concentration and serum C-
reactive protein concentration over days 0-3 or between the % change in plasma 
zinc concentration and serum C-reactive protein concentration over days 1-3. 
 
 CRP (mg/L) Vs plasma zinc (µg/L) 
 r2(%) p value 
Day 0 6.4 0.193 
Day 1 7.2 0.254 
Day 2 1.2 0.721 
Day 3 1.0 0.812 
 CRP (mg/L) Vs % change plasma zinc 
 r2(%) p value 
Day 1 1.4 0.618 
Day 2 2.6 0.596 
Day 3 0.1 0.958 
Table 9.7 Relationship between CRP (mg/L) and plasma zinc (µg/L) on day 0-3, 
and % change plasma zinc on day 1-3, using simple linear regression. 
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Fig 9.7a Scatterplots of plasma zinc concentration (µg/L) versus CRP 
concentration (mg/L) on day 0-3 
 
 
Fig 9.7b Scatterplots of % change in plasma zinc concentration versus CRP 
concentration (mg/L) on day 1-3 
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9.4 Prediction of liver zinc and day 0 plasma zinc 
 
Given that plasma zinc is the only marker related to liver zinc status, yet it 
changes with the acute phase response, it would be of value to find a model to 
predict the “non-inflamed” plasma zinc, or the liver concentration of zinc, 
during the acute phase response. Regression analysis was used to find predictors 
of baseline plasma or liver zinc concentrations during the acute phase response 
seen on days 1-3.  
 
9.4.1 Plasma zinc 
 
The relationship between plasma zinc concentration and liver zinc concentration 
on day 0 can be seen in fig 7.6a. The relationship between plasma zinc 
concentration on days 1-3 and plasma zinc concentration on day 0 can be seen in 
fig 9.8. Table 9.8 shows the results of linear regression analysis of the 
relationship between both plasma zinc day 0 (µg/L) and liver zinc concentration 
(µg/g dry weight), with plasma zinc concentration on day 1-3, using simple 
linear regression.  
 
A linear relationship exists between plasma zinc and liver zinc concentrations 
beyond day 0, but the relationship is no longer statistically significant. There is 
no relationship between plasma zinc on day 0 and day 1, but by day 2 and day 3 
there is a suggestion of a linear relationship between the plasma zinc 
concentration and the plasma zinc concentration from day 0, however it does 
not reach statistical significance. 
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 Plasma zinc (µg/L) Vs Liver Zn (µg/g dry weight)  
 r2(%) p value 
Day 0 14.4 0.046 
Day 1 11.4 0.145 
Day 2 24.7 0.084 
Day 3 26.6 0.191 
 Plasma zinc (µg/L) Vs Plasma zinc Day 0 (µg/L) 
 r2(%) p value 
Day 1 0.6 0.752 
Day 2 25.3 0.080 
Day 3 44.6 0.070 
Table 9.8 Relationship between both plasma zinc day 0 (µg/L) and liver zinc 
concentration (µg/g dry weight), with plasma zinc concentration on day 0-3 
using simple linear regression. 
 
 
Fig 9.8 Scatterplots of plasma zinc concentration (µg/L) on day 1-3 versus 
plasma zinc concentration (µg/L) on day 0. 
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9.4.2 Albumin 
 
Figure 9.9a shows the relationship between serum albumin concentration on day 
0-3 and plasma zinc concentration on day 0. Figure 9.9b shows the relationship 
between serum albumin concentration on day 0-3 and liver zinc concentration on 
day 0. The results of linear regression analysis of the relationship between both 
plasma zinc day 0 (µg/L) and liver zinc concentration (µg/g dry weight), with 
serum albumin concentration on day 1-3, using simple linear regression, can be 
seen in table 9.9. 
 
There is no relationship between serum albumin concentration on day 0-3 and 
liver zinc concentration. A linear relationship between serum albumin 
concentration and plasma zinc concentration, that is not present on day 0, 
develops over day 1-3. The linearity is statistically significant on day 2 (p=0.009) 
when serum albumin explains 23.5% of the variability of the plasma zinc 
concentration on day 0. 
 
 Serum Albumin (g/L) Vs Plasma Zn day 0 (µg/L) 
 r2(%) p value 
Day 0 2.5 0.420 
Day 1 9.0 0.120 
Day 2 23.5 0.009 
Day 3 12.9 0.061 
 Serum Albumin (g/L) Vs Liver Zn (µg/g dry weight) 
 r2(%) p value 
Day 0 1.6 0.525 
Day 1 1.5 0.535 
Day 2 8.8 0.125 
Day 3 0.2 0.833 
Table 9.9 Relationship between both plasma zinc day 0 (µg/L) and liver zinc 
concentration (µg/g dry weight), with serum albumin concentration on day 0-3, 
using simple linear regression. 
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Fig 9.9a Scatterplots of serum albumin concentration (g/L) on day 0-3 versus 
plasma zinc concentration (µg/L) on day 0. 
 
 
Fig 9.9b Scatterplots of serum albumin concentration (g/L) on day 0-3 versus 
liver zinc concentration (µg/g dry weight) 
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9.4.3 Zinc: Albumin ratio 
 
The relationship between the zinc: albumin ratio on day 0-3 and plasma zinc 
concentration on day 0 can be seen in Figure 9.10a. Figure 9.10b shows the 
relationship between the zinc: albumin ratio on day 0-3 and liver zinc 
concentration on day 0. The results of linear regression analysis of the 
relationship between both plasma zinc day 0 (µg/L) and liver zinc concentration 
(µg/g dry weight), with the zinc: albumin ratio on day 1-3, using simple linear 
regression, can be seen in table 9.10. 
 
There is a linear relationship between the zinc: albumin ratio and the plasma 
zinc concentration on day 0, but this then disappears on day 1 and day 2. There 
is an r2 of 36.7% by day 3 but this is not statistically significant (p=0.111). There 
is no linear relationship between the zinc: albumin ratio and the liver zinc 
concentration on days 0-3. 
 
 Zinc: Albumin ratio Vs Plasma Zn day 0 (µg/L) 
 r2(%) p value 
Day 0 38.5 0.000 
Day 1 0.1 0.910 
Day 2 10.6 0.277 
Day 3 36.7 0.111 
 Zinc: Albumin ratio Vs Liver Zn (µg/g dry weight) 
 r2(%) p value 
Day 0 2.4 0.435 
Day 1 4.8 0.093 
Day 2 8.4 0.335 
Day 3 3.8 0.642 
Table 9.10 Relationship between both plasma zinc day 0 (µg/L) and liver zinc 
concentration (µg/g dry weight), with albumin: zinc ratio on day 0-3, using 
simple linear regression. 
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Fig 9.10a Scatterplots of zinc: albumin ratios on day 0-3 versus plasma zinc 
concentration (µg/L) on day 0 
 
 
Fig 9.10b Scatterplots of zinc: albumin ratios on day 0-3 versus liver zinc 
concentration (µg/g dry weight) 
 
216 
 
9.4.4 C - reactive protein 
 
Figure 9.11a shows the relationship between CRP concentration on day 0-3 and 
plasma zinc concentration on day 0. Figure 9.11b shows the relationship 
between CRP concentration on day 0-3 and liver zinc concentration on day 0. 
The logarithmic transformation of day 0 CRP was used. The results of linear 
regression analysis of the relationship between both plasma zinc day 0 (µg/L) 
and liver zinc concentration (µg/g dry weight), with CRP concentration on day 0-
3, using simple linear regression, can be seen in table 9.11. 
 
There is no relationship between either plasma zinc day on day 0 or liver zinc, 
and CRP on day 0-3. 
 
 CRP (mg/L) Vs Plasma Zn day 0 (µg/L) 
 r2(%) p value 
Day 0 6.4 0.193 
Day 1 0.1 0.904 
Day 2 0.0 0.987 
Day 3 2.2 0.456 
 CRP (mg/L) Vs Liver Zn (µg/g dry weight) 
 r2(%) p value 
Day 0 0.0 0.999 
Day 1 1.1 0.596 
Day 2 0.0 0.920 
Day 3 0.3 0.777 
Table 9.11 Relationship between both plasma zinc day 0 (µg/L) and liver zinc 
concentration (µg/g dry weight), with CRP (mg/L) on day 0-3, using simple linear 
regression. 
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Fig 9.11a Scatterplots of CRP (mg/L) on day 0-3 versus plasma zinc 
concentration (µg/L) on day 0 
 
 
Fig 9.11b Scatterplots of CRP (mg/L) on day 0-3 versus liver zinc concentration 
(µg/g dry weight) 
 
 
218 
 
9.4.5 Multiple linear regression 
 
Ideally, a model would exist to predict zinc status during the acute phase 
response. Plasma zinc status on day 0 and liver zinc concentration were used as 
markers of zinc status. As they are likely to be available in clinical practice, a 
model using plasma zinc concentration (µg/L), serum albumin concentration 
(g/L), zinc: albumin ratio and serum C-reactive protein (mg/L) was built for 
each of day 1-3. Results can be seen in table 9.12. 
  R2(%) p value 
Day 1    
Plasma Zinc Day 0    
 Plasma Zinc Day 1 0.6 0.752 
 + Albumin Day 1 5.3 0.630 
 +Zn: Alb Day 1 7.1 0.751 
 + CRP Day 1 9.7 0.802 
Liver Zinc    
 Plasma Zinc Day 1 11.4 0.145 
 + Albumin Day 1 14.1 0.275 
 +Zn: Alb Day 1 15.6 0.423 
 + CRP Day 1 15.6 0.607 
Day 2    
Plasma Zinc Day 0    
 Plasma Zinc Day 2 25.3 0.080 
 + Albumin Day 2 33.5 0.130 
 +Zn: Alb Day 2 37.5 0.217 
 + CRP Day 2 39.1 0.353 
Liver Zinc    
 Plasma Zinc Day 2 24.7 0.084 
 + Albumin Day 2 36.5 0.103 
 +Zn: Alb Day 2 39.1 0.197 
 + CRP Day 2 42.8 0.290 
Day 3    
Plasma Zinc Day 0    
 Plasma Zinc Day 3 44.6 0.070 
 + Albumin Day 3 44.6 0.228 
 +Zn: Alb Day 3 73.0 0.123 
 + CRP Day 3 77.8 0.226 
Liver Zinc    
 Plasma Zinc Day 3 26.6 0.191 
 + Albumin Day 3 48.5 0.190 
 +Zn: Alb Day 3 52.3 0.351 
 + CRP Day 3 55.1 0.550 
Table 9.12a Multiple linear regression to predict plasma zinc concentration on 
day 0 and liver zinc concentration on each of day 1-3. Each step involves the 
addition of a factor to the model.  
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None of the regression models reached statistical significance, probably due to 
insufficient numbers.  However, a combination of plasma zinc concentration, 
albumin concentration, zinc: albumin ratio and CRP was the strongest model for 
predicting both plasma zinc concentration on day 0 and liver zinc concentration. 
 
In clinical practice it is unlikely there would  be a clean rise and fall of the acute 
phase response, so the stage of the acute phase response would not be known. 
Therefore, any equation to predict zinc status would have to be able to be used 
at any stage of the acute phase response. The results of day 1-3 were combined 
and the prediction model involving plasma zinc concentration (µg/L), serum 
albumin concentration (g/L), zinc: albumin ratio and serum C-reactive protein 
(mg/L) was repeated; the results can be seen in table 9.12b. 
  R2 (%) p value 
Day 1-3    
Plasma Zinc Day 0    
 Plasma Zinc 8.6 0.062 
 + Albumin  16.8 0.031 
 +Zn: Alb 21.0 0.032 
 + CRP  21.5 0.063 
Liver Zinc    
 Plasma Zinc  15.8 0.010 
 + Albumin  18.4 0.021 
 +Zn: Alb  18.5 0.054 
 + CRP  18.5 0.110 
Table 9.12b Multiple linear regression to predict plasma zinc concentration on 
day 0 and liver zinc concentration. Each step involves the addition of a factor to 
the model. Factors are a combination of the results from day 1-3. 
 
16.8% of the variance of plasma zinc from day 0 can be explained by the plasma 
zinc concentration and the albumin (p=0.031). 18.5% of the liver zinc 
concentration can be explained by plasma zinc concentration, serum albumin 
concentration and the zinc: albumin ratio (p=0.054). The addition of CRP to the 
model did not strengthen it in either case.  Neither of these models is strong 
enough to be used for the prediction of zinc status during the acute phase 
response in clinical practice. 
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9.5 Summary of findings - Zinc 
 
Plasma zinc and the zinc: albumin ratio both decrease with the evolution of the 
acute phase response on days 1-3. 
 
In the pre-operative samples, when the patients were not inflamed, plasma zinc 
concentration has a weak linear relationship with liver zinc concentration.  
 
Exploring this relationship further by splitting the data into tertiles of liver zinc 
shows that the trend was for plasma zinc to be highest in the highest liver zinc 
tertile and lowest in the lowest liver zinc tertile; however, this result does not 
reach statistical significance. No significant linear relationship existed between 
plasma zinc and liver zinc concentration during the acute phase response. 
 
A linear relationship between plasma zinc concentration and albumin 
concentration, which is not present on day 0 when the patients are non-
inflamed, developed during days 1-3 of the acute phase response. 
 
Albumin, plasma zinc and the plasma zinc: albumin ratio cannot be used to 
create a model for predicting the non-inflamed plasma zinc or liver zinc as a 
means of assessing zinc status during the acute phase response.  
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Chapter 10 
Selenium and the acute phase response 
 
10.1 Change in plasma selenium, red blood cell selenium and red blood cell 
glutathione peroxidase activity, with the acute phase response 
 
On days 1-3, in the post-operative period, a systemic acute phase response 
develops marked by a rise in CRP and a fall in serum albumin. Kruskal-Wallis 
(non-parametric) one way analysis of variance was performed to see if red blood 
cell or plasma selenium concentration, or red blood cell glutathione peroxidase 
activity varies during the acute phase response. The use of the selenium: 
albumin ratio allows the relationship between selenium concentration and 
albumin concentration to be examined while correcting for any effect of plasma 
dilution due to intravenous fluid replacement given to the patient post-
operatively.  
 
The change in the concentration of red blood cell selenium can be seen in fig 
10.1a, plasma selenium in fig 10.1b, the plasma selenium: albumin ratio in fig 
10.1c and red blood cell glutathione peroxidase in fig 10.1d. Median values, 
inter-quartile ranges and the results of Kruskal-Wallis (non-parametric) one way 
analysis of variance can be seen in table 10.1. 
 
There is no significant change in red blood cell selenium concentration 
(p=0.647), plasma selenium: albumin ratio (p=0.959), or red blood cell 
glutathione peroxidase activity (p=0.526) over days 0-3. 
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Plasma selenium concentration changes significantly over days 0-3 (p<0.001). 
Mann-Whitney comparisons were performed (Bonferroni correction p=0.017 is 
significant): day 0 to day 1 p<0.001, day 1 to day 2 p=0.867, day 2 to day 3 
p=0.890. Therefore the plasma selenium does change significantly during the 
acute phase response, with the significant change being between day 0 and day 
1. 
 
 Median (IQR)  
 
Day 0 Day 1 Day 2 Day 3 
P value 
for 
variance 
RBC Se (µg/µg 
Fe) 
0.000203 
(0.000176-
0.000245) 
0.000207 
(0.000188-
0.000234) 
0.00020 
(0.000165-
0.000231 
0.000202 
(0.000160-
0.000214) 
0.647 
Plasma Se 
(µmol/L) 
0.96 
(0.80-1.09) 
0.61 
(0.57-0.78) 
0.67 
(0.52-0.92) 
0.69 
(0.54-0.82) 
<0.001 
Se:Alb ratio 
2.02 
(1.72-2.14) 
1.94 
(1.67-2.19) 
1.95 
(1.69-2.37) 
2.04 
(1.84-2.25) 
0.959 
RBC GPX (U/g 
Hb) 
40.39 
(30.38-46.78) 
42.03 
(31.97-45.12) 
39.56 
(30.68-51.11) 
33.61 
(30.28-40.7) 
0.526 
Table 10.1 Median (IQR) values of red blood cell selenium concentration, plasma 
selenium concentration, plasma selenium: albumin ratio and red blood cell 
glutathione peroxidase activity on days 0-3. The significance of variance (p 
value) is from Kruskal-Wallis (non-parametric) one way analysis of variance. 
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Fig 10.1a Boxplot of red blood cell selenium concentration (µg/ µg Fe) on day 0-
3 
 
Fig 10.1b Boxplot of plasma selenium concentration (µmol/L) on day 0-3 
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Fig 10.1c Boxplot of plasma selenium: albumin ratio on day 0-3 
 
Fig 10.1d Boxplot of red blood cell glutathione peroxidase activity (U/g Hb) on 
day 0-3 
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10.2 Factors affecting changes in plasma selenium concentration 
 
10.2.1 Tertiles of liver selenium 
 
In order to examine the effect of liver selenium concentration on the changes in 
plasma selenium concentration seen during the evolution of acute phase 
response, data was split into tertiles by liver selenium concentration; there were 
10, 11 and 10 patient samples in each of the low, medium and high tertiles 
respectively. One way analysis of variance of CRP and Albumin was performed to 
ensure there were no differences in CRP or Albumin between tertiles on any of 
day 0-3; as it was not normally distributed, the logarithmic transformation of 
CRP day 0 was used. Mean values (SD) for CRP and Albumin by liver tertile can be 
seen in table 10.2. No differences in CRP or Albumin concentrations were seen 
between tertiles of liver selenium. 
 
 Tertile liver selenium (range liver selenium (µg/g dry weight)) 
 1 
(1.19-1.91) 
2 
(1.91-2.12) 
3 
(2.19-2.57) 
p value for 
variance 
CRP day 0 (mg/L) 6.0(6.1) 4.5(4.4) 7.1(5.8) 0.772 
CRP day 1 (mg/L) 89.9(35.5) 91.7(24.9) 103.3(42.0) 0.644 
CRP day 2 (mg/L) 151.0(71.7) 177.4(47.0) 176.0(67.8) 0.570 
CRP day 3 (mg/L) 155.3(77.3) 163.3(55.7) 158.1(60.4) 0.960 
Alb day 0 (g/L) 38.1(6.4) 36.5(3.9) 40.3(2.9) 0.180 
Alb day 1 (g/L) 28.2(4.6) 28.5(3.0) 29.5(3.8) 0.727 
Alb day 2 (g/L) 27.1(3.3) 26.6(2.7) 28.8(2.8) 0.277 
Alb day 3 (g/L) 25.2(3.3) 26.0(2.9) 27.2(3.5) 0.390 
Table 10.2 Mean values (SD) of CRP (mg/L) and Albumin (g/L) on day 0-3 for 
tertiles of liver selenium concentration (µg/g dry weight). 
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10.2.2 Plasma selenium concentrations between tertiles of liver Selenium 
 
To see if the relationship found between plasma selenium concentration and 
liver selenium concentration is maintained during the acute phase response, 
Kruskal-Wallis non-parametric analysis of variance was performed between the 
medians of plasma selenium concentration for each of the three tertiles of liver 
selenium concentration on days 0-3; this was also performed for the percentage 
change in plasma selenium to ascertain if the decrease in plasma selenium 
concentration with the acute phase response is related to the liver selenium 
concentration. 
 
Median concentration of plasma selenium (µmol/L) on day 0-3 and median 
percentage change in plasma selenium, from day 0 to day 1-3, divided by tertile 
of liver selenium, are shown in table 10.3. The median concentration of plasma 
selenium (µmol/L) for each liver tertile, at each time point can be seen 
graphically in figure 10.2a and the median percentage change in plasma 
selenium concentration between day 0 and day 1-3, for tertiles of liver selenium 
concentration, can be seen in figure 10.2b. 
 
The plasma selenium concentration across liver selenium tertile 1-3 is 
statistically significantly different on day 2; this is due to tertile 3 being higher 
than tertile 1 and 2 and fits with the relationship seen between liver and plasma 
selenium on day 0. The percentage change in plasma selenium on day 1 is less in 
tertile 1 than tertiles 2 and 3 (p= 0.012), but this does not persist on day 2.   
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 Tertile liver selenium (range liver selenium (µg/g dry weight)) 
 1 
(111.9-220.9) 
2 
(230.7-280.1) 
3 
(280.9-384.5) 
p value for 
variance 
Plasma Se day 0 
(µmol/L) 
0.78 
(0.66-0.90) 
0.98 
(0.84-1.11) 
1.01 
(0.97-1.14) 
0.005 
Plasma Se day 1 
(µmol/L) 
0.73 
(0.65-0.78) 
0.62 
(0.52-0.71) 
0.87 
(0.60-0.95) 
0.064 
Plasma Se day 2 
(µmol/L) 
0.63 
(0.39-0.77) 
0.52 
(0.47-0.67) 
0.98 
(0.82-1.11) 
0.034 
Plasma Se day 3 
(µmol/L) 
0.55 
(0.41-0.69) 
0.65* 0.86 
(0.63-0.94) 
0.229 
Change plasma 
Se day 1 (%) 
-17.0 
(-20.1 - -5.1) 
-33.8 
(-42.6 - -24.8) 
-28.0 
(-38.3 - -22.5) 
0.012 
Change plasma 
Se day 2 (%) 
-28.7 
(-39.3 - -7.6) 
-26.8 
(-56.5 - -20.5) 
-20.0 
(-31.6 - 9.2) 
0.434 
Change plasma 
Se day 3 (%) 
-28.0 
(-35.7 - -15.0) 
-20.5* -20.4 
(-20.4 - -4.6) 
0.607 
Table 10.3 Median (IQR) values of plasma selenium concentration (µmol/L) on 
day 0-3 and % change in plasma selenium concentration between day 0 and day 
1-3, for tertiles of liver selenium concentration. *only 1 sample available in this 
category. 
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Fig 10.2a Boxplot of median plasma selenium concentration (µmol/L) on day 0-3 
for tertiles of liver selenium concentration 
 
 
Fig 10.2b Boxplot of median % change in plasma selenium concentration 
between day 0 and day 1-3, for tertiles of liver selenium concentration 
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10.2.3 Relationship between plasma selenium on day 0 and days 1-3 
 
To investigate whether the change in plasma selenium concentration on days 1-3 
is related to the plasma selenium concentration on day 0 simple linear regression 
was performed. The relationship between the plasma selenium concentration on 
day 0 and the plasma selenium concentration on day 1-3 can be seen in figure 
10.3a and the relationship between the plasma selenium concentration on day 0 
and the percentage change in plasma selenium concentration from day 0, on day 
1-3, can be seen in figure 10.3b. Result of linear regression analysis can be seen 
in table 10.4.  
 
There is a linear relationship with the percentage fall in plasma selenium from 
day 0 and the plasma selenium concentration on day 0 on days 1 and 3, but not 
on day 2. However, looking at the Scatterplot (fig 10.3b) it can be seen that this 
relationship is reversed on day 3 from day 1. The lower the plasma selenium on 
day 0, the lower the percentage drop in plasma selenium from day 0; the higher 
the plasma selenium on day 0, the lower the percentage drop from day 0 is by 
day 3. In other words, if you have higher plasma selenium it has a greater 
percentage reduction on day 1 but also a smaller percentage reduction by day 3, 
therefore although it drops by a greater percentage it recovers more quickly. 
This may of course simply be regression to the mean and would require further 
investigation. 
 
Despite differences in percentage change in plasma selenium from day 0 that are 
related to plasma selenium concentration on day 0, a linear relationship remains 
with the initial plasma selenium concentration on day 0 throughout day 1-3; 
those who had the highest plasma selenium on day 0 maintained their rank 
despite increased percentage drops in selenium concentration. 
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 Plasma Se day 0 (µmol/L) Vs Plasma Se day1-3 (µmol/L) 
 r2(%) p value 
Day 1 23.0 0.038 
Day 2 39.5 0.016 
Day 3 83.4 0.001 
 Plasma Se day 0 (µmol/L) Vs % change plasma Se day1-3 (µmol/L) 
 r2(%) p value 
Day 1 25.0 0.029 
Day 2 1.3 0.694 
Day 3 38.3 0.045 
Table 10.4 Relationship between plasma selenium on day 1-3 (µmol/L) and the 
percentage change in plasma selenium form day 0, on day 1-3 with plasma 
selenium on day 0 (µmol/L), using simple linear regression. 
 
 
Fig 10.3a Scatterplot of plasma selenium on day 0 (µmol/L) versus plasma 
selenium (µmol/L) on day 1-3  
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Fig 10.3b Scatterplot of plasma selenium on day 0 (µmol/L) versus % change in 
plasma selenium concentration from day 0, on day 1-3  
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10.2.4 Relationship between plasma selenium and C-reactive protein 
 
Simple linear regression was performed to investigate the relationship between 
plasma selenium concentration and CRP concentration on days 0-3. Results are 
in table 10.5 and can be seen graphically in fig 10.4. 
 
There is no linear relationship between plasma selenium concentration and C 
reactive protein concentration.  
 CRP (g/L) Vs plasma Se (µmol/L) 
 r2(%) p value 
Day 0 0.3 0.780 
Day 1 5.5 0.322 
Day 2 2.8 0.548 
Day 3 0.3 0.885 
Table 10.5 Relationship between plasma selenium concentration (µmol/L) and 
CRP concentration (mg/L) (log CRP day 0) on days 0-3, using simple linear 
regression. 
 
Fig 10.4 Scatterplot of plasma selenium concentration (µmol/L) versus CRP 
concentration (mg/L) on day 0-3  
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10.3 Relationship between plasma selenium and serum albumin 
 
Simple linear regression was performed to investigate the relationship between 
plasma selenium concentration and serum albumin concentration on days 0-3. 
Results are in table 10.6 and can be seen graphically in fig 10.5. 
 
There is an increasingly strong linear relationship between plasma selenium 
concentration and serum albumin concentration on day 0-3. The relationship 
strengthens over days 0-3, and by day 3 the serum albumin concentration is 
responsible for 90.8% of the variation in plasma selenium concentration.  
 
 Albumin (g/L) Vs plasma Se (µmol/L) 
 r2(%) p value 
Day 0 16.7 0.025 
Day 1 36.2 0.005 
Day 2 70.4 <0.001 
Day 3 90.8 <0.001 
Table 10.6 Relationship between plasma selenium concentraion (µmol/L) and 
serum albumin concentration (g/L) on days 0-3, using simple linear regression. 
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Fig 10.5 Scatterplot of plasma selenium concentration (µmol/L) versus serum 
albumin concentration (g/L) on day 0-3  
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10.4 Relationship between liver and plasma selenium and albumin on days 0-
3 
 
Liver selenium is of interest as it acts as a surrogate for whole body tissue 
status. Simple linear regression was performed to investigate the relationship 
between plasma selenium concentration, plasma selenium:albumin ratio, serum 
albumin concentration and liver selenium concentration on days 0-3. Results are 
in table 10.7 and can be seen graphically in fig 10.6a-c. 
 
The linear relationship between plasma selenium and liver selenium 
concentration seen on day 0 disappears on day 1 but returns on day 2 and 3 
despite changes in plasma selenium concentration. When corrected for serum 
albumin by use of the selenium: albumin ratio, the linear relationship with liver 
selenium is present throughout days 0-3. There is not a significant relationship 
between liver selenium concentration and serum albumin concentration, though 
a pattern does exist most likely reflecting the strong relationship that both liver 
selenium and serum albumin have with plasma selenium. 
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 Liver Se (µg/g dry weight) Vs plasma Se (µmol/L) 
 r2(%) p value 
Day 0 37.1 <0.001 
Day 1 9.9 0.177 
Day 2 59.4 0.001 
Day 3 50.4 0.022 
 Liver Se (µg/g dry weight) Vs Se:alb ratio 
 r2(%) p value 
Day 0 16.7 0.022 
Day 1 39.5 0.002 
Day 2 67.5 <0.001 
Day 3 54.8 0.014 
 Liver Se (µg/g dry weight) Vs Serum albumin (g/L)  
 r2(%) p value 
Day 0 7.5 0.135 
Day 1 6.7 0.161 
Day 2 12.4 0.052 
Day 3 9.5 0.092 
Table 10.7 Relationship between plasma selenium (µmol/L), plasma selenium: 
albumin ratio and serum albumin concentration (g/L) with liver selenium 
concentration (µg/g dry weight) on days 0-3, using simple linear regression. 
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Fig 10.6a Scatterplot of plasma selenium concentration (µmol/L) versus liver 
selenium concentration (µg/g dry weight) on day 0-3  
 
 
Fig 10.6b Scatterplot of plasma selenium: albumin ratio versus liver selenium 
concentration (µg/g dry weight) on day 0-3  
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Fig 10.6c Scatterplot of serum albumin (g/L) versus liver selenium concentration 
(µg/g dry weight) on day 0-3  
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10.5 Correcting plasma selenium for albumin during the acute phase 
response 
 
The changes seen in plasma selenium during the acute phase response appear to 
be strongly related to changes in serum albumin and correcting for serum 
albumin by use of the selenium: albumin ratio is strongly correlated with liver 
selenium concentration. To replicate clinical practice, data from day 0-3 were 
collated and the relationship with liver selenium concentration examined by use 
of simple linear regression (fig 10.7a). 
 
Using all results from day 0-3, the selenium: albumin ratio accounted for 38.5% 
of the variance in liver selenium concentration (p<0.001).  
 
As plasma selenium was related to liver selenium anyway on day 0, when the 
patient were not inflamed, day 0 was excluded and the analysis repeated (fig 
10.7b).  
 
Using only results from day 1-3 when plasma selenium alone was unreliable, the 
selenium: albumin ratio accounted for 50.5% of the variance in liver selenium 
concentration (p<0.001).  
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Fig 10.7a Scatterplot of plasma selenium: albumin ratio versus liver selenium 
concentration (µg/g dry weight) using all results from day 0-3 
 
 
Fig 10.7b Scatterplot of plasma selenium: albumin ratio versus liver selenium 
concentration (µg/g dry weight) using all results from day 1-3 
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10.6 Summary of findings - Selenium 
 
In this study population plasma selenium concentrations are low compared to 
the local laboratory population reference interval of 0.8-2.0 µmol/L, with a 
range of 0.6-1.3 µmol/L found on day 0. 
 
On day 0, when the patients were not inflamed, linear relationships existed 
between all the selenium measures: red blood cell selenium, red blood cell 
glutathione peroxidase activity, plasma selenium concentration and liver 
selenium concentration. 
 
Red blood cell selenium concentration and red blood cell glutathione peroxidase 
activity do not change during the acute phase response. Plasma selenium falls 
during the acute phase response with the decrease being in the first 24 hours. 
 
There is a linear relationship with the percentage fall in plasma selenium from 
day 0 and the plasma selenium concentration on day 0 on days 1 and 3, but not 
on day 2. This relationship is reversed on day 3 from day 1 as the lower the 
plasma selenium on day 0, the lower the percentage drop in plasma selenium 
from day 0; the higher the plasma selenium on day 0, the lower the percentage 
drop from day 0 is by day 3. Therefore the higher plasma selenium has a greater 
percentage reduction on day 1 but also a smaller percentage reduction by day 3: 
although it drops by a greater percentage it recovers more quickly. 
 
Plasma selenium concentration has a strong linear relationship with serum 
albumin concentration and this strengthens during the acute phase response. 
 
There is a linear relationship between the selenium: albumin ratio and liver 
selenium concentration throughout the acute phase response. 
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During the acute phase response, when pooling data from days 1-3, there is a 
linear relationship between the selenium: albumin ration and liver selenium 
concentration. The selenium: albumin ratio accounts for 50.5% of the variance in 
liver selenium concentration making it a potential surrogate marker for selenium 
status during the acute phase response. 
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Chapter 11  
Magnesium 
The relationship between tissue and blood concentrations of Magnesium and 
the effect of the acute phase response 
 
11.1 Normality of data and outliers 
 
To ensure the normality of the data and exclude any outlying samples, the 
Anderson-Darling test for normality was performed. The results are summarised 
below and further details and probability plots can be found in appendix 4. 
 
Liver magnesium concentrations were found to be normally distributed 
(p=0.423).  
 
An outlying sample (sample 13) was seen when examining a probability plot of 
muscle magnesium and this sample was excluded from all further magnesium 
analysis. With this sample removed muscle magnesium was normally distributed 
(p=0.2). 
 
Red blood cell magnesium levels on day 0 and day 1 were not normally 
distributed. Outlying samples from day 0 (samples 14, 20 and 26) and day 1 
(samples 20 and 31) were removed from further analyses. After these were 
removed days 0-3 were normally distributed; day 0 p=0.119, day 1 p=0.434, day 
2 p=0.836, day 3 p=0.518.  
 
The Anderson-Darling normality test was performed on plasma magnesium 
concentrations on day 0-3 and all were normally distributed; day 0 p=0.528, day 
1 p=0.734, day 2 p=0.992, day 3 p=0.507.  
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11.2 Magnesium status of the study population at baseline 
 
As plasma magnesium is routinely measured in our laboratory, a reference 
interval of 0.7-1.0 mmol/L is in place. The plasma magnesium status of the 
study population at baseline was investigated. Median plasma magnesium 
concentration was 0.72 mmol/L (inter-quartile range 0.64-0.84). The range of 
plasma magnesium concentrations, and the relationship with the reference 
interval, can be seen in figure 11.1. 
 
Within the study population, a number of samples fall below our laboratory 
reference interval with the median being at the lower limit of the reference 
interval. 
 
 
Fig 11.1 Histogram of plasma magnesium concentration (mmol/L) on day 0. 
Upper (1.0mmol/L) and lower (0.7mmol/L) limits of the reference interval are 
marked by dotted lines 
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11.3 Relationship between blood and tissue magnesium concentrations at 
baseline  
 
The relationship between tissue and blood concentrations of magnesium at 
baseline, without the contribution of a systematic inflammatory response 
(characterised by a “normal” C-reactive protein), allows recommendations to be 
made as to whether plasma or red blood cell magnesium concentrations are a 
reliable measure of tissue status in the non-inflamed patient. Simple linear 
regression was used to examine the relationships between liver, muscle, red 
blood cell and plasma magnesium. 
 
There is no linear relationship between either RBC magnesium concentration on 
day 0 (r2=2.5%, p=0.417) (fig 11.2a) or plasma magnesium concentration on day 0 
(r2=1.2%, p=0.517) (fig 11.2b) and muscle magnesium concentration.  
 
There is also no linear relationship between RBC magnesium concentration on 
day 0 (r2=0.7%, p=0.662) (fig 11.3a) or plasma magnesium concentration on day 0 
(r2=0.5%, p=0.712) (fig 11.3b) and liver magnesium concentration. 
 
No significant linear relationship was found between liver and muscle magnesium 
concentrations (r2=2.1%, p=0.394) (fig 11.4) or between red blood cell 
concentrations on day 0 and plasma magnesium concentrations on day 0 (r2= 1.2, 
p=0.578) (fig 11.5). 
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Fig 11.2a Scatterplot of Muscle Mg (µg/g dry weight) versus RBC Mg on Day 0 
(µg/ µg Fe) 
 
 
Fig 11.2b Scatterplot of Muscle Mg (µg/g dry weight) versus Plasma Mg on Day 0 
(µg/L) 
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Fig 11.3a Scatterplot of Liver Mg (µg/g dry weight) versus RBC Mg on Day 0 (µg/ 
µg Fe) 
 
 
Fig 11.3b Scatterplot of Liver Mg (µg/g dry weight) versus Plasma Mg on Day 0 
(µg/L) 
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Fig 11.4 Scatterplot of Muscle Mg (µg/g dry weight) versus Liver Mg (µg/g dry 
weight)  
 
 
Fig 11.5 Scatterplot of Plasma Mg (µg/L) versus RBC Mg (µg/ µg Fe) on Day 0 
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11.4 Change in plasma and red blood cell magnesium with the acute phase 
response 
 
On days 1-3, in the post-operative period, a systemic acute phase response 
develops marked by a rise in CRP and a fall in serum albumin. Kruskal-Wallis 
(non-parametric) one way analysis of variance was performed to see if red blood 
cell or plasma magnesium concentration varied during the acute phase response. 
The change in the concentration of RBC magnesium can be seen in fig 11.6a and 
plasma magnesium in fig 11.6b. 
 
 
Fig 11.6a Boxplot of median red blood cell magnesium concentration (µg/ µg Fe) 
on day 0-3 
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Fig 11.6b Boxplot of median plasma magnesium concentration (µg/L) on day 0-3 
 
11.4.1 Red blood cell Magnesium 
 
Median values of red blood cell Magnesium (µg/ µg Fe) on days 0-3 are shown in 
table 11.1. There is no significant change in RBC magnesium over day 0-3 
(p=0.743) (fig 11.6a). 
 
 Median RBC Magnesium (µg/ µg Fe) (IQR) 
Day 0 0.058 (0.054-0.061) 
Day 1 0.057 (0.052-0.060) 
Day 2 0.058 (0.053-0.066) 
Day 3 0.062 (0.053-0.064) 
Table 11.1 Median (IQR) values of red blood cell Magnesium (µg/ µg Fe) on days 
0-3 
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11.4.2 Plasma Magnesium 
 
Median values of plasma magnesium (µg/g L) on days 0-3, and the percentage 
change in plasma magnesium from day 0 on days 1-3 are shown in table 11.2. 
Kruskal-Wallis (non-parametric) one way analysis of variance showed that plasma 
magnesium concentration varies significantly over days 0-3 (p=0.049) (fig 11.6b).  
 
Mann Whitney comparisons were performed to examine the differences between 
each day (Bonferroni correction p=0.017 is significant): there was no significant 
change in concentration between day 0 and day 1 (p=0.298) but the plasma 
magnesium concentration changes significantly from day 1 to day 2 (p=0.014). 
From day 2 to day 3 the difference in plasma magnesium concentration was not 
significant (p=0.777). Differences between the median percentage change in 
plasma magnesium from day 0 to day 1-3 did not reach significance (p=0.059)(fig 
11.6c).  
 
Plasma magnesium concentration decreases with the evolution of the acute 
phase response on day 1 and returns to baseline level on day 2 and 3. Although 
not reaching a statistically significant difference (p=0.059), it can be seen that 
there is a negative percentage change of plasma magnesium on day 1 (approx 
11%) which normalises on day 2.  
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 Median Plasma Magnesium (µg/ L) (IQR) 
Day 0 17580 (15595 - 20420) 
Day 1 16175 (14328 - 19115) 
Day 2 19445 (17775 - 20835) 
Day 3 18810 (16955 - 21550) 
 Median % change in Plasma Magnesium (IQR) 
Day 1 -11.79% (-23.59 - 8.25) 
Day 2 3.41% (-9.36 – 34.37) 
Day 3 1.3% (-5.71 - 18.21) 
Table 11.2 Median (IQR) values of Plasma Magnesium (µg/L) on days 0-3, and the 
percentage change in Plasma Magnesium from day 0 on days 1-3 
 
 
 
Fig 11.6c Boxplot of percentage change in plasma magnesium concentration 
from baseline (day 0) on day 1-3 
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11.5 Factors affecting changes in plasma magnesium concentration 
 
11.5.1 Tertiles of plasma magnesium 
 
Magnesium is utilised intra-cellularly and it may be that the decrease in plasma 
magnesium seen on day 1 is due to the shifting of magnesium into cells. In order 
to examine what factors affect the changes in plasma magnesium, firstly plasma 
magnesium was split into tertiles to allow visualisation of any patterns. There 
were 10, 9 and 9 samples in each of the low medium and high (1-3) tertiles 
respectively.   
 
Kruskal-Wallis (non-parametric) one way analysis of variance of CRP and Albumin 
was performed to ensure there were no differences in CRP or Albumin between 
tertiles on any of day 0-3; as it was not normally distributed, the logarithmic 
transformation of CRP day 0 was used. Median values (IQR) for CRP and Albumin 
by plasma tertile can be seen in table 11.3a. No differences in CRP or Albumin 
concentrations were seen between tertiles of plasma magnesium. 
 
Figure 11.7a shows plasma magnesium concentrations for each of the three 
tertiles over days 0 to 3. Table 11.3b shows the median values for plasma 
magnesium concentration for each of the three tertiles over days 0 to 3, and the 
p values for the variance between tertiles on each day (Kruskal-Wallis one way 
analysis of variance). 
 
Obviously, median values of plasma magnesium on day 0 are significantly 
different by tertile of day 0 plasma magnesium (p<0.001), but by day 1 there is 
no difference between the concentrations of plasma magnesium for the 3 
tertiles of plasma magnesium concentration. Visually, in fig 11.7a, it appears 
that the lowest concentration tertile (tertile 1) increases, while the highest 
concentration tertile decreases. 
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To examine this further, the relationship between the percentage change in 
plasma magnesium on days 1 to 3, and the initial plasma concentration on day 0 
was examined; fig 11.7b shows this relationship. Table 11.3c shows median 
values for the percentage change in plasma magnesium concentration from day 0 
and the p values for the variance between tertiles on each day (Kruskal-Wallis 
one way analysis of variance). 
 
Therefore, the percentage change in the plasma magnesium concentration from 
day 0 to day 1 and day 2 differs by tertile; the lowest tertile (tertile 1) increases 
and the highest tertile (tertile 3) decreases. There is not a statistically 
significant difference at day 3, but it is not known if this is due to changes 
pertaining to the resolution of the acute phase response, or simply a result of a 
small sample size.  
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 Tertile plasma magnesium (range plasma magnesium (mmol/L)) 
 1 
(0.53-0.66) 
2 
(0.67-0.78) 
3 
(0.80-0.97) 
p value for 
variance 
CRP day 0(mg/L) 2.6 
(0.9-5.5) 
5.8 
(3.3-7.7) 
4.7 
(1.8-17) 
0.193 
CRP day 1(mg/L) 95.5 
(66.0-123.5) 
96.0 
(65.5-107.5) 
86.5 
(66.0-127.8) 
0.823 
CRP day 2(mg/L) 156.5 
(89.3-191.3) 
164  
(144.5-209) 
185  
(140-245.5) 
0.392 
CRP day 3(mg/L) 153.5 
(120.3-175) 
155 
(119-214) 
176 
(113.3-220.8) 
0.911 
Alb day 0 (g/L) 41.5 
(37.5-45.5) 
37 
(34.5-39) 
38 
(34.3-40.5) 
0.063 
Alb day 1 (g/L) 28.5 
(25.5-32.25) 
27 
(26-32) 
28 
(26.3-32.5) 
0.909 
Alb day 2 (g/L) 27.5 
(26-29.5) 
27 
(24-31) 
26 
(26-30) 
0.837 
Alb day 3 (g/L) 26 
(22.8-29.5) 
27 
(23-29) 
25.5 
(23.8-28.3) 
0.935 
Table 11.3a Median values (IQR) of CRP (mg/L) and Albumin (g/L) on day 0-3 for 
tertiles of plasma magnesium concentration 
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              Tertile plasma magnesium  
 
1 2 3 
p value for 
variance 
Plasma Mg day 0 
(mmol/L) 
0.62 
(0.53-0.65) 
0.72 
(0.69-0.74) 
0.88 
(0.82-0.92) 
<0.001 
Plasma Mg day 1 
(mmol/L) 
0.77 
(0.62-0.87) 
0.64 
(0.57-0.72) 
0.66 
(0.59-0.79) 
0.411 
Plasma Mg day 2 
(mmol/L) 
0.73 
(0.69-0.83) 
0.74 
(0.69-0.95) 
0.83  
(0.80-0.85) 
0.418 
Plasma Mg day 3 
(mmol/L) 
0.72* 
 
0.70* 
 
0.84 
(0.76-0.93) 
0.087 
Table 11.3b Median values (IQR) of plasma magnesium concentration (mmol/L) 
on day 0-3 for tertiles of plasma magnesium concentration at day 0. *only one 
value available. 
 
 
Fig 11.7a Boxplot of plasma magnesium concentration (mmol/L) for tertiles of 
plasma magnesium concentration (1-3), over days 0-3.  
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Fig 11.7b Boxplot of % change in plasma magnesium concentration from day 0, 
for tertiles of plasma magnesium concentration (1-3), over days 1-3  
 
              Tertile plasma magnesium  
 1 2 3 p value for 
variance 
% change plasma 
Mg day 1 
24.4 
(-4.4-75.5) 
-11.78 
(-18.9-0.3) 
-28.49 
(-30.2--11.8) 
0.013 
% change plasma 
Mg day 2 
38.2 
(14.4-50.7) 
2.8 
(-6.7-28.2) 
-8.13 
(-14.92-2.68) 
0.027 
% change plasma 
Mg day 3 
24.4* 
 
-0.53*  
 
-14.25 
(-3.01-7.07) 
0.087 
Table 11.3c Median values (IQR) of plasma magnesium concentration (µg/L) on 
day 0-3 for tertiles of plasma magnesium concentration at day 0.*only one value 
available. 
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11.5.2 Albumin concentration 
 
In the circulation, magnesium is partly bound to protein, the most abundant of 
which is albumin. Albumin changes during the acute phase response on days 0-3 
(fig 6.2) and this change may be why magnesium changes on day 1. Figure 11.8 
shows that the change in magnesium does not follow the change in albumin. 
 
 
Fig 11.8 Change in serum albumin concentration (g/L) and plasma magnesium 
concentration (µg/L), over days 0-3 
 
In order to further examine the relationship between plasma magnesium and 
albumin concentration during the acute phase response, simple linear regression 
was performed on the percentage change from day 0 of both plasma magnesium 
and serum albumin; the results can be seen in table 11.4. Scatterplots of the 
percentage change in plasma magnesium from day 0 versus the percentage 
change in albumin from day 0, on days 1-3 can be seen in fig 11.9. 
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There is no relationship between the percentage change in plasma magnesium 
concentration and the percentage change in serum albumin concentration. 
 
 % change albumin Vs % change plasma magnesium 
 r2(%) p value 
Day 1 1.1 0.610 
Day 2 6.5 0.379 
Day 3 0.0 0.989 
Table 11.4 Relationship between percentage changes in plasma magnesium from 
day 0 on day 1-3, with percentage changes in serum albumin from day 0 on day 
1-3 using simple linear regression. 
 
 
Fig 11.9 Scatterplots of % change plasma magnesium concentration versus the 
percentage change in serum albumin concentration from day 0, on days 1-3 
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As it appears that the change in plasma magnesium is possibly related to the 
initial plasma magnesium (fig 11.7), the magnesium: albumin ratio was examined 
for the three tertiles of plasma magnesium. The use of the magnesium: albumin 
ratio allows the relationship between albumin concentration and magnesium 
concentration and tertile of plasma magnesium concentration to be examined 
while correcting for any effect of plasma dilution due to intravenous fluid 
replacement given to the patient post-operatively. Fig 11.10a shows the median 
magnesium: albumin ratio for each of the three tertiles over days 0-3, and table 
11.5a gives the median values and result of Kruskal Wallis nonparametric 
analysis of variance for the differences between tertiles.  
 
The percentage change in the magnesium: albumin ratio from day 0 to day 1-3, 
for all three tertiles is shown in figure 11.10b and table 11.5b. Kruskal Wallis 
nonparametric analysis of variance was performed to examine variance in results 
across the three tertiles. 
 
These results show that while there is a difference in magnesium: albumin ratio 
on day 0 as expected, there is no difference in the magnesium: albumin ratio 
beyond day 1. There is a similar pattern of percentage change in the 
magnesium: albumin ratio as there is in the change in plasma magnesium 
concentration, with the lowest tertile increasing and the highest tertile 
decreasing. As table 11.3a shows, there is no difference in the albumin 
concentration on day 1-3 between tertiles. 
 
The combination of these results confirm that the change in magnesium on day 
1, when all three tertiles become similar, is not simply a function of change in 
the serum albumin concentration and therefore there must be other 
independent determinants of the change in plasma magnesium concentration 
seen during the acute phase response. 
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Fig 11.10a Boxplot of plasma magnesium: albumin ratio on day 0-3, for tertiles 
of plasma magnesium concentration (1-3) 
 
              Tertile plasma magnesium  
 
1 2 3 
p value for 
variance 
Mg:Alb day 0 346.1 
(319.4-392.1) 
459.9 
(450.8-509.9) 
555.7 
(526.1-623.3) 
<0.001 
Mg:Alb day 1 639.7 
(576.8-685.4) 
536.1 
(477.1-648.8) 
531.9 
(469.1-591.9) 
0.247 
Mg:Alb day 2 639.3 
(532.8-790.2) 
752.7  
(531.7-958.2) 
759.2  
(649.9-890.1) 
0.553 
Mg:Alb day 3 671.2* 
 
628.0* 
 
779.7 
(752.1-924.7) 
0.087 
Table 11.5a Median values (IQR) of plasma magnesium: albumin ratios on day 0-
3 for tertiles of plasma magnesium concentration at day 0 (1-3). *only one value 
available. 
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Fig 11.10b Boxplot of percentage change in plasma magnesium: albumin ratio 
from baseline (day 0) on day 1-3, for tertiles of plasma magnesium concentration 
(1-3) 
 
              Tertile plasma magnesium  
 
1 2 3 
p value for 
variance 
% change Mg:Alb 
day 1 
73.4 
(55.5-105.1) 
6.0 
(-16.1-41.2) 
-11.7 
(-18.6-15.6) 
0.007 
% change Mg:Alb 
day 2 
80.9 
(12.9-125.7) 
41.3 
(12.9-110.6) 
24.47 
(15.3-41.7) 
0.122 
% change Mg:Alb 
day 3 
91.9* 
 
35.4*  
 
31.6 
(18.1-48.6) 
0.117 
Table 11.5b Median values (IQR) of plasma magnesium: albumin ratio on day 0-3 
for tertiles of plasma magnesium concentration at day 0.*only one value 
available. 
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11.5.3 Plasma magnesium on day 0 
 
In order to further examine the relationship between plasma magnesium 
concentration on day 0 when the patients were not inflamed, the percentage 
decrease in plasma magnesium and plasma magnesium concentration on days 1-3 
during the acute phase response, simple linear regression was performed; the 
results can be seen in table 11.6. The relationship between plasma magnesium 
concentration (µmol/L) on day 0 and the plasma magnesium concentrations 
(µmol/L) on days 1-3, can be seen in figure 11.11a. The relationship between 
the percentage change in plasma magnesium concentration from day 0 to day 1-
3 can be seen in figure 11.11b (day 1), figure 11.11c (day 2), and figure 11.11d 
(day 3); reference lines are added at 0.7mmol/L which is the lower limit of our 
laboratory reference interval. 
 
There is no relationship between the plasma magnesium concentration on day 0 
and the plasma magnesium concentration on day 1-3 (p=0.435, 0.317, 0.096 
respectively). There is however a linear relationship between the percentage 
change in plasma magnesium from day 0 to day 1 (p=0.001), day 0 to day 2 
(p<0.001) and day 0 and day 3 (p=0.01). This is depicted well in figure 11.11b: 
the reference line at 0.7mmol/L, the lower limit of the reference interval, 
shows that the majority of subjects with a plasma magnesium on day 0 above 
this concentration have a decrease in plasma magnesium concentration during 
the acute phase response, while the majority below this concentration have an 
increase in plasma magnesium concentration. 
 
The strength of the linear relationship between plasma magnesium on day 0 and 
the change during the acute phase response is seen by the results of the 
regression analysis: 46.4% of the variance of plasma magnesium concentration 
from day 0 on day 1 can be explained by the plasma magnesium concentration 
on day 0, with this figure being 65.6% on day 2 and 64.0% on day 3. Therefore, 
the changes in plasma magnesium seen during the acute phase are 
predominantly a factor of the baseline plasma magnesium concentration. 
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 Plasma Mg day 0 Vs plasma Mg day 1-3 (µmol/L) 
 r2(%) p value 
Day 1 3.2 0.435 
Day 2 8.3 0.317 
Day 3 34.5 0.096 
 Plasma Mg day 0 (µmol/L) Vs %change plasma Mg day 1-3  
 r2(%) p value 
Day 1 46.4 0.001 
Day 2 65.6 <0.001 
Day 3 64.0 0.010 
Table 11.6 Relationship between plasma magnesium on day 0 and days 1-3 
(µmol/L) and plasma magnesium on day 0 (µmol/L) and the percentage change 
in plasma magnesium on days 1-3, using simple linear regression. 
 
 
 
Fig 11.11a Scatterplot of plasma magnesium concentration on day 0 (mmol/L) 
versus plasma magnesium concentration on day 1-3 (mmol/L) 
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Fig 11.11b Scatterplot of plasma magnesium concentration on day 0 (mmol/L) 
versus % change in plasma magnesium concentration on day 1 
 
 
Fig 11.11c Scatterplot of plasma magnesium concentration on day 0 (mmol/L) 
versus % change in plasma magnesium concentration on day 2 
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Fig 11.11d Scatterplot of plasma magnesium concentration on day 0 (µmol/L) 
versus % change in plasma magnesium concentration on day 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
267 
 
11.5.4 Muscle Magnesium concentration  
 
Linear regression was performed to examine the relationship between muscle 
magnesium concentration on day 0 and plasma magnesium concentration on day 
0-3, and the percentage change in plasma magnesium concentration on day 1-3; 
the results can be seen in table 11.7. The relationship between plasma 
magnesium concentration (mmol/L) and muscle magnesium concentration (µg/g 
dry weight) on day 0-3 can be seen in figure 11.12a. The relationship between 
the percentage change in plasma magnesium concentration and muscle 
magnesium concentration (µg/g dry weight) on day 1-3 can be seen in figure 
11.12b. 
 
No linear relationship was found between plasma magnesium concentration and 
muscle magnesium concentration over days 0-3 or between the percentage 
change in plasma magnesium concentration and muscle magnesium 
concentration over days 1-3. 
 
 Muscle Magnesium (µg/g dry weight)  Vs plasma magnesium(mmol/L) 
 r2(%) p value 
Day 0 1.2 0.571 
Day 1 1.5 0.602 
Day 2 17.7 0.134 
Day 3 7.8 0.466 
 Muscle Magnesium (µg/g dry weight)  Vs % change plasma magnesium 
 r2(%) p value 
Day 1 4.5 0.356 
Day 2 25.4 0.066 
Day 3 23.8 0.183 
Table 11.7 Relationship between muscle magnesium concentration (µg/g dry 
weight) and plasma magnesium (mmol/L) on day 0-3, and % change plasma 
magnesium on day 1-3, using simple linear regression. 
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Fig 11.12a Scatterplots of muscle magnesium concentration (µg/g dry weight) Vs 
plasma magnesium concentration (mmol/L) on day 0-3 
 
Fig 11.12b Scatterplots of muscle magnesium concentration (µg/g dry weight) 
Vs % change in plasma magnesium concentration on day 1-3 
 
 
 
269 
 
11.5.5 Liver Magnesium Concentration 
 
In order to further examine the relationship between plasma magnesium 
concentration, the percentage decrease in plasma magnesium and liver 
magnesium concentration during the acute phase response, simple linear 
regression was performed; the results can be seen in table 11.8. The relationship 
between plasma magnesium concentration (mmol/L) and liver magnesium 
concentration (µg/g dry weight) on day 0-3 can be seen in figure 11.13a and the 
relationship between the percentage change in plasma magnesium concentration 
and liver magnesium concentration (µg/g dry weight) on day 1-3 can be seen in 
figure 11.13b. 
 
There was no relationship found between plasma magnesium concentration and 
muscle magnesium concentration over days 0-3 or between the percentage 
change in plasma magnesium concentration and liver magnesium concentration 
over days 1-3. 
 
 Liver Magnesium (µg/g dry weight)  Vs plasma magnesium (mmol/L) 
 r2(%) p value 
Day 0 0.5 0.712 
Day 1 15.3 0.079 
Day 2 0.3 0.863 
Day 3 5.4 0.546 
 Liver Magnesium (µg/g dry weight)  Vs % change plasma magnesium 
 r2(%) p value 
Day 1 14.2 0.093 
Day 2 1.4 0.685 
Day 3 0.4 0.874 
Table 11.8 Relationship between liver magnesium concentration (µg/g dry 
weight) and plasma magnesium (mmol/L) on day 0-3, and % change plasma 
magnesium on day 1-3, using simple linear regression. 
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Fig 11.13a Scatterplots of liver magnesium concentration (µg/g dry weight) Vs 
plasma magnesium concentration (mmol/L) on day 0-3 
 
 
Fig 11.13b Scatterplots of liver magnesium concentration (µg/g dry weight) Vs % 
change in plasma magnesium concentration on day 1-3 
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11.5.6 C Reactive Protein Concentration 
 
The relationship between C-reactive protein concentration and plasma 
magnesium concentration on days 0-3, and % change in plasma magnesium 
concentration on day 1-3 was examined by linear regression analysis; the results 
can be seen in table 11.9. The logarithmic transformation of CRP day 0 was 
used. The relationship between plasma magnesium concentration (mmol/L) and 
serum CRP concentration (mg/L) on day 0-3 can be seen in figure 11.14a. The 
relationship between % change of plasma magnesium concentration and serum 
CRP concentration (mg/L) on day 1-3 can be seen in figure 11.14b. 
 
No linear relationship is found between plasma magnesium concentration and 
serum C-reactive protein concentration over days 0-3 or between the % change 
in plasma magnesium concentration and serum C-reactive protein concentration 
over days 1-3. 
 
 CRP (mg/L)  Vs plasma magnesium(mmol/L) 
 r2(%) p value 
Day 0 11.2 0.075 
Day 1 1.8 0.563 
Day 2 3.3 0.534 
Day 3 6.8 0.498 
 logCRP (mg/L)  Vs % change plasma magnesium 
 r2(%) p value 
Day 1 1.4 0.610 
Day 2 6.6 0.377 
Day 3 10.1 0.404 
Table 11.9 Relationship between CRP concentration (mg/L) and plasma 
magnesium (mmol/L) on day 0-3, and % change plasma magnesium on day 1-3, 
using simple linear regression. 
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Fig11.14a Scatterplots of CRP concentration (mg/L) Vs plasma magnesium 
concentration (mmol/L) on day 0-3 
 
 
Fig 11.14b Scatterplots of CRP concentration (mg/L) Vs % change in plasma 
magnesium concentration on day 1-3 
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11.5.7 Red Blood Cell Magnesium Concentration 
In order to examine the relationship between red blood cell magnesium 
concentration on day 0 and plasma magnesium concentration on day 0-3, and 
the relationship between the percentage change in red blood cell magnesium 
concentration and the percentage change in plasma magnesium concentration on 
day 1-3, linear regression analysis was carried out; the results can be seen in 
table 11.10. The relationship between plasma magnesium concentration 
(mmol/L) and red blood cell magnesium concentration (µg/ µg Fe) on day 0-3 
can be seen in figure 11.15a. The relationship between the percentage change in 
plasma magnesium concentration and the percentage change in red blood cell 
magnesium concentration on day 1-3 can be seen in figure 11.15b. 
 
No linear relationship was found between plasma magnesium and red blood cell 
magnesium concentration on days 0-3. Also, there was no relationship between 
the percentage change in plasma magnesium and the percentage change in the 
red blood cell concentration. 
 
 RBC magnesium (µg/ µg Fe)  Vs plasma magnesium(mmol/L) 
 r2(%) p value 
Day 0 1.2 0.578 
Day 1 0.1 0.905 
Day 2 23.3 0.083 
Day 3 17.7 0.259 
 % change RBC magnesium Vs % change plasma magnesium 
 r2(%) p value 
Day 1 8.5 0.200 
Day 2 5.8 0.408 
Day 3 10.5 0.394 
Table 11.10 Relationship between RBC magnesium concentration (µg/ µg Fe) 
and plasma magnesium concentration (mmol/L) on day 0-3, and between the % 
change in RBC and plasma magnesium on day 1-3, using simple linear regression. 
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Fig 11.15a Scatterplots of RBC magnesium concentration (µg/ µg Fe) Vs plasma 
magnesium concentration (mmol/L) on day 0-3 
 
 
Fig 11.15b Scatterplots of % change in RBC magnesium concentration Vs % 
change in plasma magnesium concentration on day 1-3 
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11.6 Summary of findings – Magnesium 
 
No relationship was found between plasma, red blood cell, liver or muscle 
magnesium concentration in the non-inflamed patient.  
 
Plasma magnesium changed significantly during the acute phase response, 
through an approximate 11 % decrease on day 1. However, when this was 
examined more closely the change in plasma magnesium ranged from a positive 
to a negative change. Examination of tertiles of plasma magnesium 
concentration on day 0, when the patients were not inflamed, showed that the 
change during the acute phase was related to the baseline concentration of 
magnesium (median of 24% increase for the lowest tertile, 28% decrease for the 
highest tertile on day 1). The change in plasma magnesium concentration 
resulted in there being no difference in plasma magnesium concentration 
between the tertiles by day 1 of the acute phase response. 
 
The relationship between the plasma magnesium concentration and the possible 
factors that may be related to the change in plasma magnesium concentration 
were explored. No relationship was found with albumin, C-reactive protein, liver 
magnesium concentration, muscle magnesium concentration or red blood cell 
magnesium concentration and either the plasma magnesium concentration or the 
change in plasma magnesium concentration from baseline.  
 
There was a relationship between the change in plasma magnesium 
concentration during the acute phase response and the initial plasma magnesium 
when the patient was non-inflamed on day 0. The baseline plasma magnesium 
concentration accounted for 46.4% of the change in plasma magnesium 
concentration from day 0 on day 1, 65.6% on day 2 and 64.0% on day 3.  
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Therefore, it can be concluded that the plasma magnesium concentration 
changes during the acute phase response but the direction and magnitude of 
change is related to the baseline, non-inflamed, plasma magnesium 
concentration. This resulted in a similar range of magnesium concentration in all 
individuals regardless of their baseline plasma magnesium concentration. 
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Chapter 12 - Discussion 
 
12.1 Suitability of methods for the routine clinical laboratory 
 
The requirements for an assay for use in a research setting and that which is to 
be used in a clinical setting can be different. The number of samples received 
may be far greater than in research, the instruments may be used for a number 
of assays meaning that a short sampling time is vital, the staff processing the 
samples will be performing a number of different tasks simultaneously so 
processes should be as simple as possible and be feasible in the routine 
reception area, and staff performing the analysis will have to be trained in this 
along with many other techniques within the laboratory, so the assay must be 
easy to learn and simple to perform. As the results will be used for clinical 
decision making they must be precise and ideally accurate. As reference 
materials are difficult to find for trace elements, local reference intervals would 
need to be developed to set decision levels for treatment. 
 
The methods developed for this study are both practical and robust enough for 
use in a routine clinical laboratory setting. Pre-analytical steps were simplified 
to ensure they could be followed with minimal error in a busy laboratory 
reception, with erythrocyte preparation simply involving centrifugation and 
separation, avoiding any laborious cell washing stage; this had no detrimental 
effect on the reproducibility of results. 
 
ICP-MS was used for the plasma and erythrocyte analysis as it allows multi-
element analysis over a wide range of concentrations and a low sample volume 
allowing all the elements to measured simultaneously, making this a very 
efficient method for use in a routine setting. To eliminate any possible matrix 
effect, acid –digestion was performed. Acid-digestion can be laborious and add a 
further source for error and contamination; however, in the method developed 
the digestion took place in the tube that would be used for analysis on the 
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instrument, meaning that diluting reagent simply had to be added to the 
digested sample before analysis.  
 
Iron was used as a mean of expressing the erythrocyte results as a surrogate for 
haemoglobin, based on the previous results from our laboratory showing that the 
haemoglobin concentration of red blood cells obtained via a standard 
haematology analyser and the iron concentration measured by ICP-MS correlate 
over a wide range of concentrations2. Iron was measured using a less abundant 
isotope as it was at far higher concentration than the other elements, allowing it 
to also be analysed on the same sample simultaneously with the other elements.  
 
The trace element and magnesium methods developed had precision that made 
them suitable for use in a clinical setting. The plasma methods all had an inter-
assay coefficient of variation <6% and the highest coefficient of variation for an 
erythrocyte method was magnesium at 11.7%, which are all suitable for clinical 
use. A recovery experiment, which is used to estimate proportional systematic 
error, particularly from a sample matrix effect, indicated no significant 
problems. 
 
The glutathione peroxidase method was a simple kit method; however, possibly 
because it was designed for use on farm animals with far higher GPX activity as 
well as humans, the manufacturer’s recommended dilutions resulted in poor 
precision which would render it unsuitable for clinical use. Changing the 
concentrations used resulted in an inter-assay CV of <8% for the combined GPX 
and haemoglobin assay, which is very acceptable for routine use. A local 
laboratory reference interval was developed allowing a decision limit to be set 
to guide clinicians when to supplement. 
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12.2 Choice of patient cohort 
 
Patients undergoing liver lobe resection for metastatic lesions were chosen for 
this study as they were having their liver resected as part of routine care, 
allowing the study sample to be taken from a healthy area of the resected 
tissue, with rectus muscle sampled from the incision site. The operation itself 
acted as the stimulus for the acute-phase response allowing changes in plasma 
and erythrocyte trace element and magnesium concentrations to be studied 
post-operatively. As liver biopsy can have significant risks of haemorrhage, it 
would not have been possible to perform this study on healthy volunteers. 
Patients undergoing liver biopsy for diagnostic purposes would also have been 
unsuitable as the liver tissue may have been diseased. 
 
However, the suitability of the patient cohort used in this study could be 
questioned. Patients with metastatic cancer may well have had recent loss of 
appetite and weight making then at higher risk of micronutrient deficiencies and 
therefore not representative of the population. They may also have had systemic 
inflammation at baseline that affected circulating micronutrient levels. These 
patients are selected for surgery on the basis of the surgeon’s opinion of their 
likelihood of a successful outcome, based on clinical and radiological findings 
including nutritional state; these clinical decisions result in the selection of a 
cohort who have a low baseline C-reactive protein concentration and albumin 
concentration within the normal range. Also, as the study is focusing on the 
relationship between tissue and blood concentrations, the overall status of the 
cohort is unlikely to be a source of bias. 
 
It should however be noted that due to the nature of the operation the 
postoperative period is not only a time of an acute-phase reaction, but also 
when a large volume of intravenous fluids may be given and the patient will be 
fasted; these may affect the micronutrient concentrations and should be 
accounted for, through the use of metal: protein ratios for example. Blood 
transfusion would also be a major source of error but this operation results in 
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less than 100mL of blood loss on average, so this combined with good pre-
operative health avoids the need for pre or post-operative blood transfusion 
interfering with results.  
 
The other issue with all but two of the participants is that they had bowel 
preparation prior to surgery. This consisted of a large volume of osmotic laxative 
which may have left them mildly dehydrated and resulted in a loss of 
magnesium. As only 2 participants did not have bowel prep it is impossible to 
analyse the two groups separately to examine for any affects of the bowel prep; 
however the 2 unaffected (number 1 and 29) had no difference in their 
haematocrit compared to the rest of the study participants. Certainly the bowel 
preparation should not have affected the main results: the majority of 
participants were affected and the use of metal: protein ratios would correct for 
any differences in fluid shifts as a result, and the tissue and blood correlations 
should have remained static even if there was loss of magnesium or trace 
elements as a result. 
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12.3 Utility of erythrocyte trace element concentrations 
 
Erythrocytes have a life span of around 12 weeks, meaning that measurements 
of their concentration reflect the status when the erythrocytes were made. It 
could therefore be argued that erythrocyte trace element concentration does 
not reflect current body status, but the status several months previously. 
However, that is making the presumption that erythrocyte trace element 
concentration is stable from the time of erythrogenesis, rather than a dynamic 
store that varies in response to whole body status. This is unknown currently and 
would require futures work, although using the example of selenium where the 
majority of the element in incorporated into seleno-proteins at the time of 
erythrogenesis, a constant concentration for the lifespan of the cell would seem 
likely. 
 
Would a constant concentration and therefore reflection of status of a longer 
time period be a major disadvantage? Certainly in patients on long term 
parenteral nutrition, one of the most established reasons for measuring trace 
element status, knowledge of the status over the previous 2-3 months would be 
advantageous. In patients with severe acute illness it is difficult to know as 
there are so many more unknowns. If a patient developed an acute severe illness 
on the background of chronic deficiency then this would be reflected in their 
erythrocyte concentration. However, if they started off with sufficient stores, 
over what time period would deficiency develop due to increased requirements 
and decreased intake during acute illness? This is unknown, as are the benefits 
of treating such deficiencies. It could certainly be argued that knowledge of 
their baseline status would give an indication as to the risk of developing 
deficiency during acute illness. 
 
Blood transfusion in the previous 3 months would render the erythrocyte 
measure uninterpretable; this is a big concern in severe acute illness where 
blood transfusions are often required and also in patients on medium-term 
parenteral nutrition where ongoing inflammatory states leave them anaemic. 
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This is probably the major flaw of this measurement and if used in routine 
practice referring clinicians would have to be made fully aware of this. 
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12.4 What is a significant result? 
 
The results of the regression analysis in this study that were found to be 
“statistically significant”, did not always show very strong associations; for 
example red blood cell copper reflects only 16% of the variance in liver copper 
concentration. That weak association would not normally get a blood measure 
accepted as a marker of tissue status; however, these results should be taken in 
the context of the current clinical situation.  
 
To use copper as an example, 5073 thousand plasma samples were received by 
the Scottish Trace Element and Micronutrient Laboratory last year, showing that 
there is a demand for knowledge of copper status, yet plasma copper 
concentration, which is measured in laboratories all over the world, has no 
relationship to liver copper concentration. It could be argued that given the lack 
of a suitable blood marker of status, and the apparent lack of knowledge of the 
limitations of these tests by referring clinicians, that these tests should not be 
offered at all. It is however difficult to go back from providing a test to 
providing no test at all, and a suitable alternative is required; while the 
relationships seen in this work are not strong, they are at least present and will 
represent a vast improvement on the current tests used, allowing studies to be 
carried out to attempt to elucidate the clinical relevance of trace element 
status. 
 
It may also be the case that the relationship between erythrocyte/plasma and 
liver status would strengthen in patients who were deficient; as these are the 
main group that are of clinical interest this should be investigated further. 
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12.5 Copper 
 
All but one of the study participants had a baseline plasma copper concentration 
which was within the laboratory reference interval, giving reassurance that they 
are representative of the general population.  
 
Despite the evolution of acute phase response on the 3 days post-operatively, 
there was no significant change in the any of the blood copper measures (plasma 
copper concentration, red blood cell copper concentration, ceruloplasmin 
concentration, ceruloplasmin: copper ratio and plasma ferroxidase activity). This 
was unfortunate as it did not allow for full study of the factors that contribute 
the changes in plasma copper and ceruloplasmin concentrations during the acute 
phase. However, this was not unexpected as previous studies have shown that 
the rise in plasma ceruloplasmin concentration, and consequently the rise in 
plasma copper concentration, is not maximal until 7 days post-operatively46;47. It 
would not have been possible to have continued this study for seven days as the 
patients tended to be discharged from hospital on the third or fourth day after 
the operation but would not have been well enough to have returned to the 
hospital or research facility for blood sampling on day 7. 
 
Erythrocyte copper was the only blood measure to reflect liver status at 
baseline; neither plasma copper nor ceruloplasmin concentration was related to 
liver copper concentration. This is possibly due to the study participants being 
copper replete, as supplementation studies have shown both plasma copper and 
ceruloplasmin to only increase in response to copper supplements if the 
participants have a low copper or ceruloplasmin concentration at baseline22;38. 
The linear relationship between red blood cell copper and liver copper, although 
statistically significant, is not strong, with liver copper only explaining 15.9% of 
the variation in red blood cell copper. The relationship was no longer 
statistically significant on days 1 and 2, but was again on day 3; however this 
may be a reflection of the small sample size as when days 1-3 were pooled the 
linear relationship was seen again.  
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The linear relationship between plasma copper and plasma ceruloplasmin was 
not surprising as ceruloplasmin is the main carrier protein for copper20. Although 
no relationship was seen between liver copper concentration and either copper 
or ceruloplasmin, when non-inflamed or in the first two days of the acute phase 
response, by day 3 both measures appeared to have a strengthening linear 
relationship with liver copper, though these did not quite reach statistical 
significance, possibly due to small numbers. It may be that this is due to initial 
changes of ceruloplasmin concentration, and consequently copper 
concentration, in response to the acute phase and that the magnitude of these 
changes is related to liver copper concentration, but further work with a larger 
sample size that followed the changes over several more days of the acute phase 
response would be required to prove this. 
 
A surprising finding was the positive linear relationship between both plasma 
copper and plasma ceruloplasmin and C-reactive protein on day 0, when the 
patients were not inflamed. This relationship did not exist on days 1-3 when the 
CRP was far higher, though it is unknown whether this reflected a lag-time in the 
up-regulation of ceruloplasmin in response to the acute phase and whether this 
relationship would have been seen again by day 7. The relationship was not seen 
across the full spectrum of CRP concentration, but instead only when the CRP 
was greater than 3 g/L; this may reflect an increase in ceruloplasmin 
concentration in response to chronic low-grade inflammation. This is almost 
certainly the explanation for recent findings that plasma copper concentration is 
positively correlated with body mass index and low-density lipoprotein 
concentrations.  Both obesity and atherosclerotic disease are thought to be 
inflammatory diseases91;92 (or at least causally related in the case of 
atherosclerosis) but a large epidemiological study would be required to show 
that the association of plasma copper concentrations with these conditions was 
attenuated by the addition of CRP to the statistical model before this was 
conclusive. It is a factor which would interfere with plasma copper being a 
useful marker for plasma status even when patients have a CRP within the 
reference interval, though when the relationship between plasma copper in 
patients with a CRP <3 g/L and liver copper was examined there was no 
relationship.  
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It would appear that red blood cell copper may be a better biomarker of tissue 
copper status than plasma copper or ceruloplasmin, but further work would be 
required to examine the relationship between erythrocyte and liver copper 
during a longer period of an acute phase response, and also to examine the 
change in erythrocyte copper concentration with copper supplementation.  
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12.6 Zinc 
 
The majority of study participants had a plasma zinc concentration below the 
reference interval. It is difficult to know the full significance of this. While no 
reference materials were available to check the accuracy of the method, the 
average value samples measured produced results that were slightly lower than 
the average value set, but this was not of sufficient magnitude to explain the 
degree of deficiency seen in the study population. It does not appear to be 
related to chronic low-grade inflammation as there is no relationship with 
baseline CRP. It should therefore be presumed that these results are genuine 
and that any associations seen are in a depleted population and cannot be 
assumed to automatically apply to a zinc replete population. 
 
Plasma zinc concentration at baseline had a linear relationship with liver zinc 
concentration; erythrocyte zinc was not related to liver zinc concentration. This 
fits with the findings from supplementation studies that show that while plasma 
zinc concentration responds to zinc supplementation, erythrocyte zinc does 
not49. This would suggest that plasma zinc concentration is the better biomarker 
for zinc status at baseline; however plasma zinc concentration falls by over 25% 
in the first 24 hours of the acute phase response. 
 
Plasma zinc concentration is associated with albumin concentration during the 
acute phase response, but not at baseline. This may be due to different 
mechanisms for zinc homeostasis during acute inflammation when there may be 
increased tissue requirements for zinc.  This is certainly suggested in the trends 
of zinc: albumin ratios for each tertile of liver zinc: the plasma zinc 
concentration has a far greater decrease in relation to albumin concentration in 
patients who had low liver zinc at baseline. This may be due to low tissue levels 
requiring the uptake of zinc from the plasma into tissue; however a larger study, 
possibly with serial tissue measurements and/or the use of isotope tracers would 
be required to prove this. 
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If the decrease in plasma zinc concentration seen during the acute phase 
response was solely due to a decrease in albumin concentration, then it should 
be possible to adjust the results to gain an idea of true zinc status. However, the 
decrease in albumin concentration is not the only factor that affects plasma zinc 
concentration, with underlying tissue status possibly also having an effect. So, 
while plasma zinc concentration may be a useful biomarker for tissue status out-
with the acute phase response, neither plasma or erythrocyte zinc appear to be 
reliable biomarkers of tissue status during the acute phase response. This is very 
unfortunate, as the possibility that underlying tissue status determines the 
change in plasma zinc during the acute phase response suggests that it is a vital 
micronutrient during that time. 
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12.7 Selenium 
 
Plasma selenium concentrations in the study cohort are low compared to the 
laboratory reference interval. 6 participants have a plasma selenium 
concentration below the reference interval with the median value only being 
0.96µmol/L while the reference interval is 0.8-2.0µmol/L. It is actually very 
likely that this is a true result as it has been noted that local plasma selenium 
concentrations have fallen in recent years, possibly due to European food policy,  
and Scotland is now felt to have low selenium status12. It should therefore be 
noted that the results of this study are from a selenium deficient population and 
that they may not hold true for a selenium replete population. 
 
At baseline there were linear associations between all selenium measures 
including liver, erythrocyte and plasma concentrations and red blood cell 
glutathione peroxidase; this reflects the relative selenium deficiency of the 
population. Similar results have been found in New Zealand, a low selenium 
status population, but not in selenium replete populations; this is felt to be 
because glutathione peroxidase activity plateaus, despite increasing selenium 
availably, once it has reached its maximum activity93 
 
Plasma selenium concentration, but not erythrocyte selenium concentration or 
glutathione peroxidase activity, falls in the first 24 hours of the acute phase 
response. A linear relationship with the percentage fall in plasma selenium from 
day 0 and the plasma selenium concentration on day 0 on days 1 and 3 was found 
but on inspection this relationship was opposite on days 1 and 3: the lower the 
plasma selenium on day 0, the lower the percentage drop in plasma selenium 
was from day 1, yet the higher the plasma selenium on day 0, the lower the 
percentage drop from day 0 is by day 3. In other words, the higher the plasma 
selenium at baseline, the greater the percentage reduction on day 1, but quicker 
it recovers to baseline levels by day 3. This may be due to mechanisms that 
move all available selenium into tissues (or excretion) leaving a required amount 
circulating in the plasma, but if the tissues are already selenium replete then 
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this selenium is not utilised and is redistributed to the plasma once the acute 
phase response is over. It may however, simply be regression to the mean with 
random changes around a fixed mean leading to weak linear relationships seen 
on days 1 and 3. It is hard to avoid this phenomena in a study such as this, 
although a larger sample size may help reduces the chance of finding a 
relationship at random. 
 
There is a strong linear relationship between plasma selenium concentration and 
serum albumin concentration on day 0-3 but the relationship actually 
strengthens over the evolution of the acute phase response, and by day 3 the 
serum albumin concentration is responsible for 90.8% of the variation in plasma 
selenium concentration. As the albumin concentration falls, which it did equally 
in all participants regardless of baseline plasma selenium status, the selenium 
which is normally bound to albumin would have to either be excreted or move 
into tissues. So if you have higher plasma selenium but a similar drop in albumin 
then there is no alternative but to have a larger drop in plasma selenium 
concentration during the acute phase response. 
 
When the plasma selenium is corrected for serum albumin concentration change 
by use of the selenium: albumin ratio, the linear relationship with liver selenium 
is present throughout days 0-3. This raises the question as to whether plasma 
selenium: albumin ratio could be used to assess selenium status during the acute 
phase response. When only results from during the acute phase response were 
used the plasma selenium: albumin ratio accounted for 50.5% of the variance in 
liver selenium concentration, making this appear to be like a reliable measure. 
Further work would be required to study the reliability of the selenium: albumin 
ratio over a range of baseline selenium statuses and also over a longer period of 
the acute phase response. 
 
Erythrocyte selenium would appear to be a superior biomarker for selenium 
status than plasma selenium in that it does not change during the acute phase 
response. Glutathione peroxidase activity does not change during the acute 
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phase response either, though is a more labour intensive assay than erythrocyte 
selenium. The effects of chronic inflammation would need to be studied along 
with the association between erythrocyte and liver selenium concentrations in a 
replete population. 
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12.8 Magnesium 
 
Magnesium is not a trace element but instead is an abundant cation with very 
important roles in physiology. It is therefore not unexpected that the 
mechanisms controlling plasma concentration during the acute phase response 
are very different from that of the trace elements. There was no relationship 
between any of the tissue or blood measures, suggesting that control 
mechanisms for plasma magnesium are independent of tissue status, which is to 
be expected given the vital importance of maintaining plasma magnesium 
concentration.  
 
Erythrocyte magnesium remained constant during the acute phase response. 
Plasma magnesium concentration changed dependent on the initial plasma 
concentration with a decrease in plasma concentration for those in the highest 
tertile at baseline and an increase for those in the lowest baseline tertile. When 
this was examined further there was a linear relationship between the 
percentage change in plasma magnesium concentration during the acute phase 
response and the plasma magnesium concentration at baseline; this appeared to 
be independent to the change in albumin concentration. Therefore, during the 
acute phase response the plasma magnesium concentration alters to a set level 
(between 0.65 and 0.8 mmol/L) in all the patients, regardless of the initial 
plasma magnesium concentration; it is likely that this is due to a homeostatic 
mechanism and may have a protective effect. Whether this is in response to the 
acute phase or to starvation is unknown, but it is independent of liver, muscle 
and erythrocyte magnesium concentrations and also CRP concentration. There is 
also a suggestion of a return to the baseline pattern of magnesium concentration 
by day 3, but whether this is due to resolution of the acute phase response, a 
return to normal eating by the patient or simply an aberrant result due to small 
numbers of samples on day 3, is unknown. There is certainly some evidence that 
plasma magnesium levels during health are genetically determined94 and 
therefore a return to the baseline results would be expected. 
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It is unlikely that these results are caused by regression to the mean but this 
should be kept in mind. The mean plasma magnesium level does appear to 
change for day 0 to day 1, though this difference does not quite reach statistical 
significance (p=0.059_ probably due to the small sample. The other factor 
against regression to the mean being the explanation for these results is that the 
relationship between plasma magnesium on day 1 and the change in plasma 
magnesium on days 1,2 and 3 are consistent and strong with baseline plasma 
magnesium explaining 65% of the variance in the percentage change. 
 
Overall the patient group have a low plasma magnesium concentration compared 
to the laboratory reference interval, with mean plasma magnesium of 
0.72mmol/L. The assay achieved values very similar to the assigned values of the 
quality control material used to assess accuracy, so this is unlikely to be an 
analytical problem. Given that homeostatic mechanisms appear to regulate the 
plasma magnesium to a concentration that is below the population reference 
interval, without evidence of harm, it may be that this reference interval is 
inappropriate and needs to be reviewed.  
 
Again, the use of bowel preparation should be considered as a potential 
interfering source in these results. All but 2 patients had bowel preparation; 
interestingly the 2 who did not had initial plasma magnesium of 0.6 and 0.9 
mmol/L which is in keeping with the rest of the cohort. If the participants who 
had bowel preparation lost a significant amount of magnesium during it, would 
that have affected the results? It would certainly not affect the tissue and blood 
correlations; it the patient became magnesium depleted during this time, then if 
the plasma or erythrocyte concentrations were a reflection of tissue 
concentration you would expect them to fall too and the relationship remain 
constant. It also seems unlikely to be an explanation of the changes in 
magnesium concentration seen post operatively, which are seen even when using 
magnesium:albumin rations to account for any differences in fluid status. While 
you may expect a patient who is magnesium depleted to correct that over the 
next few days, this would not explain the decreases in plasma magnesium in 
those whi had a higher plasma magnesium at teh time of operation. 
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Unfortunately no insight could be gained into which biomarker was the best 
surrogate for tissue magnesium status. It may be that a population with a low 
plasma magnesium concentration would be required to study this; homeostatic 
mechanisms will tightly control plasma magnesium concentrations, maintaining a 
tight plasma concentration range throughout a range of tissue concentrations. 
However, this study has discovered new factors in the regulation of plasma 
magnesium concentration and placed doubt on the accuracy of currently 
accepted reference intervals.  
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12.9 Strengths and Weaknesses 
 
The major strength of this work is the generation of a unique data set of paired 
tissue and blood samples in patients who are then followed through the 
evolution of the acute phase response. This has allowed conclusions to be drawn 
about which blood measures best reflect tissue status. It has also allowed insight 
into the physiological changes in trace metal and magnesium concentration 
during the acute phase response, in the context of tissue status. As this work 
used methods easily performed in the routine clinical laboratory, the findings 
are directly transferable to clinical practice. 
 
The main weakness of this work goes hand in hand with the unique nature of this 
dataset, in that the sample size is limited resulting in limited power; where 
correlations and significant changes were seen, the limited power means the 
size of these may be underestimated.  
 
The other major weakness include the incomplete sample collection: this was 
due to a combination of early discharge home and ward changes and is not 
unexpected in a study which relied fully on NHS staff to collect samples. In 
hindsight using dedicated research staff for sample collection would have 
resulted in a more complete data set, but at additional financial cost.  Also, the 
length of hospital stay post-operatively meant that the acute phase increase in 
copper concentration was not able to be studied and future work will be 
required in this area. However, what would have been possible was more 
complete baseline data collection including body mass index and weight change 
prior to surgery; though again the small sample size would have made sub-group 
analyses challenging. 
 
Potential bias in the study participants has been discussed in section 12.2. These 
include the potential for preoperative malnutrition due to cancer cachexia, 
which could have been better understood by having collected details of 
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pre=operative weight loss. Also the effects of bowel preparation, intravenous 
fluids and fasting pre and post operatively had potential to influence results to a 
degree; though these are unlikely to affect tissue and blood correlations by their 
very nature. 
 
The suitability of the patient group and generalisability of the results could 
therefore be questioned; however these are a very “well” patient group despite 
their diagnosis and have low baseline inflammatory status. It is difficult to find 
another patient group with whom this study would be ethically possible as liver 
biopsies would not be permitted on volunteers. 
Another problem with this study was the use of skeletal tissue measurements. 
Selenium and copper concentrations in skeletal tissue were too low to measure 
accurately and were excluded from analyses. It may be possible to alter the 
methods to make this possible, including using a lower volume of acid for 
digestion and increasing the integration time when analysing the samples. Zinc 
and magnesium concentrations could be measured but no correlations were 
found. This may be due to the status of the participants. It may be that 
homeostatic mechanisms exist to maintain plasma zinc and magnesium at the 
expenses of the metals stored in muscle, or vice versa. Again, examination of 
cohorts with low magnesium and zinc status may show positive correlations 
between blood and muscle concentrations that are not otherwise seen. 
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12.10 How are we to assess whether trace element deficiency is present and 
supplementation helpful? 
 
To assess whether trace element deficiency is present you need a suitable 
marker of deficiency and a definition of deficiency. The marker should reflect 
the status at a tissue level. In this study a number of potential markers were 
identified but all the correlations with tissue status were weak. This does not 
necessarily make them useless for identifying deficiency, but further work would 
be required to ensure a particular marker was sensitive enough to changes in 
status to pick up a patient who developed deficiency. It may be the case that 
one single marker is not going to be identified which can accurately identify 
deficiency, and a range of plasma, cellular and functional measures would be 
required in combination with corrections for carrier protein status. 
 
How you define deficiency is a much harder question. Deficiency would be a 
state whereby low levels of a trace element result in an adverse clinical 
outcome. For many analytes population reference intervals are used to define 
deficiency; however this definition is at the mercy of the status of the 
population. If an entire population were relatively deficient in an element then 
deficiency would not be correctly identified. Conversely, a population with high 
levels of an element would result in a reference interval which incorrectly 
labelled patients with deficiency when they may still have a concentration far 
above the level at which they would be adversely affected. However, in the 
absence of a better definition, population reference intervals may help identify 
severe deficiency. Large scale epidemiological studies would be required to 
identify concentrations of trace elements which appeared to be related to 
adverse clinical outcomes; but even then that does not prove a causal link. 
 
A causal link between a deficiency state and an adverse clinical outcome could 
only truly be established if a supplementation study showed a reversal or 
prevention of the adverse clinical outcome. This would require an accurate 
measure of deficiency to ensure the correct population were being targeted. 
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Lack of a way to define deficiency, or not selecting the study cohort on the basis 
of status, may be why supplementation studies have so far had little success in 
improving outcomes. It would also be useful if a marker of supplementation 
which increased in proportion to the amount of supplement given was found; 
erythrocyte selenium is known to increase with supplementation and the same 
should be established for copper.  
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12.11 Future work 
 
There are still many unknowns in measuring trace element status and a lot of 
work is required before the full validity of measurements and their usefulness in 
clinical practice are known. 
 
The relationship between blood and tissue concentrations over a range of trace 
element status 
 
In the current work, the cohort had low plasma selenium and zinc status, and 
normal plasma copper status; this may have an effect on the relationships seen 
with potential for stronger relationships in deficiency. Examining these 
relationships over a range of baseline status would be beneficial as the 
relationship in deficiency is the clinically relevant model. However, finding a 
cohort with low plasma status that liver samples could be obtained from would 
be very difficult. 
 
The change in erythrocyte trace element concentration during prolonged 
inflammation 
  
While we know from previous work that erythrocyte concentration does not 
change over 7 days in a simple model of the acute phase response (post knee 
arthroplasty), this is not the typical patient model in which trace element 
concentration is of clinical interest. Investigating the change in erythrocyte 
concentration in a patient with a prolonged severe inflammatory illness would 
be advantageous as confounding factors of decreased erythrogenesis; iron 
deficiency, poor oral intake and increased utilisation would become important 
and may affect the concentration and its relationship with tissue status. This 
would help answer the question as to whether erythrocyte concentrations of 
trace elements where determined at the time of erythrogenesis or where 
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dynamic in response to tissue status. Such a study could be performed in 
patients in intensive care, or with severe inflammatory conditions such as 
rheumatoid arthritis or inflammatory bowel disease. 
 
The change in erythrocyte copper concentration with supplementation 
 
Erythrocyte selenium is known to increase with supplementation and erythrocyte 
zinc is known to not increase with supplementation but no such study has been 
performed for copper. Given that erythrocyte copper appears to be a potentially 
useful marker of copper status, such a study would be useful. This study would 
have to use a palatable and bioavailable form of copper for supplementation and 
supplementation would have to continue for over 12 weeks to allow 
incorporation into new erythrocytes.  
 
The development of population reference intervals 
 
Given the lack of suitable reference materials, local laboratory reference 
intervals for erythrocyte trace elements and magnesium would have to be 
developed. It should be noted that population reference intervals and optimal 
concentrations required for health are not synonymous; however, until more 
information is known about the potential risks from subclinical deficiency and an 
optimal concentration for health is ascertained, population reference intervals 
provide useful guidance for clinicians. 
 
The relationship between erythrocyte and plasma concentrations and clinical 
outcomes 
 
There is no point having a blood test if you are not able to make clinical 
recommendations on the basis of the results which will have a positive effect on 
301 
 
patient outcomes. This is the major missing area in trace element research. 
However, until you have a valid marker of deficiency, it is difficult to select a 
patient cohort who may benefit from supplementation. For example, there have 
been many studies of selenium supplementation in intensive care which have 
had inconclusive results15;95; it may be that selecting a cohort of patients who 
are truly selenium deficient would result in a positive effect on outcome.  
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12.12 Conclusions 
 
• Erythrocyte copper concentration, not plasma copper, is weakly related 
to liver copper concentration and does not change during the acute phase 
response. This suggests erythrocyte copper is a potential suitable 
biomarker for tissue copper status during the acute phase response, 
however further studies looking at the relationship over a longer period of 
inflammation are required.  
 
• Plasma copper concentration is related to C-reactive protein 
concentration when the patient does not have an inflammatory response. 
This may be the explanation for epidemiological studies linking higher 
copper status and cardiovascular disease and should be considered when 
interpreting plasma copper results. 
 
• Plasma zinc concentration is weakly related to liver zinc concentration, 
but the concentration decreases during the acute phase response. The 
decrease in concentration may be related to liver concentration; however 
it is not possible to accurately ‘correct’ for the decrease by adjusting for 
the serum albumin concentration. Erythrocyte zinc concentration is not 
related to liver zinc concentration. Neither plasma nor erythrocyte zinc 
appear to be a reliable biomarker for zinc status during the acute phase 
response. 
 
• Plasma and erythrocyte selenium concentration, and erythrocyte 
glutathione peroxidase concentration, all have a linear relationship with 
liver selenium concentration. However plasma selenium concentration 
decreases during the acute phase response; adjustment for serum albumin 
concentration may be possible but this requires further research. 
Erythrocyte selenium concentration or erythrocyte glutathione peroxidase 
activity both appear to be potential biomarkers of tissue selenium status, 
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but these studied would have to be repeated in a selenium replete 
population. 
 
• Plasma magnesium concentration changes during the acute phase 
response to what appears to be a set concentration, regardless of the 
original plasma magnesium. This homeostatic set-point concentration is 
lower than the standard laboratory reference interval and the validity of 
this reference interval during acute illness needs to be re-visited.  
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Appendix 1 – Reference range values 
 
Whole blood glutathione peroxidase (U/ g Hb) for reference interval 
 
Sample Hb (g/L) GPX U/L GPX U/ g Hb 
1 18.8 542.5 28.86 
2 15.7 517.5 32.96 
3 16.9 871.5 51.57 
4 19.7 811.3 41.18 
5 19.1 653.3 34.20 
6 18.1 727.8 40.21 
7 17.6 629.1 35.74 
8 18.8 495 26.33 
9 15.8 545.2 34.51 
10 17.7 580.4 32.79 
11 17.7 421.7 23.82 
12 15.4 576.7 37.45 
13 17.4 505.9 29.07 
14 17.5 789.3 45.10 
15 17.4 546 31.38 
16 12.3 363.7 29.57 
17 19.2 537.1 27.97 
18 15.7 579.5 36.91 
19 15 446.3 29.75 
20 17.1 551.5 32.25 
21 11.1 133.1 11.99 
22 17.6 369.6 21.00 
23 13.1 378.4 28.89 
24 17.6 465.8 26.47 
25 18 310.1 17.23 
26 12.8 305.8 23.89 
27 19.6 458.9 23.41 
28 19.7 590.6 29.98 
29 14.6 535.4 36.67 
30 15.1 676.1 44.77 
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Sample Hb (g/L) GPX U/L GPX U/ g Hb 
31 17.6 475.5 27.02 
32 13 742.1 57.08 
33 17.4 563.9 32.41 
34 16.7 704.8 42.20 
35 17.4 592.2 34.03 
36 15.8 669.2 42.35 
37 14.1 771.9 54.74 
38 13.6 422.6 31.07 
39 11.6 451.7 38.94 
40 15 653.5 43.57 
41 16.2 560.6 34.60 
42 13.8 622 45.07 
43 15.5 566.3 36.54 
44 14.6 561.6 38.47 
45 14.7 636.3 43.29 
46 17.6 724.9 41.19 
47 10.5 356.3 33.93 
48 15.7 453.1 28.86 
49 10.3 728.4 70.72 
50 17.1 523.9 30.64 
51 17 568.9 33.46 
52 15.8 572.8 36.25 
53 14.3 382.8 26.77 
54 20.4 465.8 22.83 
55 15.6 596.2 38.22 
56 14 573.5 40.96 
57 15.5 790.8 51.02 
58 17.1 555.5 32.49 
59 14.1 543.9 38.57 
60 14.7 655.2 44.57 
61 13.1 618.1 47.18 
62 15 446.6 29.77 
63 14.2 492.1 34.65 
64 13 384.9 29.61 
    
306 
 
    
    
Sample Hb (g/L) GPX U/L GPX U/ g Hb 
65 12.8 624.4 48.78 
66 18.2 644.8 35.43 
67 14.8 497 33.58 
68 13.7 497.5 36.31 
69 14.7 631.3 42.95 
70 18.2 612.1 33.63 
71 15.4 324.7 21.08 
72 16 553.1 34.57 
73 15 604.6 40.31 
74 14.3 503.9 35.24 
75 14 599.4 42.81 
76 14 454.4 32.46 
77 15.7 525.5 33.47 
78 13.9 436.3 31.39 
79 13.3 567.3 42.65 
80 13.4 368.4 27.49 
81 15.8 350.7 22.20 
82 15.6 308.7 19.79 
83 13 285.8 21.98 
84 12.9 382.4 29.64 
85 13.6 587.2 43.18 
86 16.3 339 20.80 
87 13.7 486.9 35.54 
88 12.3 151.7 12.33 
89 14.3 387.7 27.11 
90 13.9 364.5 26.22 
91 16.1 474.7 29.48 
92 14 314.1 22.44 
93 13.6 368.7 27.11 
94 14.6 335.7 22.99 
95 16.2 300 18.52 
96 13.1 446.1 34.05 
97 14 144.3 10.31 
98 13.9 238.9 17.19 
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Sample Hb (g/L) GPX U/L GPX U/ g Hb 
99 12.5 439 35.12 
100 13.6 406.1 29.86 
101 10.1 139.2 13.78 
102 13 409 31.46 
103 16.5 464.4 28.15 
104 13.7 446 32.55 
105 14.6 547.4 37.49 
106 15.1 504.2 33.39 
107 15.9 513.4 32.29 
108 14.4 637.1 44.24 
109 15.2 428.9 28.22 
110 16.3 518.4 31.80 
111 12.6 501.2 39.78 
112 12.8 569.5 44.49 
113 12.9 475.5 36.86 
114 15 446.3 29.75 
115 15.9 572 35.97 
116 15.5 600.6 38.75 
117 13.2 524.5 39.73 
118 13.4 603.7 45.05 
119 13.7 497.6 36.32 
120 12.3 372.9 30.32 
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Red blood cell glutathione peroxidase (U/ g Hb) for reference interval 
 
Sample Hb (g/L) GPX U/L GPX/ g Hb 
1 31 492 31.74 
2 29 534.8 36.88 
3 23.6 811.8 68.80 
4 37.4 882.4 47.19 
5 30.4 635.2 41.79 
6 39.2 745.5 38.04 
7 30.2 632.1 41.86 
8 30.8 464.7 30.18 
9 29.4 595.2 40.49 
10 34.2 613.6 35.88 
11 35 416.5 23.80 
12 33 677.4 41.05 
13 37.8 536.9 28.41 
14 31.8 788.1 49.57 
15 27.8 192 13.81 
16 28.4 354.3 24.95 
17 31.2 626.3 40.15 
18 28.4 456.3 32.13 
19 31.4 486.9 31.01 
20 27.2 659.7 48.51 
21 31 525.8 33.92 
22 29.4 567.5 38.61 
23 26.8 423.7 31.62 
24 28.4 479.7 33.78 
25 20 190.7 19.07 
26 28.6 394.5 27.59 
27 29.6 419.6 28.35 
28 33 540.7 32.77 
29 28.6 621.7 43.48 
30 30.4 464.7 30.57 
31 28 684.7 48.91 
32 29 840.4 57.96 
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Sample Hb (g/L) GPX U/L GPX/ g Hb 
33 28.6 480.1 33.57 
34 31.8 673.6 42.36 
35 28.4 574.1 40.43 
36 25.2 538.1 42.71 
37 27.6 750 54.35 
38 27.6 389.8 28.25 
39 29.6 337.6 22.81 
40 27.6 581.2 42.12 
41 31.2 489.6 31.38 
42 31.2 457.5 29.33 
43 26.6 548.1 41.21 
44 30.4 548.4 36.08 
45 29.8 676.4 45.40 
46 30.4 691.8 45.51 
47 28.6 462.5 32.34 
48 31 437.2 28.21 
49 29.4 601.7 40.93 
50 29.4 551.2 37.50 
51 28.8 515.5 35.80 
52 28 528.5 37.75 
53 27.2 398.7 29.32 
54 28.2 364.8 25.87 
55 27.8 609.7 43.86 
56 30.2 413 27.35 
57 28.6 741.8 51.87 
58 30.4 482.5 31.74 
59 30.2 564.3 37.37 
60 30.2 649.1 42.99 
61 28.2 582.4 41.30 
62 27.8 423.3 30.45 
63 29 502.6 34.66 
64 29 404.4 27.89 
65 29.4 698.9 47.54 
66 26.4 476.8 36.12 
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Sample Hb (g/L) GPX U/L GPX/ g Hb 
67 28 460.5 32.89 
68 28 483 34.50 
69 28.8 621.6 43.17 
70 28 480.8 34.34 
71 27.4 261.9 19.12 
72 27.2 442.7 32.55 
73 30.2 569.8 37.74 
74 32.8 441 26.89 
75 29 551.9 38.06 
76 28 391.6 27.97 
77 35.6 464.1 26.07 
78 30.4 420.7 27.68 
79 28.8 541.8 37.63 
80 27.4 151.1 11.03 
81 28.6 373.5 26.12 
82 28.2 392.4 27.83 
83 26.6 369.3 27.77 
84 22.4 320.6 28.63 
85 23.4 443.4 37.90 
86 26.4 353.3 26.77 
87 27.4 582.2 42.50 
88 27.6 286.6 20.77 
89 25.6 417.3 32.60 
90 20.2 334.4 33.11 
91 28.2 508.9 36.09 
92 29 371.6 25.63 
93 28.2 462.3 32.79 
94 27.6 428.9 31.08 
95 30.4 346.9 22.82 
96 25.4 613.2 48.28 
97 27 276.3 20.47 
98 24.4 379.4 31.10 
99 27.2 653.5 48.05 
100 24.4 569 46.64 
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Sample Hb (g/L) GPX U/L GPX/ g Hb 
101 27.8 395.3 28.44 
102 26 531.3 40.87 
103 21.4 420.9 39.34 
104 26.8 585 43.66 
105 27.2 595.3 43.77 
106 27 491.4 36.40 
107 25.2 430.9 34.20 
108 26.4 687.5 52.08 
109 24.8 373.6 30.13 
110 25 502.2 40.18 
111 25.2 537.6 42.67 
112 26.6 659.7 49.60 
113 25.6 490.1 38.29 
114 26.2 419.9 32.05 
115 25.6 520.5 40.66 
116 25.2 562.4 44.63 
117 23.2 502.3 43.30 
118 25.8 560.3 43.43 
119 24.2 435.2 35.97 
120 24.6 446.3 36.28 
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Appendix 2 
Patient Information Sheet V2 02/02/2008 
 
 
 
A study of the relationship between tissue and blood concentrations of trace 
metals and micronutrients, and the effects of the acute inflammatory 
response on these concentrations. 
 
A comparison of blood, liver, and muscle levels of metals and vitamins in 
patients who have had an operation. 
 
You are being invited to take part in a research study. Before you decide 
whether to take part, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Thank you for reading this. 
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What is the purpose of this study? 
 
For normal body metabolism, skin to heal and to help fight infections, we need 
to take the correct amount of micronutrients (metals, such as copper and zinc 
and vitamins) in our food. 
 
In our laboratory we routinely measure the concentrations of metals and 
vitamins in patients’ bloods. This is particularly important in patients who 
receive their food directly to their blood (total parenteral nutrition) and also 
patients in intensive care.   
 
You may have noticed that when you are sick for any reason, such as a common 
cold or the flu, you tend to not feel hungry and may have a high temperature. 
These symptoms are part of what is called the inflammatory response. Your body 
has an inflammatory response to a very wide variety of things such as infection, 
trauma (such as breaking a leg), surgery etc.  
 
Other features of the inflammatory response include changes to the 
concentration of many components of the blood. These include a decrease in the 
concentration of the metal zinc in the blood even though the amount of zinc in 
the body is normal. The concentration of the metal copper can increase in the 
blood during inflammation, even when the body is lacking in copper.  We are 
now able to measure these metals and vitamins in blood cells, which we not able 
to do in the past. 
 
We are looking for a better way to measure the amounts of metals and vitamins 
in the body. We would like to compare the concentrations of metals and 
vitamins in blood cells with the levels in body tissues, to see if the blood cells 
contain similar amounts to other parts of the body, such as the liver and muscle. 
We would like to obtain liver and abdominal muscle samples from patients 
undergoing operations on their livers and compare their metal and vitamin 
concentrations to those measured in the blood. We would also like to measure 
the blood after the operation, whilst there is an inflammatory response, to see 
which type of blood cells keep a constant level of metals and vitamins. 
 
 
Why have I been chosen? 
 
You have been asked to participate in this study because you are undergoing a 
liver resection (operation where part of your liver is removed). This will allow 
us, if you agree to participate, to use a small amount of the spare liver tissue 
removed at the time of your operation. 
 
We hope to recruit 50 patients. 
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Do I have to take part? 
 
No, it is up to you to decide whether or not to take part. Whether or not you 
decide to take part will not in any way affect your treatment. 
 
If you do decide to take part you will be given this information sheet to keep and 
be asked to sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
What will happen to me if I take part? 
 
The majority of the study will take place during your hospital admission. It will 
not affect the treatment you receive in any way.  
 
During your surgery, when part of the liver is removed, there will be left over 
liver that is normally destroyed. We wish to take a liver sample from the part of 
the liver that has been removed. We will take 2 x 1cm3 of this liver tissue (about 
the size of 2 garden peas). 
 
We will also take a small slither of muscle from your abdominal wall. Mr Horgan 
and his team will have to cut through your abdominal wall (your tummy) to 
enable them to see and operate on your liver. When they are finishing up their 
surgery and closing your wound, they will take a very thin strip from the 
abdominal wall under the skin, measuring 5mm by 10cm (about the size of the 
lead inside a pencil).  
 
We will measure metal and vitamin levels on these samples. 
 
 
We will take blood samples to measure the level of inflammation in your blood 
and also the concentrations of vitamins and metals in your blood. We will do this 
on the day before your surgery and one, two, three and six days after surgery.  
We will take 4 tubes of blood (around 20 ml or 4 teaspoons of blood) each time.  
 
All efforts will be made to try and take the blood samples at the same time as 
routine bloods are being taken during your hospital stay. 
 
If you have had a blood transfusion in the last three months this will have an 
effect on the concentrations on vitamins and metals in your blood cells (as they 
are will not be all your own), therefore you would not be able to participate in 
the study. 
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We appreciate that this can seem confusing so we have summarised what will 
happen to you below: 
 
 
Day of admission to hospital A doctor will come and speak to you 
about taking part in the study. You 
will have routine bloods taken and at 
this time we will take 4 further tubes 
(20ml or 4 teaspoons) as part of the 
study. 
Day of the operation When Mr Horgan is starting the 
operation and is cutting through your 
abdominal wall (tummy) to get to your 
liver, a very small slither of muscle 
will be taken (5mm by 10cm - about 
the size of the lead inside a pencil). 
 
During the operation, when Mr Horgan 
has removed part of your liver, a small 
part of the liver that is removed is 
used for the study (2 x 1cm3 - about 
the size of 2 garden peas). 
 
 
Each morning after the operation 
whilst you are in hospital 
Mr Horgan’s team will be taking bloods 
from you each day to monitor your 
recovery from the operation. At this 
time an additional 4 blood tubes will 
be taken for the study. 
 
It may be the case that in the future new tests are invented and it would be 
helpful if we could look at blood and tissues levels of it. Therefore, so we can 
get the maximum benefit from your donated samples, we would ask you to 
consider letting us keep your samples for use in future research projects. Your 
samples will be kept anonymised (without your name on them) so that they 
cannot be traced to you. 
 
What do I have to do? 
 
There are no restrictions placed on you if you take part in this study, for 
example there are no changes in diet, lifestyle or medication required. 
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What are the side effects of taking part? 
 
Collecting the liver and muscle samples will not cause any significant discomfort 
to you over and above that of your operation. The muscle sample will have no 
effect on your wound, how it will look or how it will heal. 
 
As with every blood test, there is a risk of pain or bruising on the arm from the 
needle. We will try to reduce this risk by having experienced persons taking your 
blood sample and trying to coordinate sampling so that the additional samples 
are collected with the routine bloods tests that your doctor requests. 4 tubes 
(20ml or 4 teaspoons) can seem like a lot of blood, but we can reassure you that 
this is very small compared to how much blood is in your body and you will have 
no ill-effects from this. 
 
What are the possible disadvantages and risks of taking part? 
 
There will be no alteration in your treatment if you participate in this study.  
We, therefore, do not you feel you will be disadvantaged by taking part in this 
study. 
 
What are the possible benefits of taking part? 
 
You will not benefit from taking part in this study as your treatment is 
unchanged. 
 
We hope that the results of this test will help us treat future patients with 
nutritional problems better. 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms may be 
available to you. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it. 
As a matter of courtesy, we will write to your GP to inform them that you have 
participated.  
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What will happen to the results of the research study?  
 
You will not be identified in any report or publication of results from this study. 
We hope the study results will be published in a journal aimed specifically at 
specialist doctors and scientists. Results may be presented at meetings of 
specialist doctors and scientists. 
 
Your samples will be analysed up to one year after you have left hospital. This, 
plus the fact that this is such an unknown area, means that there would be no 
results which we feel would be significant to your health, that we would want 
your doctor to act on. 
 
Who is organising and funding the research? 
 
The research is organised by the Scottish Trace Element and Micronutrient 
Reference Laboratory in the Department of Biochemistry at Glasgow Royal 
Infirmary. Financial support for the study may be sought from NHS research 
funds in Scotland. None of the researchers involved are being paid over and 
above their normal salary for undertaking this research. 
 
Who has reviewed the study? 
 
This study has been reviewed by the Glasgow Royal Infirmary Research Ethics 
Committee. 
 
 
Contact for further information 
 
If you require further information please contact: 
 
Dr Jennifer Logue   Tel: 0141 211 4390 
Department of Biochemistry 
McEwan Building 
Glasgow Royal Infirmary 
84 Castle Street 
Glasgow 
G4 0SF 
 
Or ask a member of Mr Paul Horgan’s team during your hospital admission. 
 
Thank you for taking the time to read this information sheet. 
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Patient Invite Letter V1 10/12/2007 
 
 
Scottish Trace Element and Micronutrient Reference Laboratory 
Department of Biochemistry 
McEwan Building 
Glasgow Royal Infirmary 
 
Department of Surgery 
Glasgow Royal Infirmary 
84 Castle Street 
Glasgow 
G4 0SF 
 
 
Date: 
 
 
Dear  
 
 
 
We are currently doing research involving patients who are having your type of surgery. 
We would like to invite you to take part. Enclosed is an information leaflet explaining why 
we are doing the research and what it will involve if you agreed to take part. Please take 
time to read the information and discuss it with others if you wish. When you come into 
hospital for your operation you will be able to discuss it further and ask any questions you 
may have, before deciding whether to take part. 
 
Thank you for taking the time to read this. 
 
 
Yours Sincerely 
 
 
 
 
 
 
 
Dr Jennifer Logue     Mr Paul Horgan 
SpR in Chemical Pathology   Senior Lecturer and Honorary Consultant  
Scottish Trace Element and Micronutrient Department of Surgery  
Reference Laboratory    Glasgow Royal Infirmary 
Glasgow Royal Infirmary 
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Consent form V2 02/02/2008 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project: A study of the relationship between tissue and blood concentrations 
of trace elements and micronutrients, and the effects of the acute inflammatory 
response on these concentrations. 
 
Name of Researcher: Dr Jennifer Logue       
 
1. I confirm I have read and understand the information sheet dated 02/02/2008 
(Version 2) for the above study. I have had the opportunity to consider the 
information, ask questions, and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes may be looked at by 
individuals from regulatory authorities the NHS trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have  
            access to to my records. 
 
4. I agree to my GP being informed of my participation in the study. 
 
 
5. I agree to my tissue samples being stored for use in future studies. 
 
 
6.   I agree to take part in the above study. 
                
 
 
__________________           ______________         ________________________ 
Name of Patient                     Date                              Signature  
 
 
 
__________________           ______________         ________________________ 
Name of Person                      Date                              Signature  
taking consent 
 
  When completed, 1 for patient, 1 for researcher site file, 1 (original) to be kept in medical 
notes. 
 
 
 
 
 
 
 
Please initial box 
320 
 
Management approval 02/07/2008 
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Satisfactory ethical opinion 31/01/2008 
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Appendix 3 Demographics and baseline results of participants and available samples: 
Study 
number 
Sex Age 
Reason for liver 
resection 
Albumin 
(g/L) 
CRP 
(mg/L) 
Haematocrit 
(i/L) 
Plasma Mg 
(mmol/L) 
Plasma Cu 
(µmol/L) 
Plasma Zn 
(µmol/L) 
Plasma Se 
(µmol/L) 
Samples 
available 
1 F 76 Hydatid cyst 40 17 0.402 0.9 24.0 11.6 1.0 0,1,2 
2 M 76 
Liver metastases 
(Colorectal) 
39 5.8 0.36 0.7 13.1 13.3 1.2 0,1,2 
3 M 61 
Liver metastases 
(Colorectal) 
42 3 0.437 0.5 11.7 9.3 1.1 0 
4 F 62 
Liver metastases 
(Colorectal) 
37 8 0.392 0.7 15.8 11.7 1.0 0 
5 F 76 
Liver metastases 
(Colorectal) 
40 0.8 0.368 0.8 15.8 11.4 1.1 0,1,2 
6 M 73 
Liver metastases 
(Colorectal) 
32 3 0.357 0.8 14.4 11.3 0.8 0,1,3 
7 F 35 
Liver metastases 
(Breast Ca) 
35 1.4 0.322 0.9 15.1 13.9 1.3 0,1 
8 M 72 
Liver metastases 
(Colorectal) 
38 0.9 0.375 0.5 10.8 8.3 0.7 0,1,3 
9 F 79 
Liver metastases 
(Colorectal) 
38 0.5 0.391 0.8 18.0 11.6 1.3 0,1,2 
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10 M 66 
Liver metastases 
(Colorectal) 
42 3 0.481 0.9 17.7 18.5 1.7 0,1,2,3 
11 F 71 
Liver metastases 
(Colorectal) 
39 5.4 0.363 0.7 13.4 11.2 0.8 0,1,2 
12 M 48 
Liver metastases 
(Colorectal) 
40 17 0.409 1.0 16.5 13.6 0.9 0,1,2,3 
13 F 69 
Liver metastases 
(Colorectal) 
35 1.3 0.391 0.9 11.9 14.8 0.7 0 
14 M 68 
Liver metastases 
(Colorectal) 
33 16 0.408 0.7 15.8 10.2 0.7 0,1,2,3 
15 M 73 
Liver metastases 
(Colorectal) 
24 9.4 0.431 0.9 15.5 10.2 0.6 0,2,3 
16 M 54 
Liver metastases 
(Colorectal) 
38 17 0.303 0.9 18.9 12.2 1.0 0 
17 F 51 
Liver metastases 
(Colorectal) 
43 6.4 0.398 0.9 15.6 13.4 1.2 0,1 
18 F 60 
Liver metastases 
(Colorectal) 
47 7.4 0.384 0.7 17.5 10.9 1.1 0,1 
19 M 57 
Liver metastases 
(Colorectal) 
36 1.2 0.386 0.7 6.4 10.7 0.8 0,1,3 
20 M 64 
Liver metastases 
(Colorectal) 
41 5 0.429 0.5 9.2 11.7 1.0 0,1,2 
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21 M 62 
Liver metastases 
(Colorectal) 
36 7.3 0.454 0.7 12.6 14.8 1.1 0,1 
22 M 53 
Hepatocellcular 
carcinoma 
36 2.2 0.432 0.6 10.9 10.8 0.8 0 
23 F 47 
Liver metastases 
(Colorectal) 
31 5.3 0.388 0.7 13.9 10.3 0.8 0,1 
24 F 64 
Resection – no cancer 
on histopathology 
45 0.7 0.408 0.6 9.2 10.6 0.7 0,1 
25 F 73 
Liver metastases 
(Colorectal) 
35 3.3 0.384 0.6 12.8 9.2 0.8 0,1,2 
26 F 50 
Liver metastases 
(Colorectal) 
39 7 0.419 0.7 16.5 14.1 1.0 0,1 
27 F 53 
Resection – no cancer 
on histopathology 
48 0.9 0.447 0.6 15.3 12.1 1.0 0 
28 F 68 
Liver metastases 
(Colorectal) 
37 6.8 0.413 0.7 18.3 12.6 0.8 0,1,2,3 
29 F 52 Hydatid cyst 42 0.5 0.367 0.6 11.7 11.0 1.0 0,1,2,3 
30 M 43 
Liver metastases 
(Colorectal) 
38 1.9 0.377 0.8 13.2 12.8 1.0 0 
31 F 71 
Liver metastases 
(Colorectal) 
39 15 0.364 0.8 17.0 12.0 0.9 0,1,2,3 
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Appendix 4 
Normality of data – expanded details 
C-Reactive Protein 
 
To ensure the normality of the data and exclude any outlying samples, the 
Anderson-Darling test for normality was performed.  
 
Serum CRP Day 0 (pre-operative sample) was found to not be normally 
distributed (p<0.005) (fig A4.1a) and was therefore logarithmically transformed 
to achieve normality (p=0.132) (fig A4.1b). Post-operatively, CRP on day 1, CRP 
on day 2, and CRP on day 3 were all found to be normally distributed (p=0.849, 
0.635, 0.907 respectively)(fig A4.1c). 
 
Fig A4.1a Probability plot of CRP concentration on day 0 (mg/L)  
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Fig A4.1b Probability plot of the logarithmic transformation of CRP 
concentration on day 0 (mg/L)  
 
 
Fig A4.1c Probability plots of CRP concentration on day 1-3 (mg/L) 
 
 
327 
 
In order to allow pooling of results, it would be ideal to log transform all CRP 
data; unfortunately logarithmic transformation of day 2 and 3 rendered them 
non-normal (day 1 p=0356, day 2 p<0005, day 3 p=0.015; fig A4.2) so this was not 
done. 
 
Fig A4.2 Probability plots of logCRP concentration on day 0-3 (mg/L) 
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Albumin 
Using the Anderson-Darling test for normality, Albumin Day 0, Day 1, Day 2 and 
Day 3 were found to all be all normally distributed (p=0.306, 0.177, 0.267, 0.135 
respectively) (fig A4.3). 
 
 
Fig A4.3 Probability plots of albumin concentration on day 0-3 (g/L) 
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Haematocrit 
Normality of data  
 
Using the Anderson-Darling test for normality, haematocrit Day 0 was normally 
distributed (p=0.760).  Examination of probability plots for haematocrit on day 
1, 2 and 3 revealed outlying samples (fig A4.4a): day 1 samples 8, 10 and 21; day 
2 samples 10, 18 and 22; day 3 sample 10. With these removed all samples were 
normally distributed: day 0 p=0.760, day 1 p=0.208, day 2 p=0.322 and day 3 
p=0.410 (fig A4.4b). 
 
 
Fig A4.4a Probability plots of haematocrit concentration (i/L) on day 0-3  
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Fig A4.4b  Probability plots of haematocrit concentration (i/L) on day 0-3 with 
outlying samples removed 
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Copper 
Liver copper concentration 
The Anderson-Darling test for normality was performed to ensure the normality 
of the data and exclude any outlying samples. Liver copper concentrations were 
found to be normally distributed (p=0.100) (fig A4.5).  
 
Fig A4.5 Probability plot of liver copper concentration (µg/g dry weight)  
 
Plasma copper concentration 
Plasma copper concentrations on days 0, 2 and 3 were normally distributed 
(p=0.661, 0.132 and 0.782 respectively; fig A4.6a). Plasma copper concentration 
on day 1 was not normally distributed (p=0.015) and a histogram was draw to 
examine the pattern of distribution (fig A4.6b). After logarithmic 
transformation, days 0-3 were all normally distributed (p=0.595, 0.097, 0.390 
and 0.576 respectively; fig A4.6c). 
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Fig A4.6a Probability plot of plasma copper concentration (µg/L) on day 0-3 
 
 
Fig A4.6b Histogram of plasma copper concentration (µg/L) on day 1 
333 
 
 
Fig A4.6c Probability plot of log plasma copper concentration (µg/L) on day 0-3 
 
Plasma ferroxidase activity 
 
Plasma ferroxidase activity was non-normal on day 0 (p=0.018; fig A4.7a). An 
outlier (study number 18) was identified and removed from future analyses. 
After this removal, plasma ferroxidase activities on days 0-3 were all normally 
distributed (p=0.656, 0.411, 0.874 and 0.828 respectively; fig A4.7b).  
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Fig 4.7a Probability plot of plasma ferroxidase activity (U/L) on day 0 
 
 
Fig A4.7b Probability plot of plasma ferroxidase activity (U/L) on day 0-3 with 
study number 18 removed from day 0 
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Plasma ceruloplasmin concentration 
 
Initial examination of probability plots for plasma ceruloplasmin concentration 
showed outlying samples on day 0 (study number 21) and day 1(study number 1) 
(fig A4.8a); these were removed from further analyses. Day 2 was seen to be 
non-normally distributed (p=0.045) (fig A4.7b). Logarithmic transformation and 
removal of outliers resulted in days 0-3 all being normally distributed (p=0.6, 
0.599, 0.118 and 0.804 respectively) (fig A4.7c).  
 
 
Fig A4.7a Probability plots of plasma ceruloplasmin concentration (g/L) on day 
0-3  
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Fig A4.7b Probability plot of log plasma ceruloplasmin concentration (g/L) on 
day 2 
 
 
Fig A4.7c Probability plots of log plasma ceruloplasmin concentration (g/L) on 
day 0-3 (study number 21 removed from day 0, study number 1 removed from 
day 1). 
 
 
337 
 
Red blood cell copper concentration 
 
Day 0 and day 1 red blood cell copper concentrations were non-normally 
distributed (both p<0.005). Dot plots were generated of red blood cell copper 
concentrations on days 0-3 (fig A4.8a) and these showed day 0 and day 1 red 
blood cell copper concentrations to be right-skewed. The data was therefore 
logarithmically transformed, but day 0 was still non-normal (p<0.005, fig A4.8b). 
Three high concentration outlying samples (study numbers 11, 20, and 26) were 
therefore removed from further analyses and the distribution was normalised 
(p=0.280; fig A4.8c). 
 
 
Fig A4.8a Dot plots of red blood cell copper concentration (µg/µg Fe) on day 0-3 
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Fig A4.8b Probability plot of log red blood cell copper concentration (µg/µg Fe) 
on day 0 
 
 
Fig A4.8c Probability plot of log red blood cell copper concentration (µg/µg Fe) 
on day 0 (study number 11, 20 and 26 removed) 
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The concentrations of red blood cell copper day 1 were also still non-normal 
(p<0.053, fig A4.8d) after logarithmic transformation. One high concentration 
outlying sample (study number 26) was therefore removed from further analyses 
and the distribution was normalised (p=0.933, fig A4.8e). 
 
 
Fig A4.8d Probability plot of log red blood cell copper concentration (µg/µg Fe) 
on day 1 
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Fig A4.8e Probability plot of log red blood cell copper concentration (µg/µg Fe) 
on day (study number 26 removed) 
After logarithmic transformation and the removal of outlying samples the red 
blood cell copper concentration on day 0-3 were all normally distributed 
(p=0.28, 0.933, 0.173 and 0.889 respectively; fig A4.8f). 
 
Fig A4.8f Probability plots of log red blood cell copper concentration (µg/µg Fe) 
on day 0-3 (study numbers 11, 20 and 26 removed from day 0, study number 26 
removed from day 1). 
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Zinc 
 
To ensure the data followed a normal distribution to allow statistical analyses to 
take place, the Anderson-Darling normality test was performed. 
 
Muscle zinc concentrations (µg/g dry weight) were found to be non-normally 
distributed (p<0.005, fig A4.9a). Logarithmic transformation of the data did not 
normalise it therefore the two outlying data points (samples 13 and 29) were 
removed for the zinc statistical analyses. With outliers removed the muscle zinc 
was normally distributed (p=0.14, fig A4.9b). 
 
 
 
Fig A4.9a Probability plot of muscle zinc concentration (µg/g dry weight) with 
all 31 samples 
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Fig A4.9b Probability plot of muscle zinc concentration (µg/g dry weight) 
excluding samples 13 and 29 
 
Analysis of a probability plot of plasma zinc concentration (µg/L) on Day 0 (fig 
A4.10) revealed an outlying sample (sample 10) and this was also removed from 
further statistical analysis of zinc results. After this removal the plasma zinc 
concentration on Day 0 was normally distributed (p=0.727). 
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Fig A4.10 Probability plot of plasma zinc concentration (µg/L) on day 0, 
excluding samples 13 and 29 
 
Plasma zinc concentration (µg/L) on day 1, 2 and 3 all had a normal distribution 
(p=0.642, 0.778, 0.965 respectively). 
 
Liver zinc concentrations (µg/g dry weight) were normally distributed (p=0.915).  
 
RBC zinc concentrations (µg/ µg Fe) on day 0-3 were all normally distributed 
(p=0.715, 0.532, 0.123, 0.433 respectively). 
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Selenium 
 
The Anderson-Darling test for normality was performed to ensure the normality 
of the data and exclude any outlying samples.   
Liver selenium concentrations were found to be normally distributed (p=0.232) 
(fig A4.11).  
 
 
Fig A4.11 Probability plot of liver selenium concentration (µg/g dry weight)  
 
The Anderson-Darling normality test was performed on plasma selenium 
concentrations on day 0-3 and outlying samples were identified; day 0 p=0.284, 
day 1 p=0.035, day 2 p=0.891, day 3 p=0.559. Probability plots of plasma 
selenium concentrations on day 0-3 can be seen in fig A4.12a. Outlying samples 
(day 0 sample 10, day 1 samples 20 and 29) were removed and all plasma 
selenium concentrations on day 0-3 were normally distributed; day 0 p=0.726, 
day 1 p=0.522, day 2 p=0.891, day 3 p=0.559. Probability plots of plasma 
selenium concentrations on day 0-3 with outlying samples removed can be seen 
in fig A4.12b. 
345 
 
 
Fig A4.12a Probability plot of plasma selenium concentration (µg/L) 
 
 
Fig A4.12b Probability plot of plasma selenium concentration (µg/L) day 0 
sample 10 and day 1 samples 20 and 29 removed 
 
 
 
346 
 
Examination of probability plots of red blood cell selenium concentration on 
days 0-3 revealed outlying samples (fig A4.13a); day 0 p=0.026, day 1 p=0.372, 
day 2 p=0.226, day 3 p=0.257. Sample 20 on day 0, 1 and 2 was removed from 
analysis and red blood cell selenium concentration was then normally distributed 
(fig A4.13b); day 0 p=0.479, day 1 p=0.625, day 2 p=0.233, day 3 p=0.257. 
 
 
Fig A4.13a Probability plots of RBC selenium concentration on day 0-3 (µg/µg 
Fe) 
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Fig A4.13b Probability plots of RBC selenium concentration on day 0-3 (µg/µg 
Fe) with sample 20 removed on days 0-2 
 
Red blood cell glutathione peroxidase was normally distributed on day 0-3; day 0 
p=0.353, day 1 p=0.702, day 2 p=0.748, day 3 p=0.391 (fig x). 
 
 
Fig A4.14 Probability plots of RBC glutathione peroxidase activity on day 0-3 
(U/g Hb) 
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Magnesium 
 
To ensure the normality of the data and exclude any outlying samples, the 
Anderson-Darling test for normality was performed.  
 
Liver magnesium concentrations were found to be normally distributed 
(p=0.423).  
 
An outlying sample (sample 13) was seen when examining a probability plot of 
muscle magnesium (fig A4.15) and this sample was excluded from all further 
magnesium analysis. With this sample removed muscle magnesium was normally 
distributed (p=0.2). 
 
 
Fig 4.14 Probability plot of muscle magnesium concentration (µg/g dry weight)  
 
Red blood cell magnesium levels on day 0 and day 1 were not normally 
distributed; p=0.048 and p=0.030 respectively. Examination of a probability plot 
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(fig A4.15a) and histogram (fig A4.15b) of day 0 RBC magnesium showed outlying 
samples (Samples 14, 20 and 26) and these was removed from further analyses. 
Samples 20 and 31 were outliers on day 1 and were also removed (fig A4.15c). 
After these were removed days 0-3 were normally distributed and probability 
plots can be seen in fig A4.15d; day 0 p=0.119, day 1 p=0.434, day 2 p=0.836, 
day 3 p=0.518.  
 
 
Fig A4.15a Probability plot of day 0 RBC magnesium concentration (µg/µg Fe)   
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Fig A4.15b Histogram of day 0 RBC magnesium concentration (µg/µg Fe)   
 
 
Fig A4.15c Probability plot of day 1 RBC magnesium concentration (µg/µg Fe)  
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Fig A4.15d Probability plots of RBC magnesium concentration on day 0-3 (µg/µg 
Fe) 
 
The Anderson-Darling normality test was performed on plasma magnesium 
concentrations on day 0-3 and all were normally distributed; day 0 p=0.528, day 
1 p=0.734, day 2 p=0.992, day 3 p=0.507. Probability plots of plasma magnesium 
concentrations on day 0-3 can be seen in fig A4.16. 
 
Fig 4.16. Probability plots of Plasma magnesium concentration on day 0-3 (µg/L) 
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